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The most beautiful thing we can experience is the mysterious. 
It is the source of all true art and all science. 
He to whom this emotion is a stranger, who can no longer pause to wonder and stand 
rapt in awe, is as good as dead: his eyes are closed.
   Albert Einstein 
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The aspartic protease (HIV-Pr) of the human immunodeficiency virus, responsible agent for 
AIDS, is  surely one of the most studied enzymes in terms of structure and activity. HIV-Pr is 
responsible for cleaving the viral polyprotein precursor into structural proteins and enzymes 
and plays an essential role in the viral replication and maturation. HIV-Pr has thus  become the 
target of numerous efforts to design antiviral therapeutic agents suitable for the treatment of 
AIDS.
In the field of organic chemistry, the search for effective HIV-Pr inhibitors  has boosted the 
development of new  methodologies for the stereoselective synthesis of compounds containing 
multiple chiral centers, on which reversible inhibitors are generally based.
HIV-Pr shows peculiar characteristics as it is able, unlike any other eukaryotic aspartic protease, 
to hydrolyze amide bonds with proline as the N-terminal residue. Moreover, it is active in a 
dimeric form, possessing C2 symmetry, in which each monomer contributes a catalytic aspartate.
The first part of the present doctoral work described in Chapter 2, has been dedicated to the 
synthesis of hydroxyethylene Phe-Pro isosters in which the pyrrolidine ring is expanded by a 
condensed aromatic ring in order to provide a better fit to the enzyme’s catalytic site. During the 
synthesis of the isoster a novel reaction was discovered in which enaminones are directly 
formed by treatment of  α,β-unsaturated ketones with trimethylsilylazide and fluoride. Phe-Pro 
isosters based on the enaminone structure showed moderate activity as HIV-Pr inhibitors.
The direct amination of α,β-unsaturated ketones is the subject of Chapter 3.  This reaction is 
demonstrated to be general for enones containing a β-hydrogen. A mechanism based on azide 
activation via formation of a pentacoordinated silicon species followed by a 1,3-dipolar 
cycloaddition is proposed and supported by experimental results and calculations.
In Chapter 4 is reported the synthesis of a library of triazole inhibitors by a combinatorial 
approach based on click chemistry. The library was screened for HIV-Pr inhibition and 
deconvoluted. A set of promising members from the library was synthesized as  single, 
enantiomerically  pure compounds that confirmed to be active HIV-Pr  inhibitors.
Finally, in Chapter 5 the development of an alternative approach to dipeptide isosters, based on 
the ring closing metathesis of aminoacid-derived allylamines, is  described. Building of the four 
carbon atom backbone of the isosteres is obtained after mounting the olefins on designed 
linkers that allow  selectivity in the cross metathesis, and easy final cleavage. Carbamate linkers 
will also allow  also protection of the amino groups during the next steps of the synthesis 
leading to the desired di- and monohydroxyethylene isosters.
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La proteasi aspartica (HIV-Pr) del virus della immunodeficienza umana, l'agente responsabile 
dell'AIDS, è sicuramente uno degli enzimi più studiati in termini di struttura e di attività. HIV-Pr 
è responsabile della scissione della poliproteina virale in proteine strutturali ed enzimi e svolge 
un ruolo essenziale nella replicazione e maturazione del virus. HIV-Pr è così diventato il 
bersaglio di numerosi studi mirati alla progettazione di agenti terapeutici antivirali adatti per il 
trattamento dell'AIDS. 
Nel campo della chimica organica, la ricerca di efficaci inibitori dell'HIV-Pr ha stimolato lo 
sviluppo di nuove metodologie per la sintesi stereoselettiva di composti contenenti più centri 
chirali, che costituiscono la base strutturale della maggior parte degli inibitori reversibili. 
HIV-Pr presenta caratteristiche peculiari in quanto è in grado, unica tra le proteasi aspartiche da 
eucarioti, di idrolizzare legami ammidici con la prolina come residuo N-terminale. Inoltre, 
l’enzima è attivo in una forma dimerica, con simmetria C2, in cui ogni monomero contribuisce 
con un residuo catalitico di acido aspartico. 
La prima parte del presente lavoro di dottorato, descritta nel Capitolo 2, è stata dedicata alla 
sintesi di isosteri idrossietilenici del dipeptide Phe-Pro, contenenti un anello pirrolidinico 
espanso  al fine di migliorare le interazioni con il sito catalitico dell'enzima. Durante la sintesi 
dell’ isostere è stata scoperta una nuova reazione di formazione di enaminoni per trattamento di 
chetoni α,β-insaturi con trimethylsilylazide e fluoruro. Alcuni isosteri Phe-Pro basati sulla 
struttura enaminonica hanno mostrato una moderata attività come inibitori della HIV-Pr. 
L'amminazione diretta di chetoni -insaturi è il soggetto del Capitolo  3. Questa reazione si è 
dimostrata essere generale per enoni contenente un idrogeno in posizione β. Un meccanismo 
basato sulla attivazione della azide attraverso la formazione di una specie pentacoordinata di 
silicio seguita da una cicloaddizione 1,3-dipolare viene proposto sulla base dei risultati 
sperimentali e di calcoli teorici. 
Nel Capitolo  4 è riportata la sintesi di una libreria di inibitori triazolici ottenuti con un approccio 
combinatoriale. La libreria è stato analizzata per l'inibizione di HIV-Pr e deconvoluta. Alcuni 
membri promettenti della biblioteca sono stati sintetizzati come composti singoli, in forma 
enantiomericamente pura, confermandosi attivi inibitori della HIV-Pr. 
Infine, nel Capitolo 5, é descritto lo sviluppo di un approccio alternativo a isosteri di dipeptidi, 
basato sulla “ring closing methatesis” di allilamine derivate da aminoacidi. La costruzione dello 
scheletro degli isosteres si ottiene dopo l’assemblaggio delle olefine su un nuovo linker che 
consente una cross-metatesi selettività nonché un facile distacco del prodotto. Il linker può 
anche essere utilizzato come gruppo proteggente nella successiva elaborazione sintetica dei 
prodotti.
Riassunto
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Introduction
1.1 Aspartic Proteases
1.1.1 The biological role of proteases and their involvement in disease
Proteolytic enzymes can be classified into four major classes: aspartic, serine, cysteine and 
metallo proteases.[1] They selectively catalyze the hydrolysis of peptide bonds  and their control 
over protein synthesis, turnover and function enables them to regulate physiological processes 
such as  digestion, fertilization, growth, differentiation, cell signaling or migration, 
immunological defense, wound  healing and apoptosis. Proteases also play an essential role in 
several diseases and protease inhibitors are emerging as useful drugs in the treatment of cancer, 
parasitic, fungal and viral infections (e.g. schistosomiasis, malaria, C. albicans, AIDS, hepatitis, 
herpes), and inflammatory, immunological, respiratory, cardiovascular and neurodegenerative 
disorders including Alzheimer's disease.[2] At present many designed potent and selective 
protease inhibitors slow  down or halt disease progression; among them, inhibitors of the 
human immunodeficiency virus protease (HIV-1 Pr) show  great promise in anti-AIDS therapies 
and are notable for the speed with which they became available.[3]
1.1.2 Aspartic proteases
Aspartic and metalloproteases  differ from serine and cysteine proteases because the nucleophile 
attacking the scissile peptide bond is an activated water molecule rather then the nucleophilic 
side chain of an amino acid. In the former two classes, catalysis involves amino acid residues 
that act as ligands, activating the water molecule either directly, as in aspartic peptidases, or by 
binding one or two metal ions that in turn bind and activate the water molecule in the 
metallopeptidases. 
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Aspartic proteases are so named because aspartase (Asp) residues act as ligands of the activated 
water molecule in all examples for which the catalytic residues have been identified. The primary 
example is pepsin, in which the side chains of  two Asp residues bind to water.[1]
One distinguishing characteristic of aspartic proteases is that all the enzymes of this  class 
described so far are endoproteases  (i.e. they cleave internal and specific peptide bonds), 
although their is  no obvious reason why this type of catalytic mechanism should not be used in 
exoproteases (i.e. non-specific proteases that degrade a peptide sequence starting from either 
the N or C terminal).
Tertiary structures are known for four families of aspartic proteases. Enzymes belonging to the 
A1 family are bilobed, with an active site located between the lobes (Figure 1.1  a,c). Each lobe 
bears one Asp residue of the catalytic dyad, and it is generally accepted that the second lobe has 
derived from the first one by an accidental gene duplication event. In contemporary proteases, 
only very limited similarities in the amino acid sequence of the two lobes remain, but the three-
dimensional structures  are very similar. The discovery of the common origin of the lobes 
however raised a question: how  could the product of the original gene have functioned as a 
protease if  it consisted of  only one lobe, with a single 
 
(a) (b)
(c) (d)
Figure 1.1 Schematic structure of monomeric aspartyl proteases (a: renin; b: plasmepsin) and  dimeric 
proteases (c: HIV1 Pr; d: EIAV protease)
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Asp residue? A possible answer came when the first crystal structure of  retropepsin from family 
A2 was resolved, showing a single lobe bearing one catalytic Asp, very similar in structure to one 
lobe of  pepsin. Retropepsins are active only as homodimers, and the catalytic site is formed 
between the two protein molecules (Figure 1.1, c,d). The similar protein folds of  the proteases 
in families A1 and A2 support the view that they have evolved from a common ancestor.
There are a number of other families  included in the AA clan, on the basis  that the enzymes 
possess similar amino acid sequence motifs around catalytic Asp residues. Most of these 
families comprise monomeric enzymes from RNA viruses or retrotranspons, and the enzymes 
are assumed to require dimerization for activity, as retropepsins.
Tertiary structures have also been solved for families  A6 and A21, comprising endopeptidases 
that are proteins of nodaviruses and tetraviruses, respectively. The tertiary structures are 
different from those of  known any other protein, and the family is assigned to clan AB.
Aspartic proteases can be found in vertebrates, fungi, plants and retroviruses. However, unlike 
cellular aspartic proteases such as pepsin or renin, which are single molecules  containing two 
topologically similar domains and more then 300 amino acids,[4] retroviral proteases  are much 
smaller. They are active only as symmetric dimers with a single active site, formed by two 
identical monomers. This type of molecular architecture is unique among enzymes, and there 
are no other known examples of  active sites formed in a similar manner.[5] 
All aspartic proteases have two triads Asp-Thr/Ser-Gly which through a network of hydrogen 
bonds (“fireman’s grip”) form the active site. Inside the active site aspartic proteases generally 
bind 6-10 amino acids of their polypeptide substrates.[6] In addition, some aspartic proteases 
also have one or more flaps that close down on top of the bound substrate interacting with it 
and increasing the basis for selectivity. 
The binding pockets that recognize the residues of the peptide substrate define a number of 
subsites in the enzyme’s active site. Subsites are usually described using the nomenclature of 
Schechter and Berger,[7] in which subsites on the N-terminal side of the scissile bond (or its 
nonscissile replacement in an inhibitor) are unprimed and those on the C-terminal are primed. 
The two residues that are immediately adjacent to the scissile bond are therefore labeled P1 and 
P1’; the next two P2 and P2’ and so on. The corresponding binding pockets in the enzyme are 
labeled S1, S1’, S2, S2’, etc.
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1.1.3 HIV Protease (HIV-Pr)
HIV-Pr has an essential role in the replication cycle of the HIV-1 virus. HIV-Pr cleaves 
poliproteins PR55gag and PR160gag/pol (expressed by gag and pol genes) allowing maturation of a 
new  viral particle. Since HIV-Pr is  a common target for anti-HIV therapy, it has become one of 
the most studied enzymes in terms of function and structure; in fact the Brookhaven Protein  Data 
Bank currently holds more then 270 different structures  of HIV-Pr and its mutated forms 
complexed with inhibitors. 
Homology studies have revealed the presence of the Asp-Thr-Gly[8] triad while other 
investigations proved its affiliation to the aspartic protease family.
Mutation of aspartic residue in position 25 (Asp25) with different residues like Asn[9] produce 
proteins  with no catalytic activity; HIV-Pr is inhibited in vitro  by pepstatin, inhibitor of natural 
origin with great selectivity for aspartic proteases[10] and its crystallographic structure reveals an 
active site similar to those of  other enzymes of  the same family.[11]
1.1.3.1 Tridimensional structure
HIV-Pr, in its active form, is a homodimeric protein. Its two monomers, each containing 99 
amino acids  and showing C2 symmetry, are forming an active site. Dimer stability largely 
depends on an intramolecular hydrogen bond network  between β  structures of N- and C- 
termini segments of  each monomer.[12]
The active site is  formed by residues 8, 23, 25, 27-30, 32, 47-50, 53, 80-82 and 84 of both 
monomers (Figure 1.2). Catalytic triads Asp25-Thr26-Gly27 and Asp25’-Thr26’-Gly27’ are situated at 
the bottom of the cavity of the active site, internally of a loop which is  stabilized by a hydrogen 
bonds network. The loops of each monomer are connected by four hydrogen bonds which 
form an interaction called “fireman’s grip”.[13]
The carboxylate groups of Asp25 from both chains are nearly coplanar and show  close contacts 
between two oxygen atoms (2.8-3  Å), indicating the presence of an acidic proton in the bridge. 
The carboxylate residues are also bridged by a water molecule, which is within hydrogen bond 
distance[5] to the oxygen atoms of both carboxylates. Similar water molecules are found also in 
nonviral proteases and are likely to be the catalytic water in this family of  enzymes.
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Segment Ile47-Gly48-Gly49-Ile50-Gly51-Gly52, with the corresponding segment 47’-52’ in the other 
monomer, form so called “flap” structures. These structures are flexible  and play important 
role in substrate recognition.[14]
Significant differences between the structure of the HIV-1-Pr apoenzyme and its complexes are 
often observed, indicating that an inhibitor may introduce significant conformational changes 
Figure 1.2 Crystallographic  structure of the active site of HIV-Pr complexed with inhibitor JG-365 
(ball&stick). In the green hydrogen bond network called “fireman’s grip”
Figure 1.3 Structure of  native (a) and complexed HIV-1 Pr (b) shoving open and closed flaps, respectively.
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(a) (b)
upon binding to the enzyme. This motion consists  in a slight tightening of the cavity of the 
active site and mainly in a very large movement of the flap region - as much as 7 Å for the tips 
of  the flap (Figure 1.3).[15]
Most of the resolved crystallographic structures of HIV-Pr and its inhibitors reveal the 
presence of a second water molecule (also called “flap water”) which is tetrahedrally 
coordinated between two carbonyl groups in P1 and P1’ and two amide groups  of Ile50 and Ile50’ 
residues of the flap region. This water molecule is completely inaccessible to the solvents[16] and 
is not present eucariotic aspartic proteases.
1.1.3.2 Subsites of the active site
A number of distinct subsites that host the side chains of the inhibitors (or substrates) can be 
indentified in retroviral proteases. These subsites  are named according to the already described 
nomenclature of Schechter and Berger.[7] In the retroviral proteases, the primed and unprimed 
sites are identical, due to the symmetry of these enzymes. Three subsites (S1-S3) are very well 
defined, while the more distant subsites are not as distinct.
The protease side chains that form S1 and S1’ subsites are mostly hydrophobic, with the 
exception of the active site aspartates. These are involved in polar contacts mediated by 
hydrogen bonds with the main-chain hydroxy groups of inhibitors based on hydroxy-containing 
isosters .
!
Figure 1.4 Schematic representation of hydrogen bonding between poliprotein  and the residues of the 
active site
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Subsites S2 and S2’ are inner pockets and are smaller than the S1/S1’ or S3/S3’ pockets. They also 
turned out to be more specific, limiting the size and the type of residues at P2/P2’ in the 
substrates or inhibitors relative to the other binding pockets.[17] Although these pockets are at 
least partially hydrophobic, both hydrophilic and hydrophobic residues of substrates or 
inhibitors can occupy the sites.
Subsite S3 and S3’ in retroviral proteases are known to have rather broad specificity, being able to 
accept residues of different types and sizes.[18] This is  due to their ability to maintain aliphatic, 
polar and ionic interactions with different ligands. In addition, these subsites are quite large and 
exposed to the solvent. They can host a variety of  side chains, some of  which can be very large.
Subsites S4/S4’ and S5/S5’ have not been described in detail, due to the small number of available 
structures of  retroviral proteases with ligands extending beyond P3/P3’.
1.1.3.3 Mechanism of hydrolysis
Aspartic protease’s  catalytic mechanism, most likely follows a general acid-base mechanism 
(Figure 1.5), which requires one Asp residue to be protonated, while the second one must be 
ionized. In fact there is  experimental evidence that two aspartates  share a single proton at 
physiological pH. The scissile amide bond undergoes nucleophilic attack by a water molecule 
which is activated by the deprotonated[19] catalytic aspartic residue. The protonated aspartic acid 
donates a proton to the amide bond nitrogen, generating a tetrahedral zwitteronic intermediate 
which collapses  to the cleaved products with a similar mechanism, in the slow  step.[20] An 
additional water molecule binds between the substrate and main chain amide groups of the 
enzyme (at the level of Ile50 and Ile50’) and is thought to twist the scissile peptide bond out of 
planarity, thereby facilitating the cleavage of this bond.[21] The partial loss of amide resonance, 
caused by twisting the amide group out of planarity makes the carbonyl more eletrophilic and 
thus more prone to react with water molecule.[22]
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1.1.3.4 Enzyme specificity
Hydrolysis  of a peptide bond represents the final event of a vast chemical process which 
implies  the recognition of a peptide sequence. Knowledge of the peptide sequences which are 
recognized by the active site is fundamental for the design of efficient inhibitors. Identification 
of new  hydrolytic sites of gag and gag/pol poliproteins[23] clearly showed that HIV protease is 
rather versatile in terms  of substrate recognition, although certain alternations of hydrophilic 
and hydrophobic residues in amino acids next to the scissile bond were determined. Most 
proteolitic enzymes  show  a strong preference for specific amino acid in P1 and/or P1’  position. 
The peculiarity of HIV protease is  its ability to hydrolyze different types of amide bonds 
including those with proline in P1’  position.[24]
Hydrolytic sites  can be divided in two categories. One, between two hydrophobic residue and 
another  between one aromatic residue (Tyr or Phe) and proline residue (Pro). This ability places 
HIV-Pr in the class of enzymes called “Prolilpeptidases”,[25] enzymes with different structure, 
mechanism of action, biological function but all capable to hydrolyze peptide sequences 
containing proline. Hydrolysis of amide bond containing proline as  N-terminus  residue is  rare 
Figure 1.5 Mechanism of  hydrolysis of  aspartic proteases
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and it represents a peculiarity of retroviral proteases;[26] mammal cellular endo-proteases do not 
have this kind of  ability.
1.1.4 Strategies of inhibition 
The active site of aspartic proteases does not in general contain groups that are sufficiently 
nucleophilic to be chemically modified by selective irreversible inhibitors. The catalytic 
aspartates can be alkylated only by strong electrophiles, such as epoxides, that are potentially 
cytotoxic.[27] Thus, the majority of inhibitors that have been developed to date bind to their 
target enzyme through noncovalent interactions, i.e. hydrogen bonds, ionic or van der Waal’s 
contacts. These compounds are therefore reversible inhibitors, and an effective inhibition results 
when the enzyme has higher affinity for the inhibitor than for its natural substrate. 
It has been proposed that stable structures which resemble the transitions state of an enzyme 
catalyzed reaction should be particularly effective as  inhibitors. This assumption is  based on 
Pauling’s principle, according to which the transition state of an enzyme catalyzed reaction is 
more tightly bound to the active site than the substrate and the products.[28] An approach that 
has proved very successful for the design of efficient aspartic protease inhibitors is based on the 
incorporation of a transitionstate analog into a peptidomimetic structure. For proteases, a 
transitionstate isoster is defined as a functional group that can mimic the tetrahedral transition 
state of amide bond hydrolysis, but is  stable and non hydrolyzable. Studies on the general 
aspartic protease inhibitor pepstatin (which incorporates the statine isoster) suggest that this 
increased affinity, which can be up to 104-fold, is not only due to mimicry of the transition state 
for amide hydrolisis but also to the displacement of the catalytic water molecule hydrogen 
bonded to the active site aspartates.[29] Some transition-state isosters that have been successfully 
used in the design of  aspartic protease inhibitors are shown in Figure 1.6.[18, 30]
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Figure 1.6 Some representative peptide bond isosters
1.1.4.1 HIV Protease inhibitors
The very first results in HIV-Pr inhibition were obtained by exploiting the vast amount of 
knowledge acquired on renin inhibition. Renin, a monomeric aspartic protease, was intensively 
studied for its important role in human hypertension. Most renin inhibitors were substrate-base 
molecules, containing non-cleavable isosters.[31] The most successful isosters  contain a hydroxyl 
group near the scissile bond, which replaces  the water molecule positioned between the catalytic 
aspartates thus generating interactions similar to those occuring in the transition state. Almost 
every FDA approved inhibitor to date contain isosters of this  kind. However,  to obtain specific 
inhibition one must consider the structural characteristics of  the entire protein.
Polipeptide natural substrates usually present a vast variety of sequences, and efficient hydrolysis 
is obtained with peptide chains containing at least seven residues.[32] Large heterogeneity of 
hydrolysis sites implies that HIV-Pr is able to interact with its  ligand in more than one manner 
depending on structural characteristics and combinations of possible interactions. The fact that 
different sites are hydrolyzed with different efficiencies indicates that the active site does not 
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have an optimal affinity for every sequence and that a regulation mechanism exists which 
sequence is priorities.[33]
All sequences recognized by the active site have two hydrophobic residues at the scissile bond 
level. This  preference is common for all types  of aspartic proteases and is determinant for the 
choice of residues in P1 and P1’ positions of peptidomimetic inhibitors.[34] HIV-Pr crystal 
structure analyses revel that inhibitors inside the active site adopt an extended conformation 
resembling a β  sheet. Inhibitor’s  lateral chains  occupy enzyme subsites establishing non-covalent 
interactions that provide a major contribution to the complexation energy.[18]
The first protease inhibitors had a strong peptide character showing remarkable specificity for 
the protease and high efficiency in cellular culture test. Although peptides display a range of 
biological properties, their use as drugs  is usually compromised by their instability, low 
bioavailability, and poor pharmacological profiles. To be effective drugs, protease inhibitors 
need to have minimal peptide character, high stability to nonselective proteolytic degradation, 
good membrane permeability, long lifetimes in the bloodstream and in cells, low  susceptibility to 
elimination, high selectivity for the target protease, and good bioavailability (preferably by oral 
delivery). These requirements usually demand for low  molecular weight compounds (≤1000 
Da).[35] 
1.1.5 General aspects of design and discovery of aspartic protease inhibitors
Protease inhibitors have been traditionally developed by screening natural products for lead 
compounds or by empirical, substrate based methods, involving truncating polypeptide 
substrate to short peptides (< 10 amino acids), replacing the cleavable amide bond by a non-
cleavable isoster, and optimizing inhibitor potency through trial and error structural 
modifications that progressively reduce the peptide nature of the molecule. More recently this 
area has advanced further with development of computer-assisted structure-based design using 
three-dimensional structures of proteases determined by X-ray crystallography and NMR 
spectroscopy. This approach uses using structural information on the active site of the receptor 
(or protease) into which designed molecules are fitted with the aid of computers. Today the 
design of protease inhibitors involves a powerful combination of all of these traditional drug 
discovery approaches, supplemented by de novo  drug design and combinatorial chemistry, and 
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supported by rapid robotic assay methods to find or optimize inhibitors leads from vast 
chemical libraries.
The key feature of many protease inhibitors is  the presence of a transition-state isoster that 
simulates to some extent the transition state of amide bond hydrolysis. The incorporation of 
amide bond surrogates has proven to be a very successful strategy for rapidly converting 
protease substrates into inhibitors, with a 10-104-fold increment of affinity for the enzyme. 
Although a number of transition-state isosters are already known, it seems reasonable to think 
that further advances can be made to reproduce more closely the transition state, increasing 
inhibitor affinity for a protease active site.
As far as the structure of the groups surrounding the transition-state isoster is  concerned, most 
proteases are sequence-specific and thus the size and hydrophobicity/hydrophilicity of the 
active sites defines possible amino acid or non amino-acid side chains of peptidomimetic 
inhibitors.
Recently, it has been demonstrated that aspartic, serine, cysteine and metallo proteases 
universally bind their inhibitors  or substrates in extended or β-strand conformations; that is, the 
peptide backbone, or its equivalent in the inhibitor, is in linear arrangement.[36] This 
conformational requirement suggests the development of conformationally restricted inhibitors 
that adopt receptor-binding conformations and thus  are entropically advantaged for binding. It 
is surprising, however, that most protease inhibitors developed to date are quite flexible 
molecules. This flexibility is  expected to rise the entropic barrier for protease binding, and it 
could be advantageous to examine inhibitors that are already fixed in a protease-binding 
conformation and thus do not need to reorganize prior to binding. Alternatively, the energy 
barrier for inhibitor-protease interactions could be reduced by designing compounds  that 
minimize their degree of solvation  by water, thus reducing the energy needed for desolvation. 
A third approach is to design compounds that replace key water molecules in the active site of 
the enzyme, a strategy that has been successfully employed for cyclic urea and other inhibitors 
of  HIV-Pr.[37]
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1.2 Reversible peptidomimetic HIV-Pr inhibitors
A number of substrates or transitionstate-mimic HIV-Pr inhibitors have reached the stage of 
clinical trials and currently over ten inhibitors have been approved by the FDA for anti-HIV 
therapy. These specific inhibitors cause significant initial lowering of the viral load in tissues and 
a general improvement in the clinical state of AIDS patients. Form a global survey of in vitro 
and in vivo activities, inhibitors containing hydroxyethylene isosters  which mimics phenylalanine 
emerged as valuable and effective compounds, showing strong affinities for the HIV-Pr 
enzyme’s active site and good pharmacological properties.
The observation that absolute configuration of carbinolic carbons of hydroxyethylene isosters 
has an important impact on inhibitor’s affinity for the active site has motivated the development 
of many stereoselective methodologies for the synthesis of these pseudopeptides as  single 
diastereoisomers.
1.2.1 Dihydroxyethylene isosters
An elegant approach to the design of inhibitors exploits the C2 symmetry axis  of the native 
enzyme. A hypothetical axis  of symmetry is  thus drawn across the C-N bond of the tetrahedral 
transition state (Figure 1.7), reproducing the C2 symmetry axis  of the protease. The P’ portion is 
deleted and a C2 symmetry operation is performed on the P residue to give an α-diketone; 
replacing two carbonyl groups with two hydroxyl groups, which are more prone to accept and 
to donate hydrogen bonds,  gives three possible diastereoisomers of diaminodiols; if R and R’ 
residues are different non symmetric analogues are obtained. Coupling of the diaminodiol N-
termini with peptide chains will yield peptidomimetic inhibitors in which the normal amide 
bond alternation is inverted. The diaminodiol core offers the possibility to attach two different 
or two identical peptide chains on the amino termini of the core producing either non-
symmetric or symmetric inhibitors of  general structure Pn--P2-P1-P1’-P2’--Pn’.
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1.2.1.1 Approches to dihydroxyethylene isosters
Several approches to the synthesis  of 1,4-diamino-2,3-diols have been published and can be 
broadly classified into two categories:
1) pinacol-type homo-coupling of  α-aminoaldehydes
2) elaboration of compounds from the “chiral pool” such as  sugar, aminoacids or 
other chiral materials
1.2.1.2 The homo-coupling method
The reductive dimerization of aminoaldehydes in the presence of low-valent metals is perhaps 
the most straightforward, convergent approach to C2-symmetric diaminodiols and also one of 
the first synthesis to be described for this type of isoster (Scheme 1.1). The starting materials 
are protected aminoaldehydes, directly derived from natural aminoacids  such as phenylalanine, 
valine, leucine, lysine, methionine and tryptophane. The dimerization of N-Boc-phenylalaninal 
under McMurry coupling conditions (TiCl3(DME)2  treated with Zn-Cu couple)[38] was the first 
example of the application of this reaction to aminoaldehydes and resulted in ca. 2 : 1 : 1 
mixture of  (S,R,R,S), (S,S,S,S) and (S,R,S,S) diaminodiols (Scheme 1.1).[39]
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Figure 1.7 Schematic representation of  a virtual C2 symmetry operation yielding various structures of  
hydroxyethylene isosters
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Although it proved very difficult to separate the three products, formation of a mixture had the 
practical advantage that all the possible stereoisomers were available in a sufficent amount to 
evaluate the biological activities of  inhibitors based on these central cores.
A major advance came when it was reported that a better selectivity could be obtained in the 
presence of the readily available vanadium(III) complex [V2Cl3(THF)6]2[Zn2Cl6].[40] In this case 
the pinacol coupling of a variety of aminoaldehydes gave a predominant diastereoisomer to 
which, in all the cases, the (S,R,R,S) configuration could be assigned. When applied to N-Boc- 
or N-Cbz-phenylalaninal this  approach gave the (S,R,R,S), (S,S,S,S) and (S,R,S,S) diaminodiols 
in a 8:1:1 ratio.[41] In this case the mixture could be conveniently purified, isolating the main 
product by acetonide formation and recrystallization. 
Other reagents  have been used for the pinacol homocoupling: among these samarium(II) iodide, 
gave a 2.3:1.4:1 ratio of the (S,R,R,S), (S,S,S,S) and (S,R,S,S) diastereoisomers when starting 
from Boc-phenylalaninal,[42] while with NbCl3(DME) results  were similar to those obtained with 
the vanadium reagent.[43] The main limitation of the homocoupling approach is its applicability 
only to the synthesis of symmetric diaminodiols, with identical R and R’ groups, as  mixtures of 
homo- and cross-coupled products may be expected from the coupling of two different 
aminoaldehydes.
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Scheme 1.1 Low valent-metals mediated homocoupling. P=Boc, Cbz; R=Bn, iBu, iPr, (CH2)4NHCbz, 
(CH2)2SCH3, CH2-(3-indolyl)
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1.2.1.3 Sugar based routes to diaminodiols
Reduced hexoses present a useful, and extensively exploited, pool of chiral precursors of 
dihydroxyethilene isosters. This route provides a preformed carbon skeleton with fixed 
configurations which can be conveniently converted to the target molecules, without the need 
for a stereocontrolled asymmetric synthesis or for separation of mixture of diastereoisomers, 
which is often difficult. D-Mannitol is a very common starting material in this approach, mainly 
chosen in order to get an (S,R,R,S) configuration in the final diaminodiol. This choice excluding 
the other possible diastereoisomers, is probably due to the first results in the evaluation of the 
biological activity of diaminodiol-based inhibitors. Central cores with benzyl residues 
(mimicking the natural HIV-Pr substrates) proved to be most effective and the R,R 
configuration of the diol resulted generally in better solubility and in  vivo  activity of the 
inhibitors.[44] One of the synthetic strategies described in literature, is  based on the addition of 
organocuprates to bis-aziridine (Scheme 1.2), deriving from D-mannitol[45] or D-treitol.[46]
Aziridine are very versatile intermediates in diaminodiol synthesis, however their use is not 
common because the aziridine ring is rather difficult to open. Actually, ring opening is only 
possible if the nitrogen is  activated by an ester or sulfonyl group. By far more common are 
strategies based on epoxides rather then aziridines. These routes are in general longer because it 
is necessary to convert two hydroxy groups into the required amines, but have the advantage 
that it is possible to obtain either free amino groups or amines protected with easily cleavable 
groups like Boc or Cbz. Several authors resorted to this strategy to obtain cleanly symmetric 
(S,R,R,S) diaminodiols;[47] the synthesis, involving in every case the same diepoxide 
intermediate, is depicted in Scheme 1.3.
HO OH
OH
OH
OH
OH O O
ZN NZ R
NHZ
OH
OH
NHZ
R
D-mannitol
Scheme 1.2 Preparation of  different diaminodiolic diastereoisomers from D-mannitol via bis-aziridine 
R=CH3, nBu; Z=Boc, Ts
Introduction
16
With the same approach it was also possible to obtain unsymmetrical diaminodiols  with 
different R residues.[48] In this case the bis-epoxide was treated with phenol and the reaction 
stopped at a low conversion to obtain a 31% yield of  a mono epoxy intermediate. (Scheme 1.4)
Reduced tetroses can also serve as useful chiral starting materials, but in this case two additional 
chiral centers must be generated. A synthesis from D-thretiol appeared,[49] in which the key step 
is the generation of two asymmetric carbons, based on a bis hydrazone, to afford symmetric 
diaminodiols (Scheme 1.5).
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Scheme 1.3 Bis-epoxide based synthesis of  diaminodiols from D-mannitol
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Scheme 1.5 Symmetric diaminodiols synthesis from D-treitol; Z=Cbz
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This synthesis  relies on a highly stereoselective addition of BnLi to the hydrazone intermediate: 
only the (S,R,R,S) diastereoisomer could be detected by HPLC analysis. 
1.2.1.4 Routes to diaminodiols from tartaric acid
A route to the (R,R,R,R) diaminodiol[50] involves L-tartaric acid as starting material. An example 
is reported in Scheme 1.6. This approach involves  a dinitrone which are easily obtained by 
treatment of L-tartrate with benzyl-hydroxyamine. Stereoselective addition of a Grignard 
reagent affords two new chiral centers with 85% selectivity.[51]
Another example is given by the Michael addition of a primary amine to a bis-enone derived 
from diethyl L-tartarate[52] (Scheme 1.7). This  route was aimed at the production of (R,S,S,R) 
diastereoisomers, to be used for the synthesis of cyclic urea inhibitors. The reaction is limited by 
the G group, which must be an activating group like an ester or a nitrile, thus making it difficult 
to introduce an alkyl group at these positions. The stereoselectivity depends on the geometry of 
the starting alkenes, going from 11:1 for the (Z,Z) isomer to 5:1 for the (E,E). This approach is 
also restricted by the use of alkyl amines in the addition, making it suitable only for the 
production of  N-alkylated ureas.
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Scheme 1.6 Diaminodiols synthesis from a dinitrone deriving from dimethyl-L-tartarate
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1.2.1.5 Amino acid based routes to diaminodiols
Other than pinacol homo-coupling, there are not many literature examples that use amino acids 
as starting materials. In one of these examples,[53] a trans alkene, obtained by Julia olefination, 
leads to the dihydroxyethylene isostere by dihydroxilation with OsO4 (Scheme 1.8). This 
convergent route allows the introduction of different residues  on the two sides of the isoster, 
yet the stereoselectivity in the dihydroxylation of the double bond is low, leading to a 3:2 ratio in 
favor of  the all-S compound.
Treatment of the double bond with reagent other than OsO4 results  in the production of other 
interesting compounds such as, for example, epoxide- and monohydroxyetylene- based isosters, 
but the stereoselectivity remains the weak point.
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Scheme 1.7 Diaminodiol synthesis from a bis-enone deriving from diethyl-L-tartarate
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Scheme 1.8 Diaminodiols synthesis by alkene dihydroxylation
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In another example,[54] carbamates of N-dibenzyl α-aminoaldehydes are employed (Scheme 1.9). 
The lithiated compound shown in the scheme predominates (ca. 9:1), and this ratio is reflected 
in the final anti,syn,anti (S,S,S,S main product) and syn, anti, anti (S,R,S,S) diaminodiols, as the 
coupling with the aldehyde is completly stereoselective.
1.2.2 Proline based isosters
Among the twenty natural amino acids, proline is unique because it is the only amino acid with a 
secondary amine group. This imparts particular functional and structural characteristics to 
proteins or peptides which contain proline in their sequences. 
Among the enzymes specific for proline containing substrates, besides HIV-Pr and other viral 
proteases should also be mentioned,[55] the peptidyl-prolyl cis/trans  isomerase these enzymes 
assist in protein folding by catalyzing the isomerisation of Xaa-Pro amide bonds and serve as 
receptors for immunosuppressive drugs.[56] Their important role has  stimulated the synthesis of 
proline analogues and Xaa-Pro peptidomimetic  isosters.[57]
Several inhibitors based on Tyr-Pro or Phe-Pro isosters were developed for HIV-Pr, in most 
cases these molecules contain groups that are able to mimic the stereoelectronic features of the 
five memberd ring and, at the same time, to maximize the hydrophobic interactions with the 
enzyme subsites. Good examples  are Nelfinavir© and Saquinavir© (Figure 1.8),  two protease 
inhibitors which are currently used for treatment of AIDS, in which the proline is not present as 
such but mimiched by the larger decahydro-isoquinidine ring. 
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Scheme 1.9 Diaminodiols synthesis from N,N-dibenzyl diaminoalcohol 
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Several examples of cores containing pyrolidine ring were reported in the literature, in particular 
hydroxyethylamine, phosphinic acid derivatives, α-ketoamides, pyrrolidinones and modified 
peptides. However, presence of a secondary amine group, somewhat limits the design and 
synthesis of analogues, and for example, hydroxyethylene isosters containing pyrrolidine were 
not reported in the literature. All reported Xaa-Pro isosters were synthesized from proline itself, 
alkylating the secondary nitrogen which is then incorporated into the isoster. Isosters thus 
obtained have amino and carboxyl termini as in a normal dipeptides, unlike diaminodiol isosters 
which introduce an inversion point in the peptide sequence. Some of the synthetic approaches 
are described below.
A hydroxyethylamine structure, described by Rich in the early ‘90s,[58] was incorporated into the 
inhibitor JG-365; the isoster was designed on the basis of its close resemblance to the 
tetrahedral intermediate for the hydrolysis  oh Phe-Pro amide bond (Figure 1.9) in the p17/p25 
sequence (Ser-Leu-Asn-Phe-Pro-Ile-Val) of  the polyprotein natural substrate of  HIV-Pr.
!
Figure 1.8 Structures of  Nelfinavir© and Saquinavir©, two protease inhibitors currently on the 
market for AIDS treament
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Figure 1.9 Hydroxyethylamine Phe-Pro and tetrahedral intermediate of  sequence p17/p24 hydrolysis 
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The hydroxyethylamine Phe-Pro isoster is inserted into the peptide chain of the inhibitor by 
alkylating the pyrrolidine nitrogen of the HN-Pro-Ile-Val-OMe tripeptide with a chloro-methyl 
ketone, obtained from the Ac-Ser-Leu-Asn-Phe tetrapeptide.[59] The NaBH4 reduction of the 
carbonyl group  unfortunately gives an equimolar mixture of  two alcohols (Schema 1.10).
The procedure was subsequently adapted to obtain the (S,S,S) diastereoisomer, which has a 
higher activity against protease (Scheme 1.11) by alkylation of proline with an epoxide obtained 
from allylamine derived from N-Boc-phenylalanine.[60]
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Scheme 1.10 Hydroxyethylamine Phe-Pro synthesis by alkylation with a peptidyl chloro-methyl ketone
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Scheme 1.11 Synthesis of  S isomer of  the JG-365 inhibitor  by alkylation of  an epoxide
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The knowledge acquired during the synthesis of JG-365, was used by the Roche group for the 
synthesis of Saquinavir©. In which the pyrrolidine ring was replaced by a larger, bicyclic 
analogue. Structural studies and molecular modeling indicated that the five membered ring is 
not large enough to completely occupy the S1’ sub-site and for this reason the research was 
oriented towards bicyclic structures. Replacement of proline with a cis-decahydroxyisochinolin 
gave an IC50 of  2.7 nM for the R diastereomer, while the S turned out to be essentially inactive.
Finally, after incorporation of the terminal N-2-quinoline in this structure, a further increase of 
activity was observed, and the inhibitor Ro 31-8959 (Saquinavir©) was considered a promising 
"lead", subjected to further biological tests and then approved for human use.[61] The crystal 
structure of HIV-Pr complexed with Saquinavir© indicates that the inhibitor binds, as  expected, 
in extended conformation and that the hydroxyl group of the isostere is located between the 
two catalytic aspartate residues (Figure 1.11). The (S,S,S) stereochemistry of the 
decahydroxychinolin ring is optimal, because it occupies almost completely the S1’ sub-site, 
while the methyl tert-butyl group is occupying the S2’ sub-site. Compared with other HIV 
protease inhibitors, the terminal amide is shifted by about 1.8 Å, which precludes its  extension 
in S3' sub-site.[62]
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Figure 1.10 Comparison between two precursors of  inhibitors JG-365 and Saqinavir©
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Despite the limited oral bioavailability (1-4%) due to poor absorption and extensive degradation 
by cytochrome P450, Saquinavir© shows excellent activity, especially in combination therapy 
with ritonavir and reverse transcriptase inhibitors, inhibiting HIV-1 and HIV-2 with IC50 values 
of less than 0.5 nM. Moreover, its use in concentrations up to 10 μM does not cause inhibition 
of  other human aspartic proteases such as renin, pepsin, gastricina, cathepsin D and E.
Another example of a transition state analogue of the Phe-Pro amide bond hydrolysis  is the 
phosphinic acid derivate.[63] This structure evolves from modification of a phosphoamidate, an 
analogue widely used for protease inhibition;[64] the introduction of a methylene between 
phosphorus and nitrogen provides a non-hydrolyzable isostere, which at physiological pH is in 
zwitterionic form (Figure 1.12).
!
Figure 1.11 Crystallographic structure of  the HIV-Pr-Saquinavir complex. The dotted lines represent the 
hydrogen bonds between the inhibitor, the water molecule and the residues Asp25, Asp25 ', Ile50 and Ile50'. 
Saquinavir is represented in “ball&stick” 
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Figure 1.12 Phosphorus based transition state analogue 
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The final inhibitor (Scheme 1.12) is  obtained from N-Cbz-1-amino-2-phenylethyl phosphite 
which is converted into the corresponding phosphinate by treatment with formaldehyde and 
trimethylphosphite. The primary alcohol group is activated with CF3SO2Cl and then used for 
the alkylation of  tripeptide HN-Pro-Ile-Val-OMe (Scheme 1.12).
Best results in terms of inhibition, were obtained using pseudopeptides  based on α-ketoamide 
(Figure 1.13).[65] The crystallographic structure of the complex with HIV-Pr reveals that these 
inhibitors bind to the active site in their hydrated form through a hydrogen bonds network that 
blocks the catalytic activity of  aspartate residues 25 and 25'.
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Scheme 1.12 Synthesis of  peptidomimetic inhibitors based on phosphorylated analogues
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Figure 1.13 Schematic representation of  the interactions of  an α-keto-amide with the catalytic residues, 
aspartate 25 and 25’ in the active site of  HIV-Pr
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The synthesis  is  reported in Scheme 1.13. Partial epimerisation of the α carbon of 
phenylalanine is due to the high acidity of the proton adjacent to the carbonyl and is typical for 
this class of  compounds.[66]
The specificity of HIV-Pr for the hydrolysis of Phe-Pro and Tyr-Pro bonds was also exploited 
for the development of inhibitors which are not transition state analogues.[67] In this  case, the 
inhibitors are pseudopeptides where proline was replaced by 2-benzyl-pyrrolidine-3-ol or a 2-
benzyl-pyrrolidine-3-one (Figure 1.14). These structures bind with high affinity to the active site 
making it inaccessible to the substrate. The substituted  pyrrolidine ring interacts with S1’ subs-
site (Ile50’, Ile84’, Leu23’) through the ring methylenes, and with the S2’ sub-site (Ile47’, Val32’) 
through the benzyl residue in position 2. The aromatic ring of phenylalanine, or tyrosine, 
occupies the S1 sub-site (Ile50, Ile84, Leu23), while the tert-buthyl group occupies S2 sub-site (Ile47-
Val32). The dipeptides interact also with the two catalytic residues by binding a water molecule.
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Scheme 1.13 Synthesis of  α-ketoamide, Phe-Pro isoster
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An enantio-convergent synthetic approach (Scheme 1.14) which allowed the synthesis of the 
(2S, 3S)-benzyl-pyrrolidine-3-ol and the corresponding (2S)-2-benzyl-pyrrolidine-3-one in 
enantiomerically pure form starting from N-Boc-L-phenylalanine. Pyrrolidine derivatives  are 
then condensed with L-phenylalanine or Cbz-L-tyrosine to yield the corresponding 
pseudopeptides.
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Figure 1.14 Structure of  pseudopeptides containing functionalized pyrrolidine ring and schematic 
representation of  their interactions with the active site of  HIV-Pr
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1.2.2.1 Dihydroxyethylene Xaa-Pro isosters
Until the mid-nineties, most diaminodiol syntheses which appeared in the literature regarded the 
(S,R, R,S) diastereoisomers, primarily obtained by pinacol condensation or modification of 
sugars, despite biological data indicating high activity of inhibitors based on (S,S,S,S) and 
(S,S,R,S) diaminodiols;[44] these cores  were obtained only as byproducts of the pinacol 
condensation or by inversion of  the main product (S,R,R,S). 
Stereoselective approaches for the synthesis of different diastereoisomers would allow  to 
investigate the influence of stereochemistry on the activity of inhibitors, as well as their 
pharmacokinetics, bioavailability and solubility. A few  years ago, a general methodology has 
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Scheme 1.14 Synthesis of  (2S, 3S)-2-benzyl-pyrrolidine-3-ol and (2S)-2-benzyl-pyrrolidine-3-one
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Figure 1.15 Three possible diasteroisomers of  symmetric diaminodiols 
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been developed for the stereoselective synthesis of (S,S,S,S) diaminodiols,[68] epimeric 
diaminoalcohols,[69] and S,S,S,S dihydroxy-δ-amino acids[70] based on the regio- and 
stereoselective opening of  epoxy-alcohols derived  from natural amino acid.
This new  synthesis significantly expands the scope of synthetic approaches for HIV-Pr 
inhibitors in terms of stereochemical control and versatility, as the two terminal amino groups 
of diaminodiols and diaminoalcohols can be differentiated by orthogonal protecting groups, 
offering also the possibility to introduce different R, R’ residues.
This methodology was also extended to the synthesis of a new  type of dipeptide isosters 
containing the proline ring. The new  approach is based on the intramolecular, rather than 
intermolecular, epoxy ring opening by an amino group (Scheme 1.15) conveniently positioned at 
the end of the chain of the epoxy-alcohol intermediate, thus  generating the desired pentatomic 
ring.[71]
Complete synthesis of monoprotected diaminodiol Phe-Pro and Val-Pro isosters is  shown in 
Scheme 1.16. The two diaminodiols were obtained with a total yield of around 20% starting 
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Figure 1.16 General methodology for the synthesis of  diaminodiols, diaminoalcohols, and dihydroxy-δ-
aminoacids from a common epoxy-alcohol intermediate
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Scheme 1.15 Pyrrolidine ring formation through intramolecular cyclization of  a terminal amino group on 
a epoxy-alcohol
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from the Boc protected phosphonates  of phenylalanine and valine, which is an acceptable result 
considering the large number of  steps.[72]
The stereochemistry of  (S,S,S,S) diaminodiol was confirmed by X-ray crystallography.[71]
Recently, this approach was optimized[72] by starting from 2-pyrrolidone (Scheme 1.17). This 
allowed to obtain the Phe-Pro isoster with an overall yield of 30% from phosphonate, 
compared to 20% of the previous synthesis, and with considerable reductions both in cost and 
in the number of  required steps.
O O
MeOH
reflux 12h HO O
O
PCC, DCM
97%
O O
O
95%
BocHN O
R
O
P
O
H3C OCH3
OCH3
n-BuLi
THF, -78° BocHN P
R
O
OCH3
OCH3
O
90%
BocHN P
R
O
OCH3
OCH2
O
O O
O
K2CO3
EtOH BocHN
R
O
O
O
79%
BocHN
R
O
OOH
97%
TBDMSCl
DMF BocHN
R
O
OOTBS
LiOH 1N
THF, 8h
BocHN
R
OH
OOTBS
NaBH4
MeOH
90%
90%
i. (PhO)2P(O)N3
ii. BnOH
BocHN
R
NHCbz
OH
66%
TBAF
THF
92%
mCPBA
DCM
BocHN
R
NHCbz
OH
O
72%
BocHN
R
NHCbz
OTBS
H2, Pd/C 5%
MeOH
BocHN
R
OH
OH H
N
90% R=i-Pr, Bn
Scheme 1.16 Synthesis of  Val-Pro and Phe-Pro isosters
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1.2.2.2 Peptidomimetic inhibitors based on Phe-Pro dihydroxyethylene isoster
A small series of inhibitors (Table 1.1), obtained by coupling the isoster Phe-[Ψ]-Pro ([Ψ]= 
CHOHCHOH) with side chains  derived from inhibitor JG365[73] or side chains previously used 
on Phe-[Ψ]-Pro isosters,[74] showed excellent activity with in the nanomolar range.
In particular, the heptapeptide (Entry 1, Table 1.1) shows activity comparable to that of the 
referecnce inhibitor JG-365. The pseudo-hexapeptide (Entry 2, Table 1.1) proved to be even 
more active of one order of magnitude. The sequence tryptophan-valine is actually very 
important for the activity, and the replacement of one or both Trp-Val chains with a shorter 
residue, as in the case of compounds in entry 3  and 4 leads to a decrease of affinity for about 
two orders of magnitude. The residue of dimethylphenoxyacetic acid (DmPoa) however, is 
about 10 times more active than phenoxyacetic acid (Poa), so the compound in entry 4 of Table 
1.1  is still very active. Increasing the size of the heterocyclic ring (Entry 6  and 7  of Table 1.1) 
does  not lead to any improvement of the activity. The result is somewhat surprising and could 
perhaps  be explained by the greater flexibility of  the five membered ring that could ensure a 
better fit to the catalytic site. 
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Scheme 1.17 Optimized synthesis of  Phe-Pro isoster
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Preliminary studies  of cytotoxicity and antiviral activity on infected cells, carried out in 
colaboration with the Department of Virology of the National Center for Infectious Diseases, 
Sofia (Bulgaria), showed that the inhibitors (Entry 1 and 2, Table 1.1) have low  cytotoxicity and 
good anti-replicative activity on virus,[75] thus confirming the interest of this new  type of 
isoster.
The crystal structure analysis of the complex between the inhibitor TS-126  (Entry 2; Table 1.1) 
and HIV-Pr (I84V),[76] besides conferming the potential therapeutic applicability of the new 
inhibitors,[77] shows that the inhibitor adopts within the site, an extended conformation similar 
to that of JG-365  (Figure 1.17 left) and provides useful information for further structural 
elaboration.
Figure 1.17 (right)  Crystallographic structure of the complex between HIV-Pr and the inhibitor JG-365 
(ball&stick).  (PDB file: 7HVP); (left) Crystallographic  structure  of the  complex between  HIV-Pr and  the 
inhibitor TS-126 (Entry 2; Table 1.1, PDB file: 2A1E); In green are shown the residues of the catalitic 
aspartate and the hydrogen bond network that stabilizes the complex in the configuration called “fireman’s 
grip”
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Entry Inhibitor IC50
1
N
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N
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N
CONH2
O
N
H
O
AcHN
HO
O HN O
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0.61 nM
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H
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OH
OH
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O
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O
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HN HN O
NHAc
NH
0.06 nM
3
N
H
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OH
OH
N
O
O HN O
NHAc
NH
O
73.3 nM
4
N
H
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OH
OH
N
O
O
O
O
9.6 nM
5
N
H
Ph
OH
OH
N
O
O
O
O
84.7 nM
6
N
H
Ph
OH
OH
N
O
O
O
AcHN
HN HN O
NHAc
NH
1.8 nM
7
N
H
Ph
OH
OH
N
O
O
O
O
1.2 μM
Table 1.1 IC50 values of  inhibitors with with Phe-[Ψ]-Pro isoster core
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1.2.3 Monohydroxyethylene isosters
1.2.3.1 Approaches to monohydroxyethylene isosters
Approaches to monohydroxyethylene isosters are, in general, more demanding than those to 
diaminodiol structures. The former isoster is not symmetric and this feature adds several 
problems to the synthesis. Thus, usually, these isosters are generated via linear synthesis, in 
which each stereocenter is created in a different step. 
The first example of this approach relied actually on older strategies  directed to the synthesis of 
conventional pseudopeptides, i.e. with an amino and a carboxy terminal group. In this case, at 
the end of the synthesis, the terminal carboxylic acid must be converted into the required amino 
group. Aminolactones derived from 5-amino-4-hydroxyacids, mimicking the Phe-Phe dipeptide, 
are common intermediates  in this approach; these lactones were obtained from aminoacids 
(Scheme 1.18),[78] sugars (Scheme 1.19),[79] or from achiral compounds, using an asymmetric 
Sharpless  dihydroxylation (Sheme 1.20).[80] The key step, after hydrolysis and protection of the 
hydroxy group, is a modified Curtius  type rearrangement, with diphenyl phosphorazidate and 
triethylamine, which, in the presence of the suitable alcohol, leads directly to the amine 
protected as carbamate. 
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Scheme 1.18 Synthesis of  lactones from amino acids
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A similar approach (Scheme 1.21) involves again an aminoacid as starting material. The second 
alkyl residue is introduced via the addition of a Grignard reagent to a cyanoketone; the main 
features of this synthesis resemble those of the lacton-based route but this time the key step is 
the stereoselective reduction of an enaminone.[80] The reduction is carried out with two 
reducing agents  (NaBH4/MsOH, then NaBH3(OTFA)),  without isolation of the aminoketone 
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Scheme 1.19 Synthesis of  lactones from sugars
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Scheme 1.20 Synthesis of  lactones from achiral compounds with Sharpless dihidroxylation
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intermediate. This double reduction gave the desired stereoisomer in 93% yield, with surprising 
control of the configuration of the amine stereocenter which is generated in the first reaction. 
A final recrystallization, after deprotection, afforded the (S,S,S) diaminoalcohol with a higher 
than 99% purity.
An alternative approach to diaminoalcohols is  based on the desymmetrization of diaminodiols, 
for which convergent approaches are available, as it was already mentioned. A straightforward 
and up-scalable approach was proposed by the group of Kempf, at the Abbott laboratories.[81] 
Having in hand the very convenient synthesis of the diaminodiol moiety based on pinacol 
coupling (see par. 2.1.2), their idea was to simply deoxigenate the central diol (Scheme 1.22). The 
activated hydroxy group is displaced by bromide ion, obtaining a bromo-acetate, which is then 
reduced with nBu3SnH and deprotected to the desired monohydroxyethylene isostere.
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Scheme 1.21 Enaminone route towards diaminoalcohol  isosteres 
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Scheme 1.22 Desymmetrization of  diaminodiols as an approach towards diaminoalcohols
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This approach is  convenient but has limitations imposed by the synthesis of the symmetric 
diaminodiol. In this case, the lateral residues were necessarily identical, only the (S,S,S) 
stereoisomer was readily accessible and the amino terminals were identically protected. The last 
point is critical if the diamine has to be coupled to two different flanking residues, as in the 
synthesis of the Ritonavir© inhibitor.[82] In this case 50% of the starting material was lost in the 
first coupling through statistical formation of  the wrong regioisomer. 
1.2.3.2 Monohydroxyethylene Xaa-Pro isosters
Given that inhibitors based on diaminodiol Phe-Pro core gave promising results in terms of 
anti-HIV-Pr activity (see par. 2.2.2), considerable interest has  developed for the 
monohydroxyethylene equivalents of the Phe-Pro core. The asymmetry of 
monohydroxyethylene isosters causes several problems to the synthesis, in particular for the 
stereocontrolled generation of the remote stereocenter. In a recent approach, this  problem was 
solved via the aza-Michael addition of azide to an aminoacid-derived enone, which proceeds via 
acceptable (3:1) stereoselectivity (Scheme 1.23). Conditions for the reaction were optimized in a 
previous PhD thesis[83] where addition of  azides to α-aminoketones was extensively studied.
The complete synthesis  is shown in Scheme 1.23, the initial steps are similar to the diaminodiol 
synthesis and the key step is  the addition of azidotrimethylsilane to the enone double bond. The 
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Scheme 1.23 Synthesis oh Phe-Pro monohydroxyethylene isostere
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reaction was carried out in DCM at -18°C in the presence of brucine and catalytic amount of 
acetic acid; the conditions led to the formation of the (S,S) azidoketone with a 3:1 excess over 
the (S,R) diastereoisoner. This intermediate was then readily converted in three steps to the Phe-
Pro isoster. 
1.2.3.3  Peptidomimetic inhibitors based on Phe-Pro monohydroxyethylene isoster
Two monohydroxyethylene-based inhibitors were obtained by coupling the Phe-[Φ]-Pro isostere 
([Φ]=CHOHCH2) with Ac-TrpVal and DmPoa side chains. As  aspected, the inhibitor with Ac-
TrpVal side chain shows 20 fold higher activity than the DmPoa derivative. 
The monhydroxy derivatives are less active than the corresponding diols, the decrease in activity 
is within an order of magnitude, in the case of DmPoa derivatives, while it appears much 
greater in the case of Ac-TrpVal derivatives. However, it is still compatible with the loss of one 
or two hydrogen bonds (in principle each of the two hydroxyl groups in the diol could be 
involved in two hydrogen bonds with the catalytic aspartate residues, respectively, as donor or 
acceptor).
Entry Inhibitor IC50
1
N
H
Ph
OH
N
O
O
O
AcHN
HN HN O
NHAc
NH
32.7 nM
2
N
H
Ph
OH
N
O
O
O
O
684 nM
Table 1.2 IC50 values of  inhibitors with Phe-[Φ]-Pro isostere core
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Introduction
Hydroxyethylene isosters  offer several advantages over corresponding dihydroxyethylene 
equivalents, namely a higher hydrophobic character which allows a better diffusion through 
plasmatic membrane and better accordance with Lipinski rules of five since one hydrogen 
donating group is left out. 
However, as it was shown in Chapter 1 for inhibitor TS126, if a hydroxy group is simply 
removed, the inhibiting power of a compound is reduced by almost two orders of magnitude. 
This reduced activity is  due to a loss of hydrogen bonds between the inhibitor and aspartic acid 
residues within the catalytic site. A possible solution for compensating this loss of interaction is 
to achieve a better occupation of  the binding site and thus improve VdW interactions 
Figure 2.1 Crystallographic structure of  the complexes between HIV-PR and inhibitor TS126 (a) and 
Nelfinavir (b). The figure shows a better occupation of  the S1’ subsite by Nelfinavir, with respect to TS126
!
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(a)
(b)
From the analysis of the crystallographic structure of the complex  between HIV-Pr and 
hydroxyethylene inhibitor TS126 (Figure 2.1a) we can notice that the pyrrolidine ring does not 
occupy completely the S1’ pocket. Ideally, to achieve good inhibitor-enzyme interactions and a 
good activity of the inhibitor, all of the free space in the cavity of the enzyme catalytic site 
should be occupied by the inhibitor. A good example of this  principle is the commercial 
inhibitor Nelfinavir©, where, in order to achieve better enzyme-inhibitor interactions at the level 
of  the S1’ pocket, the proline ring was replaced by a decahydroisoquinolin bicycle (Figure 2.1b).
Applying the same principle to the TS126 inhibitor, the occupation of the S1’ sub site may be 
improved by increasing the dimension of the heterocyclic ring that mimics proline in the P1’ 
position of the isoster. Thus, as an initial target of this thesis, the synthesis of the Phe-Pro 
monohydroxyethilene core 1 was chosen (Figure 2.2).  In 1 the pyrrolidine ring  is substituted by 
a condensed bicyclic system which should offer a better occupation of  S1’ sub site. 
Figure 2.2 Replacement of  the pyrrolidine ring by a condensed aromatic system 
2.1 Substitution of the pyrrolidine ring with condensed phenyl ring 
The isostere 1 (Figure 2.2), our desired product, presents three different stereocenters: the 
carbon 1 stereocenter derives  from the natural amino acid phenylalanine and has (S) 
configuration; as  for the stereocenter present on carbon 2 we have initially chosen the (R) 
configuration since this  configuration corresponds to that of the reference inhibitor TS126. 
Given that these two stereocenters on adjacent carbons, it is possible that stereocenter on 
position 1 can control formation of the stereocenter present on carbon 2, however such control 
is not as easy for the stereocenter on position 4 that is remote from the other two. In fact, 
control of the stereochemistry of the sterocenter on position 4 represents a key point of the 
BocHN
OH
H
N
1
2
3
4
1
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synthesis. Two possible routes were identified which differ for the approach leading to the 
formation of  the third stereocentere and the related substituted pyrrolidine ring (Scheme 2.1).
BocHN
OH
H
N BocHN
O
H2N
1a
BocHN
OH
H
N BocHN
OH
NH2
X
1b
Scheme 2.1 Possible strategies for the synthesis of  monohydroxyethylene Phe-Pro isosters with a 
condensed bicyclic system
In case of the approach (a), the third stereocenter and pyrrolidine ring are formed 
simultaneously through intramolecular addition reaction of an N-nucleophile to the enone 
double bond. In the approach (b) the stereocenter is  formed first via a Michael addition with 
azide[1], whereas the pyrrolidine ring is formed after by an intramolecular reaction. 
2.1.1 Synthesis via intramolecular addition. Compound 1a
Synthetic approach (a), because of its brevity, appeared the be most promising. Actually, the 
final product can be obtained in just three steps starting from the phosphonate of Boc 
protected phenylalanine and Cbz protected 2-hydroxyindoline as the two partners of initial 
Hornner-Emmons olefination (Scheme 2.2). 
Scheme 2.2 Retrosynthetic analysis of  synthetic approach (a)
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O
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Enone formation, is followed by intramolecular nucleophilic attack of the Cbz protected amino 
group to the enone double bond, which represents the key step of the synthesis. The last step 
of  the synthesis is represented by stereoselective carbonyl group reduction. 
2.1.1.1 Synthesis of N-Cbz-2-hydroxyindoline
The route starts with the synthesis  of N-Cbz-2-hydroxyindoline 3  which can be obtained in two 
steps from 2-indolinone (Scheme 2.3). The Cbz protection of 2-indolinone, proved to be a 
somewhat demanding task. Treatment of 2-indolinone with benzyl chloroformate and NaH in 
dry THF afforded a mixture of products. The same reaction was tried with LDA (Lithium 
Diisopropylamide) as base but the outcome remained the same. When triethylamine was used as 
base and benzyl N-succinimidyl carbonate (CbzOSu) as protective agent, just the starting 
material was recovered. NMR analysis of the product mixture showed that, besides the desired 
N-acylation, also O-acylation had taken place. It was then decided to carry out the reaction 
under milder condition using a biphasic, organic solvent/inorganic base  (Na2CO3.10H2O) 
system.[2] Accordingly, treatment of 2-indolinone with dibenzyl dicarbonate and sodium 
carbonate in THF at room temperature for 10h afforded just the N-protected product 2 in 49% 
yield.
The N-protected lactam was  then reduced with DIBALH in dry THF at -78°C[3], following the 
literature procedure, to furnish N-Cbz-2-hydroxyindoline 3. However, neither the reduction step 
was devoid of problems, as the hydroxy group of the newly formed N-Cbz-2-hydroxyindoline 
readily eliminated to give N-Cbz-indole 4 as byproduct (Scheme 2.3).
Scheme 2.3 a) Na2CO3.10H2O, THF, 10h; b) DIBALH, THF(dry) -78°
N
H
O
N
Cbz
O
N
Cbz
OHa) b)
O
NHCbz NCbz
32 4
New Monohydroxyethylene Xaa-Pro Isosters
46 
2.1.1.2 Synthesis of the enone 6 and cyclization
The cyclic aminal 3  (i.e. the synthetic equivalent of the open form aldehyde 3’) was then reacted 
with the the phosphonate 5a derived from the reaction of N-Boc-L-phenylalanine with lithiated 
methyl-dimethylphosphonate[4] However, under the conditions generally used for the Horner-
Emmons olefination[5] we have obtained almost exclusively the product 7 resulting from the 
nucleophilic attack of the Cbz protected nitrogen to the enone double bond (Scheme 2.4), while 
the α,β-unsaturated ketone 6 is present only in trace amounts.
Scheme 2.4 a) 3, base, EtOH, rt
The same result is obtained when the reaction is carried out in a polar, aprotic solvent like 
acetonitrile, with good ability to dissolve inorganic salts[6] and K2CO3 as a base.
Unfortunately, the cyclization of 6 is  not stereoselective and the heterocyclic compound 7  is 
obtained as a 1 : 1  mixture of diastereoisomers. Since the chromatographic separation of the 
diastereoisomers proved  to be very hard, this route was not pursued any further.
.
2.1.2 Synthesis via azide addition. Compound 1b
Scheme 2.5  reports  the retrosynthetic analysis of the second approach which takes advantage of 
the 1,4  addition of azide to aminoacid-derived enones controlled by a remote chiral center.[1] 
According to this approach, it was planned to obtain the substituted pyrrolidine ring of the 
isostere 1b  by the reduction of a lactam. This can be obtained from an azido-ester which, in 
turn, derives from the stereoselective hydroazidation of the corresponding α,β-unsaturated 
ketone.  
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Scheme 2.5 Retrosynthetic analysis of  synthetic approach (b)
The key point of this synthesis is  the 1,4 addition of azide to an enone, that leads to the 
formation of a new  chiral center which is  distant from the pre-existing stereocenter. This 
reaction was already extensively studied in our laboratories  (Table 2.1) and it was found that a 
high degree of diastereoselectivity can be obtained if the reaction is carried out in DCM with 
azidotrimethylsilane (TMSiN3) as azide donor, in the presence of acetic acid and a catalytic 
amount of  base (brucine or proline methyl ester). 
TMSiN3, AcOHDCM, -18°
amine (0.2 eq)BocHN
R
O
R 1 BocHN
R
O
R 1
N3
BocHN
R
O
R 1
N3
R= Bn, iPr, Me
R1= Bn, iPr,
syn anti
Entry amine syn/anti
1 Et3N 1 : 1
2 (i-Pr)2NH 1 : 1
3
N
N
H
2 : 1
4
N
O
5 : 1
5 brucine 6 : 1
6
H
N COOMe 7 : 1
Table 2.1 1,4 azide addition to enones
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H
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The first step of the synthesis (Scheme 2.6) was the Horner-Emmons olefination of 
phosphonate 5a with the methyl ester of 2-formylbenzoic acid to give the α, β–unsaturated 
ketone 8a. The addition of azide to enone 8a was then attempted following the conditions 
already optimized for azide addition to α-aminoenones (AcOH, TMSiN3, brucine, DCM, -18) 
but the reaction failed to give any product. The same reaction was tried at room temperature, 
with different bases, at reflux in various solvents (DCM, CHCl3, toluene), but always failed to 
give the desired product and in every case the α,β – unsaturated ketone 8a was recovered 
unchanged. This failure could be possibly explained by the presence of the phenyl ring 
conjugated to the double bond of the α,β–unsaturated ketone which delocalizes the charge on 
the double bond, reducing the electrophilic character of the β position. A similar lack of 
reactivity of azide with α, β  – unsaturated ketones conjugated to an aromatic ring was already 
described in the literature[7] where the reaction of cinnamic aldehyde with sodium azide was 
reported to fail to give the desired azidoketone.
Scheme 2.6 a) nBuLi, CH3PO(OCH3)2, THF, -78°C; b) methyl 2-formylbenzoate, K2CO3, EtOH; c) 
TMSiN3, AcOH, base, see text; TMSiN3, TBAF, THF, MW, 80°C
2.1.2.1 Synthesis of enaminones 9
Since the classic procedure for the addition of azide failed to give any result, we decided to use a 
modified approach. It is well known that fluoride ion has  a great affinity for silicon, being the 
Si-F bond among the strongest single bonds. We decided to exploit this affinity and catalyze the 
addition of azide to enone 8a with tetra n-buthylammonium fluoride (TBAF), as fluoride ion 
RHN COOMe
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source. The use of TBAF as an efficient activator for the cycloaddition of TMSiN3 to 
unsaturated organic nitriles[8] and as a catalyst of the TMSiN3 [3+2] cycloaddition to electron 
poor olefins[9] was already reported in the literature.
However, when enone 8a was reacted with azidotrimethylsilane (TMSiN3) and n-
buthylammonium floride in THF at 50°C, much to our surprise, the cyclic α-amino enaminone 
9a was isolated (Scheme 2.6) rather than the expected ketoazide or [3+2] cycloaddition product. 
The reaction was repeated in different solvents and in the microwave reactor, each time 
obtaining the same product. An identical result was obtained with the N-Cbz protected enone 
8b, obtained from N-Cbz phenylalanine (Scheme 2.6) which gave the enaminone 9b  in 
comparable yield. Since, to our knowledge, there are no other examples of direct enaminone 
formation from α,β-unsaturated ketones which do not have a leaving group in the β  position, it 
was decided to investigate this reaction more in detail. This  study will be the subject of Chapter 3 
of  this thesis
Although, the desired azidoketone could not be obtained by this route, nevertheless we decided 
to proceed with the synthesis as  the desired isoster 1b could be in principle obtained from 
enaminone 9 by the stereoselective reduction of the double bond and the carbonyl groups 
(Scheme 2.7)
Scheme 2.7 Reduction of  enaminones 9
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2.1.2.2 Attempted reduction of enaminone 9
Reduction of enaminones represents a challenge as this double bond is  very stable.[10] The 
enaminone system is unusually resistant to reduction, although examples of the reduction of N-
alkylated[11a-h] and N-acylated[11i] compounds have been published. Hydrogenation of an 
unprotected cyclic enaminone to an amino alcohol has also been reported,[12] but very little 
diastereoselectivity was observed. There are also several examples of enaminone reduction with 
high grade of  stereoselectivity; however most of  them use acidic conditions.[13] 
In principle, lithium aluminium hydride (LAH) should reduce the enaminone double bond, 
while leaving the carbonyl group intact, yielding γ-aminoketones;[14] however, when 9a was 
treated with LAH, the opposite was observed and the enaminone double bond remained 
unchanged while carbonyl group was reduced with no stereoselectivity. 
Enaminones can be converted into γ-aminoalcohohols  by treatment with sodium metal in 
isopropanol-THF[15], however treatment of 9a in these conditions yielded only the starting 
material.
In the attempt to modify the electronic properties of the enaminone nitrogen atom, we tried to 
reduce the lactam group first (Scheme 2.7, route b). Once again our attempts were futile and 
frustrating as none of the common procedures for lactam reduction (DIBALH, BH3.THF)[3]
have yielded the desired product and only starting material was recovered. 
Entry Reducing agent Solvent T / °C Outcome
1 LAH THF 25° carbonyl reduction
2 DIBALH THF 25° no reaction
3 Na/iPrOH-THF iPrOH/THF 25° no reaction
4 BH3.THF THF 25° no reaction
5 BH3.THF THF 50° unknown mixture
6 Pd/C (5%), H2 EtOAc/DCM 25° no reaction
7 Pd/C (10%), H2 EtOAc/DCM 25° no reaction
Table 2.2 Attempts of  enaminone 9a reduction
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Catalytic hydrogenolysis  was also attempted, once again without any result. Attempts and their 
outcomes are listed in Table 2.2.
The stereoselective reduction of enaminones to enaminoketones  has been reported to take 
place with sodium triacetoxy- or trifluoroacetoxy borohydride.[13b] The acidic conditions 
required by these reagents are not compatible with the Boc protection of enaminone 9b and the 
corresponding N-Cbz compound was synthesized to this end (Scheme 2.6). 
When 9b was  reduced with NaBH4 (4 eq) and acetic acid (4 eq) in THF/i-PrOH at 0°, no 
reaction was observed and only the starting material was recovered. The same reaction was 
carried out replacing acetic acid with trifluoroacetic acid and increasing the number of 
equivalents; once again, no reduction, or reduction of the ketone group only, was observed 
(Table 2.3). 
Entry Hydride (eq) Acid (eq) Yield
1 NaBH4 (4) AcOH (4)
no reaction or carbonyl 
reduction
2 NaBH4 (4) AcOH (8)
no reaction or carbonyl 
reduction
3 NaBH4 (4) TFA (4) 
no reaction or carbonyl 
reduction
4 NaBH4 (4) TFA (8) 
no reaction or carbonyl 
reduction
Table 2.3 Attempts of  enaminone 9b reduction
Since all our attempts to reduce the enaminone system failed, we have continued the synthesis 
by optimizing the carbonyl group reduction (Scheme 2.7, route c).
2.1.2.3 Carbonyl group reduction of the enaminone 9
Generally, the stereoselective reduction of α-aminoketones  is controlled by asymmetric 
induction and can take place either in the Cram-chelated mode[16] or in the Felkin-Anh mode.[17] 
According to Cram chelation rule (Figure 2.3A), the metal ion coordinates between the carbonyl 
and the protected amino group, this conformational lock blocking the substrate in a structure 
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where the carbonyl and amino groups are synperiplanar while the hydrogen atom and R’ are 
anticlinal. In these conditions, hydride will attack the carbonyl group from the less hindered side 
giving the anti alcohol. According to Felkin-Anh rule (Figure 2.3B), if no chelation is  present, 
the substrate’s  amino group is positioned at a right angle with the carbonyl group, therefore 
maximizing stereoelettronic interactions  in the transition state.[18] In this case, hydride attack 
from the less hindered side gives the syn alcohol.
Figure 2.3 Schematic representation of  α-aminoketone reduction with Cram and Felkin-Ahn models
With NaBH4 in THF (containing 1% H2O) 9a gives a 1.5:1 mixture of anti and syn 
enaminoalcohols  (S,R)-10a and (S,S)-10a. Reduction with LiBH4 in THF(1%H2O) is not 
stereoselective at all and gives a 1:1  mixture of the two enaminoalcohols. It is likely that, under 
these conditions, the metal ion cannot efficiently coordinate with the carbonyl and amino 
groups of the substrate since the carbonyl group is already engaged in a hydrogen bond with 
the ring amide group. (Figure 2.4)
!
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Reduction of 9a with lithium tri-tert-butoxyalluminium hydride (LTBAH) in ethanol gives the 
enamino alcohol (S,R)-10a with 10:1 diastereoselectivity (Table 2.4). The higher selectivity 
observed in this  case can be explained by the formation of a stabie complex between aluminum 
and the amino ketone, which is then attacked by hydride following Cram chelation rule. In 
alcoholic solvents aluminum ion can rapidly exchange alcoxide ligands[19] by dissociative 
mechanism[20] making it a very efficient chelator. In fact, if the same reduction is carried out in 
THF, where ligand exchange is slow, no stereoselectivity is observed. Unfortunately, reduction 
with LTBAH had only 50% conversion, while reduction with other hydrides, including L-
selectride had always conversion rates above 90%. 
BocHN
Ph
O HN
O
Nu (H-) BocHN
Ph
OH HN
O
BocHN
Ph
OH HN
O
(S, R) (S, S)
Entry Hydride(eq) Solvent Conversion (S,R):(S,S)
1 NaBH4(5) THF(1% H2O) >90% 1.5 : 1
2 LiBH4(5) THF(1% H2O) >90% 1 : 1
3 LTBAH(3) EtOH 50% 10 : 1
4 LTBAH(6) EtOH 50% 10 : 1
5 L-Selectride(3) MeOH >90% 1 : 4
Table 2.4 Carbonyl group reduction of  enaminone 9a
BocHN
Ph
O N
OH
Figure 2.4 Hydrogen bond between proton of  the lactam group and carbonyl group 
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In the absence of chelation the reduction of aminoketoness most often occurs via the Felkin-
Anh model, thus leading to syn products.
Recently, it has been reported that the reduction of α-aminoketones with tri-secbutyl 
borohydride (L-selctride) in polar solvents  such as methanol, preferably provides syn 
aminoalchohols.[21] In this case the bulky s-butyl groups make chelation difficult, while at the 
same time providing high sterical discrimination. Applying these conditions to the reduction of 
enaminone 9a, the amino alcohol (S,S)-10a was obtained with 4:1 d.e.
2.1.3 Synthesis of peptidomimetic inhibitors based on enaminone isosters
The work described so far has led to the synthesis of three compounds (9a, (S,R)-10a and 
(S,S)-10a; Figure 2.5) which are to be tested as Phe-Pro dipeptide isosters and core units for 
HIV-Pr inhibitors. Using standard conditions for peptide synthesis in solution we have obtained 
a small set of new  inhibitors (Scheme 2.9), based on the 2,6-dimethyl phenoxyacetic acid 
(DmPOA) and picolinic acid side chains.
Figure 2.5 Compounds to be used as isosters in peptidomimetic inhibitors
2,6-Dimethyl phenoxyacetic acid (DmPOA) was obtained by simple alkylation of 2,6-dimethyl 
phenol with chloroacetic acid in water and sodium hydroxide as a base,[22] or with methyl 
bromoacetate in DMF and potassium carbonate, giving a methyl ester which is then hydrolyzed 
to the free acid (Scheme 2.8). Picolinic acid is commercially available and it was used as such.
Scheme 2.8 i) methyl bromoacetate, K2CO3, DMF, rt; ii) LiOH 1N/THF, rt
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The side chains  were coupled with the three isoster cores  as reported in Scheme 2.9. The N-Boc 
protected enamino isosters were initially deprotected by treatment with trifluoroacetic acid 
(TFA) under standard conditions. However, when this procedure was applied to the 
deprotection of enamino alchohol isosters 10a, degradation of the starting material was 
observed. Thus enamino alcohols 10a were deprotected with TBAF in refluxing THF.[23] After 
deprotection the isosters were reacted with the appropriate acid (DmPOA or picolinic acid). 
Since isosters 9a and 10a  possess a single modifiable amino group they were treated with 1 
equivalent of  the corresponding acid only.
Scheme 2.9 a) TFA/DCM, rt; b) DmPOA, EDC, HOBT, NMM, CH3CN, rt; c) picolinic acid, EDC, 
HOBT, NMM, CH3CN, rt
2.1.3.1 Evaluation of biological activity
The the six compounds (11-16) thus obtained, where evaluated for their ability to inhibit HIV-Pr 
using the method described in the Appendix. The concentration of the inhibitor during the 
screening was 100 μM while HIV-Pr concentration was  0.4 nM. The value of the residual 
activity of the enzyme for the compounds with the enamino alcohol isoster  (13-16) was around 
50% for all four compounds. There are probably several reasons for this relatively modest 
inhibition. First of all, only the S2, S1, S1’ sites of the enzyme, at the best, can be engaged by the 
inhibitors, thus providing only moderate VdW interactions; secondly, the presence of the rigid 
double bond, with a Z geometry, might not allow  the bicyclic portion of the isoster to align 
efficiently with the S1’ site at which it is targeted. The two compounds (11, 12) based on the 
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enaminoketone isoster showed even lower activity at the given concentration, with the residual 
activity of the enzyme being 89% for compound 11 and 83% for compound 12. This further 
decrease of activity is  most likely due to the loss  of hydrogen bond interactions between the 
inhibitor and catalytic aspartic residues. 
Although these results might not look too exciting, it was not really expected that small and 
rigid structures like 11-16 would be highly efficient inhibitors. These should be considered no 
more than intermediates en  route to the more complex systems initially designed based on 
isosters 1a  and 1b. On the other hand, the synthetic work described in this part of the thesis has 
led to an efficient synthesis of aminoalcohols (S,R)-10a and (S,S)-10a. Their conversion to the 
final target 1b (Scheme 2.10) will represent the logical development of  this work.
Scheme 2.10 Future developments toward the synthesis of  isoster 1b
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Direct Amination of α,β-Unsaturated 
Ketones with Azidotrimethylsilane
Introduction
In the course of our studies on the synthesis and in vitro evaluation of HIV-Pr inhibitors we 
have discovered a novel reaction, namely the direct amination of α,β-unsaturated ketones to 
give enaminones (see Chapter 1). Enaminones have proven useful as precursors in organic 
synthesis[1] and in the synthesis of heterocyclic compounds.[2] Furthermore, they have been 
found to be useful in pharmaceutical development[3] In general, the synthesis of enaminones is 
not straightforward. Metal mediated reduction of oxazolines[4] and reaction of 1,3-diketones 
with amines  are the main synthetic methods to generate them. Recently, Muller et al. have 
described a sequential protocol which uses the reaction of an acid chloride and acetylenes under 
Sonogashira conditions (Pd(PPh3)3Cl2, CuI) followed by an attack of primary or secondary 
amines to generate these important intermediates.[5] In contrast to these methods, the direct 
amination of α,β-unsaturated ketones is  extremely simple, versatile and generates isomerically 
pure enaminones in moderate to good yields.
To our knowledge there are only few  examples of direct enaminone formation from α,β-
unsaturated ketones that do not have a leaving group in the α-position. Seko and Tani reported 
the preparation of enaminones by amination of chalcone with metoxyamine followed by 
treatment with tBuOK in THF or DMF.[6] Other examples are limited to the palladium-
catalyzed arylamination or amidation.[7] The reaction described herewith is the one-step 
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preparation of enaminones by treating α,β-unsaturated ketones with TMSiN3 and TBAF under 
microwave irradiation or by conventional heating.
We were interested in preparing β-azido ketones bearing an aromatic ring via 1,4 aza-Michael 
addition of azides  to α,β-unsaturated ketones (Chapter 2, par. 2.1.2). When this reaction was 
carried out by treating enone 8a with TMSiN3 and TBAF in THF at 50°C we were surprised not 
to find the desired β-azido ketone 17 (Scheme 3.1). The major product formed in this reaction 
was instead characterized as the isomerically pure (Z) enaminone 9a. This undesired reaction 
product was thought to arise from the cyclization of the primary enaminone 18 initially formed. 
We were intrigued by the mechanism by which formation of 18  took place and by the potential 
synthetic utility of  similar enaminone products and decided to study the reaction in detail.
BocHN
Ph
O COOCH3
Si
N3
a)
BocHN
Ph
O COOCH3NH2
BocHN
Ph
O HN
O
BocHN
Ph
O COOCH3N3
8a
17
9a18
Scheme 3.1 a) TBAF.3H20, THF, 50°
3.1 General synthesis of enaminones
To test the synthetic utility of this method we prepared a set of α,β-unsaturated ketones 
(Scheme 3.2) and studied their reaction with azidotrimethylsilane (TMSiN3) and tetra-n-butyl 
ammonium fluoride (TBAF) in THF at 50°C (Table 3.1). 
Enones 19-21 were prepared from the corresponding aminoacids, via phosphonates 5a,c and 
reaction of the latter’s  with the appropriate aldehydes, as described in Chapter 2  for compound 
8a (Scheme 3.2). Chalcone 22 was obtained from the base-catalyzed condensation of 
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acetophenone and benzaldehyde. Enone 23  was  obtained by the aldol addition of acetophenone 
enolate to pentanal, followed by dehydration of  the aldol.
Scheme 3.2 a) nBuLi, CH3PO(OCH3)2, THF, -78°C; b) K2CO3, EtOH; c) NaOH, PhCHO; d) i: LDA, 
pentanal; ii: TsOH
The reaction was initially optimized on substrate 8a and it was found that both the conversion 
and the yield of cyclized product 9a improved at 90 °C in toluene for 20 h. The use of a 
microwave reactor allowed to reduce the reaction time to 20 min and further increase 
conversions and product yields. All reactions  of Table 3.1 were thus carried out in THF, in a 
sealed vial, at 90 °C for 20 min, under µw irradiation (200W). 
Under these conditions, all enones  gave the corresponding enaminones in fair to good yields 
(Table 3.1). Removal of the ester group of 8a, as  in enone 19 had little or no impact on the yield 
and outcome of the reaction (entry 2). Replacement of the terminal phenyl ring with an 
isopropyl group (entry 3) did not produce any significant change in the reaction course, 
indicating that a phenyl ring in this  position is not essential for enaminone formation. 
Replacement of Boc protection (entries 1-3) with Cbz and replacement of the benzyl group of 
phenylalanine with the isopropyl group of valine (entry 4) has little effect, and the 
corresponding enaminones are also obtained in comparable yield when chalcone (entry 5) and 
enone 23 (entry 6) are reacted in the same conditions. However, methyl vinyl ketone (entry 7) 
failed to give the expected product, probably due to polymerization and partial loss through 
evaporation of the highly reactive and volatile enone. No reaction was observed with styrene 
(entry 8) and the starting material was recovered unchanged, indicating that this reaction 
requires an activated double bond to take place. Similarly, no reaction was observed when the 
enones were treated with TMSiN3 without TBAF.
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Entry Enone Producta Yield (%)
1
BocHN
Ph
O COOMe
BocHN
Ph
O HN
O
59
2
BocHN
Ph
O
BocHN
Ph
O NH2
45
3
BocHN
Ph
O
BocHN
Ph
O NH2
43
4
CbzHN
O
CbzHN
O NH2
37
5
O O NH2
40
6
O O NH2
58
7 O X 0
8 X 0
Table 3.1 a Product obtained by treatment of  enones with TMSiN3, TBAF in THF at 90° under 
microwave irradiation
3.1.1 On the reaction mechanism
It was shown in the previous paragraph that tetrabutylammoniumfluoride is  essential for the 
reaction between enones and trimethylsilylazide to take place. It can thus be postulated (Scheme 
3.3) that the first step of the reaction is the formation of a pentacoordinated complex  by attack 
of fluoride on silicon. Considering the typical reactivity of azides, two pathways would then be 
open to the activated silicon complex (Scheme 3.3): a) transfer of azide to the enone to give a 
1,4-addition product, or b) formation of  a triazoline by a 1,3-dipolar cycloaddition reaction. 
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Scheme 3.3 Scheme of  the proposed mechanism of  enaminone formation reaction
In order to test the 1,4-addition pathway, the ketoazide 29 was  synthesized by treating enone 20 
with TMSiN3, acetic acid and brucine in dry DCM (Scheme 3.4) to obtain corresponding 
ketoazide. When this ketoazide was treated with TBAF in THF, at 90 °C, in a microwave 
reactor, no reaction took place, indicating that the ketoazide does not lie in the path to the 
corresponding enaminone. Thus the 1,3-dipolar cycloaddition pathway can be proposed for the 
formation of the enaminones. According to this pathway (Scheme 3.3) the initial cycloadduct 
eliminates trimethylsilyl fluoride and N2, to give an azadienolate which is  finally protonated to 
yield the product.
Scheme 3.4 a) TMSiN3, AcOH, brucine, DCM, r.t.; b) TBAF.3H2O, 90°
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3.1.1.1 Preliminary calculations
In the mechanism of Scheme 3.3 it is proposed that formation of a pentacoordinate silicon 
complex activates trimethylsilylazide towards 1,3-dipolar cycloaddition, which does not take 
place in the absence of fluoride. To test this hypothesis the electronic structure of the 
pentacoordinate silicon intermediate has been studied in more detail.
The geometries of TMSiN3 and of the fluorinated intermediate have been optimized at the 
DFT – B3LYP/6.311++G(d,p) level of theory and the energies of the frontier orbitals  have 
been calculated for both species. Data in Table 3.2 clearly show  that the HOMO is essentially 
located on the azido group and that its energy increases by a significant amount upon fluoride 
coordination. As the 1,3-dipolar cycloaddition is controlled by the dipole’s  HOMO – 
dipolarophile’s LUMO interaction, the pentacoordinated silicon azide should indeed be more 
reactive than trimethylsilylazide.
EHOMO, eV ELUMO, eV
Si
N3
-0.26859 -0.02165
Si
N3
F
-0.16247 0.14055
Table 3.2 The geometries of  TMSiN3 and of  the fluorinated intermediate have been optimized at the 
DFT - B3Lyp/6.311+ +G(d,p) level of  theory; On the right: B3Lyp/6.311++G(d,p) optimized HOMO of 
the pentacoordinate silicon intermediate
3.1.1.2 Treatment of enones with di-substituted C3 position
The mechanistic hypothesis of Scheme 3.3 was further tested on the β-disubstituted enones 30 
and 31. The enones were synthesized (Scheme 3.5) by treatment of benzonitrile with lithiated 
dimethylmethylphosphonate to form a ketoimide phosphonate. Acetone or cyclohexanon was 
then added for in situ  Horner-Emmons olefination which yielded the corresponding unsaturatd 
imines which were finally hydrolyzed to give to enones.[8] 
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Scheme 3.5 a) nBuLi, THF (dry), -78°; b) acetone, r.t.; c) cyclohexanone, r.t.; d) 5N H2SO4, r.t.
In the 1,3-dipolar cycloaddition mechanism proposed in Scheme 3.3, elimination of N2 is 
accompanied by the migration of a proton from the enone β-carbon to the neighbouring 
nitrogen. The presence of a proton in this  position is  thus essential for enaminone formation 
and it may be expected that substrates lacking this proton would not be able to give enaminones 
upon reaction with TMSiN3 and TBAF. 
Accordingly, the reaction of enones 30 and 31  under standard conditions [TMSiN3, TBAF, THF, 
90° MW(200W)] did not yield the corresponding enaminones  but instead gave the ketoazides 
32, 33  resulting from (formal) 1,4-addition (Scheme 3.6). This result is consistent with the 
proposed mechanism as the ketozides can be formed by the collapse of the triazoline 
intermediate when no proton transfer can take place from the β-carbon. 
Scheme 3.6 Supposed mechanism of  triazoline opening and azide formation
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3.1.2 Double bond geometry
As it was mentioned earlier, all enaminones have the Z geometry of the double bond, which 
makes a strong intramolecular hydrogen bond possible between the enaminone’s NH and C=O 
(see Figure 3.1). This  geometry was confirmed by NOE experiment; enaminone 9a  is shown as 
an example (Figure 3.1). Irradiation of the vinyl proton at 6.00 ppm, gives  a clear enhancement 
of the two benzyl protons, of the alpha proton and of an aromatic proton of the bicyclic 
system (shown in blue in the figure). The latter interaction is  only possible if the vinyl proton 
and the aromatic ring are cis with respect to the double bond, thus confirming the Z geometry.
Figure 3.1 Irradiation of  the vinyl proton singlet at 6.00 ppm induces enhancment of  the signals assign to  
benzyl protons (CH2Ph), alpha proton (CHNH) and one of  the aromatic protons; this is possible only in 
the case of  the Z isomer
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Monohydroxyethylene isosters containing a 
triazole ring
Introduction
In the recent years[1] the use of so-called “click  chemistry”, reaction between an azide and a 
generic alkyne with the formation of the fuctionalized triazole, has acquired an important role 
in the synthesis of biologically active compounds.[2] Recently, this approach was used for the 
synthesis of analogs of HIV-Pr inhibitors such as Amprenavir© and Indinavir©, leading to 
structures that have shown activities which are comparable or even better, of the reference 
inhibitors (Figure 4.1).[3]
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Figure 4.1 Aprenavir©, Indinavir© and corresponding triazole containing analogues 
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We have developed in the past a methodology for the stereoselective hydroazidation of α’-
amino-α,β-unsaturated ketones that was found to proceed with remarkable selectivity in favor 
of the syn  product.[4] The reaction is carried out with a 1:1 mixture of acetic acid and 
azidotrimethylsilane, and in the presence of a moderatly basic catalyst as  proline or brucine (See 
Table 2.1, Chapter 2). Under these conditions, the reaction can occur with stereoselectivity as 
high as 1:7, being chiefly controlled by the substrate via a 1,4 induction.
We have reasoned that such a way, to azidoketones could offer a useful entery point towards 
stereo pure azido-alcohol , and by this route towards libraries  of potential HIV-Pr inhibitors of 
general structure shown on Figure 4.2.
Figure 4.2 General structure of  a potential HIV-Pr inhibitors
Such a general structure allows combinatorial chemistry at P2 position by differential acylation at 
nitrogen (R), and on the other side contains a second differentiation point (W) at the triazole 
ring. There are no known structures of HIV-Pr inhibitors obtained by click-chemistry, however 
a model has been reported[3] in which the triazole ring lies in a non-conventional arrangement 
outside the classical protease sub site, replacing the so called “flap” water molecule which links 
the protease substrate to the upper protease flaps with a network of hydrogen bonds. Under 
this point of view, the triazole ring could be regarded as an active scaffold capable to bring the 
R’ group towards S2’ being both S1’ and S1  filled by the benzyl groups of  the isoster.
In an alternative hypothesis the proline pyrrolidine and the triazole ring could be considered 
analogues (Figure 4.3), with advantage for the latter, as triazoles have the possibility to create a 
network of hydrogen bonds within the catalytic site of HIV-Pr and thus stabilizing the enzyme-
inhibitor complex.[5] In this view  W could be regarded as part of the S1’ interacting region of 
the molecule, and also by this  way the affinity could be enhanced, as it is  known that S1’ is not 
entirely filled by the proline ring in Xaa-Pro inhibitors.
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Figure 4.3 Triazole ring of  the isoster is mimicking the proline ring of  the Phe-Pro dipeptide
4.1 Strategy towards new triazole containing inhibitors
The general synthetic strategy for the synthesis of isostere is described on Scheme 4.1 as 
retrosynthetic analysis. The triazoyl alcohol is  formed after [3+2] cycloaddition of alkynes to the 
azido alcohol, obtained after the reduction of the keto-azide, which in turn was obtained threw 
the 1,4 aza-Michael addition of  azide to the double bond of  the α,β-unsaturated ketone.
The R side chain which will be attached to the amino group of the isoster as well as substituent 
group of the triazole ring were selected using the combinatorial approach reported on Scheme 
4.2.
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Scheme 4.1 Retrosynthetic analysis for triazole containing inhibitors
Chapter 4
70
We have synthesized twelve small libraries by varying six  different subsituents on triazole ring 
and six different lateral chains. Aminoacids as triptophan or asparagine, dipeptides  Trp-Val, and 
well known aminoacid isosters as dimethyl-phenoxy acetic acid, quinoline-3-carboxylic acid and 
kynureic acid were added at R, according to the known sequence selectivity of HIV-Pr. As to W, 
sets of linear, branched, cyclic and aromatic moieties were set up according to the commercial 
availability of  terminal acetylenes.
Synthesized libraries  were then tested in biological assay against HIV-Pr at the concentration of 
10 μM. The compounds from the libraries which showed a promising  activity threw  the assay 
were synthesized as optically pure compounds, after optimization of their synthesis. (Figure 
4.4).
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Scheme 4.2 Combinatorial approach used for the synthesis of  the chemical libraries; 1) K2CO3, phenyl 
propion aldehyde, EtOH; 2) TMSiN3, AcOH, brucine, DCM, r.t; 3) NaBH4, MeOH; 4),9) alkyne-W, 
CuSO4, Cu turnings, tBuOH, 5O°C, 5 days; 5),7) TFA in DCM 40%; 6),8) R-COOH, NMM, HOBt, EDC, 
DCM, r.t
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4.2 General synthesis of triazole inhibitors
4.2.1 Synthesis of azido-alcohol
The synthesis started from the commercially available Boc protected phenyl alanine which was 
converted to the phosphonate 5a of Boc protected phenyl alanine with a procedures  already 
described in Chapter 2. Thus obtained phosphonate then engaged Horner-Emmons reaction 
with phenyl propion aldehyde which resulted in formation of  enone 33.
Treatment of enone 33 with azidotrimethylsilane (TMSiN3), acetic acid with the presence of 
brucine as catalyst in dry dichloromethane at room temperature yielded diastereoisomeric 
mixture 2.5 : 1 in favor of the syn  keto-azide (34a). When the reaction was carried out at -18°C 
to increase the stereoselectivity, no products were obtained.
Figure 4.4 Compounds synthesized as optically pure disteroisomers
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The syn  keto-azide (34a) was separated from  the anti diastereoisomer (34b) by recrystallization 
from hexane and was used for further reactions. The stereochemistry of the main product was 
assigned in analogy to that previously obtained by ourselfs on similar substrates.
Stereoselective reduction of 34a with L-selectride and tri-tert-butoxy alumunium hydride 
(LTBAH) did not give the desired alcohol, instead in both cases deazidation took place and we 
got back the α,β-unsaturated ketone 33. So NaBH4 and LiBH4 were employed as reducing 
agents, this time we did not observed any deazidation, however the reduction was not 
stereoselective and diasteroisomeric mixture of azido alcohols 35a and 35b  in 3:1 ratio was 
obtained. Both the diastereoisomers were separated, by recrystallization from petroleum ether, 
and used for further reactions (Scheme 4.3).
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4.2.2 Synthesis of triazoyl alcohols and conversion to final inhibitors
Triazoyl alcohols were synthesized starting from diastereoisomerically pure azido alcohols 35a 
and 35b  respectively which underwent [3+2] cycloaddition with two different alkynes  (Phenyl 
propargyl ether propargylpropargyland 4-methyl-1-pentyene). Triazoyl alcohols (Table 4.1, entry 
1-8) were synthesized following standard condition for alkyne-azide Huisgen cycloaddition in 
which the azido-alcohols were condensated with corresponding alkynes in presence of CuSO4 
and copper turnings in tert-butanol at 50°C.[5] Deprotection of the Boc group followed by 
coupling, in standard coupling conditions, with three different carboxylic acids (picolinic acid, 
Scheme 4.3 a) K2CO3, phenyl propion aldehyde, EtOH (abs), r.t; b) TMSiN3, AcOH, brucine, DCM, r.t; 
c)recrystallization from hexane; d) NaBH4, MeOH
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2,6-dimethylphnoxyacetic acid, 2-methylphenoxyacetic acid) gave the final compounds 40-49 
(Table 4.1 and Figure 4.4).  
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Scheme 4.4 a)  alkyne-W, CuSO4, Cu turnings, 
tBuOH, 5O°C, 5 days; b) TFA in DCM 40%; c) 
R-COOH, NMM, HOBt, EDC, DCM, r.t
Entry -OH* R W Yield
a 
%
1 R N O Ph 76
2 R O
O Ph
58
3 R O O Ph 66
4 R N 56
5 R O 48
6 S N O Ph 71
7 S O O Ph 62
8 S O
O Ph
59
9b S N 46
10b S O 35
Table 4.1 Realized triazole ring containing inhibitors; 
aOverall yield calculated starting from corresponding 
azido-alcohol; bCycloaddition carried out in microwave 
reactor (200W, 30 min, 100°C), CuI, CH3CN/H2O 1:1
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Cycloaddition of optically pure azido alcohol 35b and 4-methyl-1-pentyene, when carried out in 
above described conditions, did not yielded any product and after five days of reaction time just 
the starting material was recovered. 
It was then decided to transfer the reaction into microwave reactor and to change the copper 
source from system Cu\CuSO4 to CuI. First attempts to do the cycloaddition in microwave 
reactor were carried out in tert-butyl alcohol (tBuOH), however we have fail to observe any 
product formation when the reaction was carried on 60°C for 10 or 20 minutes.
BocHN
Ph
Ph
2
N3OH
CuI, CH3CH/H2O 1:1MW BocHN
Ph
N
Ph
N
N
OH
2
Entry P(W) T ( °C Time (min) Solvent Conversion
1 100 60 10 tBuOH /
2 100 60 20 tBuOH /
3 200 75 10 tBuOH /
4 300 100 10 tBuOH /
5 200 60 20 tBuOH/H2O 1:1 low
6 200 85 40 tBuOH/H2O 1:1 low
7 300 90 20 tBuOH/H2O 1:1 low
8 300 100 60 tBuOH/H2O 1:1 low
9 100 100 10 CH3CN/H2O 1:1 low
10 200 100 30 CH3CN/H2O 1:1 complete
Table 4.2 Several conditions tested for alkyne-azide Husigen cycloaddition between azido-alcohol Xb and 
4.methyl-1-pentyene
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Effectuating the reaction on higher temperature did not yielded any result because of inability 
of the tBuOH to achieve higher temperatures under microwave irradiation. When instead of 
pure tBuOH, a tBuOH:H2O 1:1 mixture was used, we have observed some product formation, 
however neither this  time the set temperatures were reached and it was decided to substitute 
tBuOH with acetonitrile which could achieve higher temperatures more easily. Finally, after 
conducting the reaction at 100°C in mixture of CH3CN:H2O 1:1 for 30  min we have observed 
full conversion of  the reagent and the desired product 39 was formed.
4.3 Biological assay of realized triazole ring containing inhibitors
Once the synthesis of this small library of triazole based inhibitors  was  finished, we have passed 
to the stage of evaluation of their biological activity using the method described in Appendix. 
Unfortunately, just eight from ten synthesized inhibitors were screened in biological assay. The 
inhibitors 48 and 49 were synthesized after the first eight inhibitors were already tested, however 
because of lack of the enzyme we haven’t been able to effectuate the assay with last two 
inhibitors. Figure 4.5  shows the percentage of residual activity of the enzyme on inhibitor 
concentration of 1 μM. From comparison of the activities of this set of inhibitors some 
conclusions can be drawn.
1) Lateral chains: Inhibitors which have 2,6-dimethylphnoxyacetic acid as a lateral chain seem to 
have the highest activity, while inhibitors coupled with picolinic acid or 2-
methylphenoxyacetic acid have similar activity.
2) Substituent on  triazole ring: Triazole rings were substituted with two different groups. Inhibitors 
bearing isobutyl group show  greater activity when confronted to the inhibitors with the same 
lateral chain and equal geometry of the chiral centers  but barring phenoxymethyl group as  a 
substituent on triazole ring. Triazole ring with its subsistent should occupy the S1’ sub site of 
the enzyme. It is possible that due to the bulkiness and due to the rigidity, the phenoxymethyl 
group does not fit well in S1’ sub site while more mobile isobutyl group can occupy the S1’ 
pocket better. 
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2) Configuration at  C3: As can be noted from Figure 4.5, inhibitors based on isoster (S,S,S) had 
shown greater activity then their (S.R,S) diasteroisomers.
4) Nature of C2 and C5 stereocenter: The geometries of C2 and C5 chiral center were fixed to (S) 
configuration and weren't changed which corresponds to the configuration of phenylalanine 
and proline residues in natural substrates. 
Figure 4.5 Biological assay of  synthesized compounds; Y axis: Residual activity of  HIV-Pr on inhibitor 
concentration of  1μM expressed in percentage 
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A Ring Closing Metathesis Strategy Towards 
Hydroxyethylene Isosters
Introduction
The olefin metathesis reaction[1] has been, for decades since its inception, more of a chemical 
curiosity than a synthetic tool.[2] The key factor that accelerated its use in synthesis  has been the 
introduction of stable, well-defined catalysts by Grubbs (Ru-based)[3] and Schrock (Mo-based),[4] 
which are able to tolerate a large number of functionalities. Another factor that proved to be 
important in accelerating the use of this  reaction has been increase in mechanistic 
understanding of the reaction,[3] and the advent of useful strategies to control the olefin 
equilibrium distribution, which is unavoidably formed in a typical metathesis. The 
intramolecular version (ring-closing metathesis, RCM) has been especially successful, because it 
often forms ethylene as byproduct, which evaporates from reaction environment and drives  the 
equilibrium toward the formation of cyclic product.[5] The driving force for RCM is primarily 
entropic, because one substrate molecule affords  two molecules  of product. Besides  RCM, there 
are other types of olefin metathesis (Scheme 5.1); the ring opening metathesis  polymerization 
(ROMP) of monomers containing strained, unsaturated rings represent one of the earliest 
commercial applications of olefin metathesis. The driving force for ROMP is the ring-strain 
release,[6]  which  also determines the irreversible nature of ROMP, as  the reverse pathway, back 
to the cyclic compound, has to overcome a significant thermodynamic barrier. On the other 
hand, cross metathesis (CM) is more challenging than both RCM and ROMP, as it lacks the
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entropic driving force of RCM and the ring-strain release of ROMP, which can lead to relatively 
low  yields  of the desired cross-product. Other types of olefin metathesis reactions include 
acyclic diene metathesis polymerization (ADMET), ring-opening cross-metathesis (ROCM) and 
ring-rearrangement metathesis (RRM).
The generally accepted mechanism for olefin metathesis was originally proposed by Chauvin 
and Herisson in 1970.[7] According to this mechanism, olefin metathesis proceeds through 
metallacyclobutane intermediates, generated by the coordination of the olefin to a metal 
alkylidene, via series of alternating [2+2]-cycloadditions and cycloreversions (Scheme 5.2).[8] 
Because of the reversibility of all individual steps in the catalytic cycle, an equilibrium mixture 
of olefins is obtained. For the metathesis  to be productive and useful, it is necessary to shift the 
equilibrium in one direction. The goal is to achieve high yields of the cross-product with a 
minimal amount of competing dimerization (self-metathesis) products. In the majority of 
metathesis reactions, particularly when the produced olefin is required for a further 
stereoselective transformation (such as epoxidation) E/Z selectivity is also a critical issue. 
Despite its effectiveness, a major issue with metathesis reactions is the synthesis of nitrogen 
containing systems, as  the presence of basic amino groups may interfere unproductively with 
catalytic activity since ruthenium has a great affinity for nitrogen ligands. Therefore, a strategy 
has to be developed to prevent coordination of the electron pair of the nitrogen atom with 
metal-alkylidene complexes.
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Scheme 5.1 Most common types of  olefin metathesis reaction
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Our objective at this point was  the development of an alternative methodology for the synthesis 
of  dipeptide Phe-Pro isosters based on olefin metathesis. 
Our idea was to use olefin metathesis  for the synthesis of hydroxyethilene and 
dihydroxyethylene  isosters and the proposed synthetic strategy is presented on Figure 5.1 as a 
retrosynthetic analysis. The key precursor for the synthesis is alkene 50 which can be obtained 
after metathesis  of the two terminal amino olefins (53 and 56) which can be obtained from the 
corresponding amino acids.
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Scheme 5.2 Catalytic cycle of  olefin metathesis
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Figure 5.1 Retrosynthetic analysis towards Phe-Pro isoster using metathesis approach
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The alkene can be converted into dihydroxyethylene isosters by dihydroxylation of the double 
bond or into monohydroxyethylene isosters by hydration or by epoxidation and epoxide 
reductive opening.
5.1 Synthesis of terminal amino olefins
The first objective in this synthetic pathway was the synthesis of the amino olefins deriving 
from corresponding amino acids. The conversion of amino acids to amino olefins is not a 
simple task and the key step of the synthesis, namely the olefination of an intermediate 
aldehyde, has been recognized as  highly challenging because of the easy racemization of 
aminoaldehydes in basic conditions.[9] Nevertheless, we have successfully synthesized two amino 
olefins starting from Boc protected L-phenylalanine and L-proline.
5.1.1 Amino olefin synthesis from L-phenylalanine
The synthesis (Scheme 5.3) started from Boc-protected phenylalanine which was converted into 
the corresponding Weinreb amide 51 by treatment of Boc protected L-phenylalanine with 
isobutylchloroformate, N,O-dimethylhydroxylamine hydrochloride and N-methyl-morpholine 
(NMM). Reduction of the Weinreb amide with lithium aluminium hydride (LAH) in dry diethyl 
ether gave Boc protected phenylalanal 52 in very good yields. As the aldehyde of phenylalanine 
is known for its rapid racemization,[10] the aldehyde 52 was immediately subjected to a Wittig 
olefination, using methyltriphenilphosphonium bromide and potassium bis(trimethylsilyl)amide 
(KHMDS) to give the allyl carbamate 53 in 58% yield without loss of  the optical activity. 
BocHN
Ph
O
OH a) BocHN
Ph
O
N O b) BocHN
Ph
O c) BocHN
Ph
535251
Scheme 5.3 Olefination of  Boc-L-phenylalanine; a) isobutylchloroformiate, NMM, N,O-
dimethylhydroxyamine HCl, DCM, -15°; b) LAH, EtO2 (dry); c) Ph3P+CH3Br-, KHMDS, toulene (dry), r.t
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5.1.2 Amino olefin synthesis from L-proline
The procedure used for olefination of L-phenylalanine was also used in the case of L-proline. 
However, when the Boc-protected Weinreb amide of proline was reduced with LAH product 
was recovered in poor yields (10%). Similar yields were obtained when the Boc-protected 
methylester of proline was reduced with DIBALH in dry toulene, so a different road was 
chosen for the synthesis of  this amino olefine.[11] 
According to this method (Scheme 5..4), Boc-protected proline was first reduced to prolinol 54 
with borane dimethyl sulfide (BH3 DMS) in dry THF, then the prolinol 54 was treated with 
pyridinium chlorochromate (PCC) to obtain the aldehyde 55. Aldehyde was  then made to react 
with Ph3P+CH3Br- and n-buthyl lithium (nBuLi) at 0° to obtain the desired product 56 with 
preserved optical activity.
However, also this procedure gave a very low  overall yield (≅10%) so the protocol needs  to be 
optimized for the future applications.
5.2 A Cross-metathesis (CM) approach for the cross-coupling of amino 
olefins 
The first attempt to synthesize the alkene 50  was through cross-metathesis. As is the case with 
most transformations, the two most important questions concerning any CM reaction are those 
of efficiency and selectivity. The objective is to obtain high yields of the cross-coupled product 
N
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O c) N
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54 55 56
Scheme 5.4 Olefination of  Boc-L-proline; a) BH3 DMS, THF (dry), r.t; b) PCC, AcOH, DCM, r.t.; c) 
Ph3P+CH3Br-, nBuLi, THF, 0°C
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with minimal amounts of homodimerized products. In addition, as the alkene 50 is  to be used 
as a substrate for further transformations, it would be convenient  to obtain E/Z selectivity.
The CM reaction between allyl carbamates 53 and 56 was initially attempted using the first 
generation Grubbs catalyst (G1); however, after 24h the starting materials were recovered 
unchanged. A similar lack of reactivity was reported in the literature when the dimerization of 
allyl carbamates was 
attempted with the same catalyst.[12] When G1 catalyst was replaced with second generation 
Grubbs catalyst (G2) the desired cross-product was obtained together with two homodimerized 
products in equal amounts (Scheme 5.5). 
The reason for the low  selectivity is that both olefins  used in the CM reaction have a similar 
reactivity. When this is the case, the rates of homodimerization are similar and the reactivities of 
the homodimers and cross products toward secondary metathesis events are high. In these 
reactions, the desired cross product is  equilibrated with the various homodimers through 
secondary metathesis  reactions, which usually results in a statistical product mixture.[13] Since the 
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Figure 5.2 Catalysts used; G1= 1st generation Grubbs catalyst; G2 2nd generation Grubbs catalyst; HG1= 
1st generation Hoveyda-Grubbs catalyst; HG2= 2nd generation Hoveyda-Grubbs catalyst
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Scheme 5.5 CM between two allyl carbamates 53 and 56; a) G2, DCM, reflux
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selectivity towards the CM product was not increased even when the reaction was runed with an 
excess of the homodimer of allyl carbemate 53, we have abandoned the CM approach and 
concentrated on the RCM approach instead.  
5.3 A Ring closing metathesis (RCM) approach for the cross-coupling 
of amino olefins
In contrast to CM the ring closing metathesis (RCM) is much more common, as it is  more 
entropically favorable. In the case of the RCM the selectivity problem is switched from 
intermolecular reaction to intramolecular reaction. Traditionally, this  involves a high dilution 
chemistry where low  concentrations are used to prevent molecules  from reacting with each 
other as at low  concentrations, intramolecular reactions are kinetically favored over 
intermolecular ones.
In order to use the RCM for the synthesis of alkene 50  it is necessary to design and synthesize a 
linker, that would allow  easy mounting of two different amino olefins  and their easy cleavage 
from the linker once the macrocycle is formed. The strategy of the synthesis is reported on 
Scheme 5.6 for a bifunctional linker based on conventional carbamate chemistry. 
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Scheme 5.6 RCM synthetic strategy towards hydroxyethylene isosters
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 5.3.1 RCM reaction: The background
The basic RCM reaction consist of two key phases: initiation and propagation (Scheme 5.7). 
The typical Grubbs catalyst is  a 16e- complex and as such has two possible reaction modes with 
an olefin: (1) “associative”, i.e. binding the olefin first to reach the 18e- count and then 
proceeding to products, or (2) “dissociative”, i.e. by shedding a ligand to produce a 14e- 
complex, and then associating an olefin molecule. Kinetic data provided evidence supporting 
the dissociative mechanism for all known Ru-catalyzed metatheses.[14] Therefore, Grubbs 
catalysts usually posses a stationary 2e- donor ligand (L1 in Scheme 5.7) and a dissociating ligand 
(L2 in Scheme 5.7), often a phosphine, but sometimes  (as in 1st generation Hoveyda-Grubbs 
catalyst) a donor atom is intramoleculary linked to the carbene carbon. Halogen ligands (X in 
Scheme 5.7) are usually Cl (Br and I are less effective). Also it is important to note that steric 
interactions between the stationary ligand and dissociable ligand play a major role in the ligand 
dissociation process.[15] 
The second step of the initiation stage is the coordination of the olefin to form a π-complex, 
and this is followed by 2+2 cycloaddition, forming ruthanacyclobutane. In principle, for every 
diene that is not symmetric, there are two possible sites of the initiation (a and b in Scheme 5.7), 
that may lead to two RCM processes, which may be characterized by completely different 
kinetics and selectivities.
Typical ruthenium catalysts are shown in Figure 5.2. Catalyst G1  is a Grubbs “first generation” 
catalyst, characterized by good stability and broad applicability to a wide range of terminal 
olefins. Hoveyda catalyst HG1 represents a variant of G1, where the second phosphine is 
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Scheme 5.7 Mechanism of  the RCM reaction
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absent and is replaced by a pendant ether. This catalyst is characterized by slow  initiation but 
faster propagation rates (due to the absence of a second coordinating phosphine).[16] A major 
development in the field has  been the introduction of imidazolium carbenes as Ru ligands.[17] 
Such catalyst (termed “second generation”) tend to be more active then the “first generation” 
design due to a much faster olefin association step.
Catalysts such as G2 have been broadly generalized by Grubbs, who has explored the effect of 
the electronic[18] and steric factors[19]  in the imidazolium moiety on the catalyst performance 
and scope. Especially robust, effective catalysts are those combining the Hoveyda ether arm 
design with stationary imidazolium ligand, like HG2.
5.3.2 Macrocyclizations 
A very useful concept to describe intramolecular reactivity is that of effective molarity (EM).[20] 
Forming a large ring is an intrinsically difficult problem, due to entropic reasons. At large 
enough concentrations, the termini involved in the desired cyclization will tend to react with the 
termini of another molecule to form dimers and eventually oligomers. This tendency is typically 
expressed with the parameter called effective molarity (EM). The EM of a certain 
intramolecular reaction is defined as the ratio between the kinetic constant for the 
intramolecular reaction and the kinetic constant for the analogous intermolecular reaction 
(EM=kintra/kinter), and has a dimension of a concentration. Its  practical significance lies in the 
fact that one will have to operate well bellow  the EM in order to get reasonable yields of cyclic 
products, instead of  dimers and oligomers.
5.3.3 Linker design
The ideal linker for supporting the RCM of allylamines would have to possess  the following 
properties (1) allow  easy mounting of two different amino olefins; (2) be sufficiently rigid to 
allow  easy macrocycle closure; (3) offer a protection to a free amine functionality preferably 
with electron withdrawing character to minimize a chelation effect of nitrogen to the ruthenium 
metal center and (4) after the macrocyclization the product should be easily cleaved from the 
linker.
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It was resoned that good candidates possessing all the above mentioned properties could be 
obtained from 1,3-benzenedimethanol and its isomers (Scheme 5.8). These linkers offer the 
possibility of attachment of two different amino olefins, they are sufficiently rigid, they have 
electron withdrawing character, they offer protection of amine functionality and because their 
resemblance with the Cbz-protecting group they should be cleavable by catalytic hydrogenolysis. 
A linker was also made based on 1,5-pentanediol, in order to generate a more conformationally 
mobile structure which will be used for comparison during macrocycle closure studies.
5.3.4 Diene synthesis
For the initial studies diene was synthesized from 1,3-benzenedimethanol which was activated in 
situ with one equivalent of N,N’-disuccimydyl dicarbonate and then reacted with allylamine. 
This yielded 67% of the monosubstituted product and 30 % of a disubstituted adduct, to 
increase the yield of the monosubstituted product the reaction was run in the presence of a 
large excess of the dialcohol, this yielded 90% of the monosubstituted product while non-
reacted dialcohol was recovered during column chromatography. The monosubstituted product 
was then isolated and once again activated with N,N’-disuccimydil dicarbonate and then with 
the second amino olefin (derived from phenylalanine) which afforded the desired diene (Scheme 
5.9).
OO
HN
O
R1
NH
R
O =
OH OH
OHHO
HO OH
OH HO
Scheme 5.8 Dialcohols used as linkers
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Following the above procedure we have synthesized two non-symmetric diens m-58 and o-58 
(Figure 5.3) in which allylamine and the the alkene derived from phenylalanine were linked via 
1,2- and 1,3- benzenedimethanol, four symmetric diens in which two molecules of allylamine 
were liked via 1,2-, 1,3-, 1,4-benzenedimethanol and 1,5-pentanediol and one molecule of 
alkene derived from phenylalanine lined via 1,2-denzenedimethanol. These compounds served 
as a model compounds for investigating the macrocycle closure, also with respect to t E/Z.
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Scheme 5.9 General scheme for diene synthesis; a) N,N’-disuccimydil dicarbonate, CH3CN (dry), Py 
(dry); b) amino olefin, TEA, 16h
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5.3.4.1 Synthesis of diprotected dienes
As the RCM of dienes 61 and o,m,p62(three different isomers of benzenedimethanol) proved 
unsatisfactory (vide infra), N-modified compounds 61a  and o,m,p62a and 61b  and m-62b were 
also synthesized (Scheme 5.10). N-Boc (diprotected) dienes 61a and o,m,p62a were obtained by 
reacting the dienes with di-tert-butyl dicarbonate (Boc2O) with catalytic amounts of 4-
dimethylaminopyridine (DMAP) or by treatment with LDA and Boc2O at -78°C which resulted 
in higher yields for some dienes. N-methyl dienes 61b  and m-62b  were furnished by treatment of 
dienes with NaH and CH3I.
5.3.5 Study of macrocycle ring closure 
In the search for the optimal conditions for macrocyclic ring closure we have carried out the 
RCM reaction of substrates 61 and o,m,p62 with three different catalysts  (G1, G2 and HG1). All 
reactions were carried out in dichloromethane. Results are in Table 5.1
Metathesis of dienes 61 and o,m,p62 with first generation Grubbs catalyst G1 (entries 1-5) led to 
the formation of traces, if any, of the RCM product, while the main products were cyclic 
dimers and oligomers, identified by mass spectral analysis of the reaction mixture and resulting 
from competing intermolecular reactions. The situation did not improve with second generation 
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Scheme 5.10 Diprotection of  the dienes; a) Boc2O, DMAP, r.t; b) LDA, Boc2O, -78°C; c) NaH, CH3I, 
0°C 
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catalyst G2. When dienes m-62  and 60  were treated with this catalyst, only isomerisation of the 
double bonds was observed to give corresponding enamines 69 and 70 (Scheme 5.11).
It is not clear whether olefin isomerization is promoted, by the metathesis catalyst itself, 
decomposition products or impurities from the catalyst synthesis. Fürstner and coworkers have 
isolated a ruthenium dihydride complex, RuCl2(PCy3)2(H)2 that they propose may be 
responsabile for olefin isomerization, presumably  through a hydride mechanism.[21] It is clear, 
however, that, RCM isomerization occurs when the metathesis ring-closing event is relatively 
slow due to large ring sizes or conformational issues.
No reactions was observed when RCM was attempted on substrate m-62 with Hoveyda Grubbs 
catalyst HG1 and the reagent was recovered unchanged (Entries 8,9)
Since Grubb’s alkylidene catalysts are known to decompose rapidly in the presence of substrates 
containing a basic nitrogen, we reasoned that substrates in which the nitrogen atoms are 
diprotected by an additional electron withdrawing group might perform better in RCM. To this 
end, substrates 61,o,m,p62  were modified in order to introduce a further Boc protecting group 
on each nitrogen (see Scheme 5.10). Indeed, the diprotected substrates 61a,o,m,p62a furnished 
the corresponding macrocycles in very good (85-95%) yields with both catalysts G1 and G2 
(Entries 10-17), with the only exception of para substituted substrate p-62 (Entry 16). It is likely, 
in this case, that the para substituted linker introduces additional strain in the product, making 
RCM disfavored.
RCM was also carried out on the two N-methyl substituted dienes m-62b  and 61b. Both 
substrates gave the corresponding macrocycles 67  and 66, but in considerably lower yields 
(45-70%) than the corresponding N-Boc derivatives m-62a, 61a. In both reactions cyclic dimers 
were also detected as by-products. Thus it can be concluded that simple N-methylation is 
O
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H
N
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O
H
N
m-62 69
Scheme 5.11 Isomerisation of  a dienes double bond with 2nd generation Grubbs  catalyst; a) G2, DCM, 
reflux, 24h
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sufficient to prevent catalyst decomposition and drive the reaction toward the formation of 
cyclic products. However, N-Boc protection delivers  much better results, probably through a 
combination of steric and electronic factors, both preventing complexation of the protected 
species by the ruthenium catalyst. 
Finally, having found suitable conditions for efficient RCM to take place, with a catalyst load 
reduced to 7% from the initial 15% (Table 5.1), we tested the reaction at higher substrate 
concentrations. However, already at 0.05M substrate, the formation of dimers increases sensibly. 
Thus substrate concentration was kept at 0.02M in all occasions.
5.3.5.1 Controlling the double bond geometry
As we mentioned at the beginning of this chapter, E/Z selectivity is a critical issue when the 
product of the olefin metathesis is required for a further stereoselective transformation, as in 
our case. However, while formation of the E rather than the Z isomer is less critical as both 
isomers can be further elaborated to the desired products (diols, alcohols) via 
stereocomplementary pathways, it is important to obtain RCM products as single isomers, in 
order to avoid tedious and  expensive separations.
During the study of macrocycle closure we have observed that changing the linker has a 
considerable influence on double bond geometry.  In the cyclization of diene Xa, based on the 
meta-substituted linker, two isomers are formed in 1.5:1 ratio (Figure 5.4b). However, cyclization 
of the corresponding ortho-disubstiutited diene Ya proceeded with excellent selectivity, giving 
two isomers in 20:1 ratio (Figure 5.4a). An intermediate selectivity of 8:1 was observed in the 
cyclisation of Xa, based on the flexible linker derived from 1,5-pentandiol. While it was not 
possible to identify the E/Z geometry of the RCM products from the availablee spetroscopic 
data, it is clear that the ortho-benzenedimethanol linker appears to be very promising for future 
applications.
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Figure 5.4 a) 1H NMR in CDCl3 of  the adduct with linker substituted in ortho, showing just one set of  
signals; b) 1H NMR in CDCl3 of  the adduct with linker substituited in meta, showing two sets of  signals 
corresponding to mixture of  E/Z isomers
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(a)
(b)
OO
N
O
N
O
RR
OO
N
O
N
O
RR
DCM
cat
R1R1 R1R1
Entry Substrate C / M cat / mol % T / °Ca Yield (Conv.)
1 m-62 2*10-2 G1(15) 40 10(70) c
2 m-62 2*10-2 G1(15) 80b 12(70) c
3 o-62 2*10-2 G1(7) 40 0(90)
4 p-62 2*10-2 G1(7) 40 0(0)
5 61 2*10-2 G1(7) 40 10(80)
6 m-62 3*10-2 G2(15) 40 0(90)c
7 60 2*10-2 G2(7) 40 10(90) c
8 m-62 2*10-2 HG2(15) 40 0(0)
9 m-62 10-3 HG2(15) 40 0(0)
10 m-62a 2*10-2 G1(15) 40 84(100)
11 m-62a 2*10-2 G1(10) 40 82(100)
12 m-62a 2*10-2 G1(7) 40 86(100)
13 o-62a 2*10-2 G1(7) 40 94(100)
14 60a 2*10-2 G1(7) 40 30(50)
15 60a 2*10-2 G2(7) 40 81(90)
16 p-62a 2*10-2 G1(7) 40 0(0)
17 61a 2*10-2 G1(7) 40 82(100)
18 m-62b 2*10-2 G1(7) 40 67(100)
19 61b 2*10-2 G1(7) 40 44(100)
Table 5.1 Ring closing metathesis of  dienes; ain DCM bin Toluene cremainder is isomerized diene
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5.4 Conclusions and perspective
The work described so far clearly indicates that RCM is an attractive approach to the synthesis 
of  diaminoalkenes precursors of  di- and mono-hydroxyethylene dipeptide isosters.
A novel ortho-benzenedimethanol linker has been developed during this  work which allows 
RCM of aminoalkenes to proceed with high yields and excellent E/Z selectivity. Future 
development of this  new  synthetic method will be focussed on the clevage of the RCM product 
from the linker. Preliminary work has shown that this is possible by catalytic hydrogenation.
The new  synthetic approach will then be applied to the synthesis  of novel protease inhibitors, in 
particular based on isosters of  the Phe-Pro dipeptide.
A further development of this work will be the extension of the RCM approach for the cross-
metathesis of other classes of alkenes. The linker based on ortho-benzenedimethanol is very 
promising in this respect as  may be exploited to bind not only aminoalkenes, as in the present 
case, but any alkene containing a functional group that is able to react with a primary, benzylic 
alcohol.
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Experimental Part
6.1 Instrumentation
Thin  layer chromatography (TLC)  were conducted on pre-coated plastic sheets with 0.25mm 
Merck silica gel 60F-254.
Column chromatography (CC) were carried out with Merck silica gel 60 (230-240 Mesh)
The optical activity measurements([α])  were performed with a Perkin-Elmer 261 
polarimeter at the wavelength of  sodium D band (λ = 581 nm).
Melting points (m.p.) were measured on a Büchi SMP-20
Nuclear magnetic resonance (NMR) 500 MHz 1H-NMR and 125 MHz 13C-NMR spectra 
were obtained on a Varian  Gemini 500 spectrometer. 400 MHz 1H-NMR and 125 MHz 13C-
NMR spectra were obtained on a Jeol JNM-EX400. 270 MHz 1H-NMR and 67.5 MHz 13C-
NMR spectra were obtained on a Jeol JNM-EX270. Chemical shifts are reported in ppm using 
the solvent residual signal as  an internal reference (CDCl3: δH = 7.26 ppm, δC = 77.16 ppm). 
Coupling constants (J) are given in Hz. The resonance multiplicity is  described as s (singlet), d 
(doublet), t  (triplet), q (quartet), dd (doublet of doublets), two d (two doublets), m (multiplet), br 
(broad signal).
Mass spectrometry measurements (MS)  Electrospray Ionization (ESI) performed on a 
Perkin- Elmer API1  at 5600 eV and Electron Impact (EI) performed on a Ion trap GCQ Finnigan 
Thermoquest at 70 eV were recorded at Università degli Studi di Trieste by Dr. Fabio Hollan.
6.2 Materials and General Methods
Chemicals were purchased from, Aldrich, Fluka and Riedel and used as received. Solvents were 
purchased from JTBaker, Fluka and Aldrich, and deuterated solvents from Aldrich and 
Cambridge Isotope Laboratories.
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General solvents such as CH2Cl2, EtN3, Toluene, THF and were distilled from CaH2, Na and 
Na/benzophenone, respectively. Other solvents used were of  synthetic grade.
Low temperature baths were prepared using different solvent mixtures depending on the 
desired temperature: - 78°C: acetone/liquid N2; -10°C: ice/NaCl; 0°C: ice/H2O.
When anhydrous conditions were required, reaction flasks were flame dried placed under 
vacuum (aprox. 1 mmHg) using a Schlenk line and purged with Ar. To adjust the reaction flask’s 
necks silicon stoppers were used, and continuous flux of  Ar was used to keep the inert 
atmosphere. The addition of  reagents was done by means of  plastic or crystal syringes.
6.3 Experimental Procedures
6.3.1 Chapter 2
BocHN OCH3
O
Methyl (2S)-3-phenyl-2-[N-(tert-butyloxycarbonyl)-amino]propanoate Under argon 
atmosphere N-Boc-L-Phe (0.500 g, 1.78 mmol) was added to DMF (4  mL); the solution was 
then stirred for 5 min at 25 C°. KHCO3 solid (0.470 g, 5.59 mmol) was added followed by the 
addition of CH3I (0.350 mL, 5.62 mmol) dropwise. The reaction was stirred for 18 h at room 
temperature until the TLC monitoring system [AcOEt–PE (15:85)] showed no increase in the 
intensity of the product spot. The solvent was removed in vacuo. The residue was partitioned 
between AcOEt (30 mL) and water (10mL). The aqueous phase was acidified to pH 3 with HCl 
1M and extracted with AcOEt (3 x 40 mL). The combined organic extracts were washed with a 
saturated solution of NaCl (40mL), dried over anhydrous Na2SO4 and evaporated to dryness. 
Ester  was obtained as a white solid (0.480 g, 91% yield) [Rf 0.40 AcOEt–PE (15:85)]. 
[α]d=4.6 (c 1.0, MeOH)]; 1H NMR (CDCl3, 400 MHz): δ 1.32 (s, 9H, C(CH3)3 , 2.84–3.11 (m, 
2H, CH2Ph), 3.62 (s, 3H, OCH3), 4.53–4.63 (m, 1H, CHNH), 4.92  (br, 1H, NH), 7.01–7.33 (m, 
5H, Ar); 13C NMR (CDCl3, 100 MHz): δ 28.35 (C(CH3)3), 38.40 (CH2Ph), 52.25 (OCH3), 54.49 
(CHNH), 79.95 (C(CH3)3), 127.07-136.09 (C Ar), 155.13 (CO Boc), 172.41 (CO);  MS (ESI, m/
z): 280 [MH]+.
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OO
O
Methyl 2-formylbenzoate  Under a argon atmosphere 2-carboxybenzaldehyde (2g, 13.3 mmol) 
was added to DMF (30 mL); the solution was then stirred for 5 min at 25 C°. KHCO3 solid (4g, 
39.9 mmol) was added followed by the addition of CH3I  (2.5  mL, 39.9 mmol) dropwise. The 
reaction was stirred for 18 h at room temperature. The solvent was removed in vacuo. The 
residue was partitioned between AcOEt (30 mL) and water (30 mL). The aqueous  phase was 
acidified to pH 3 with HCl 1M and extracted with AcOEt (3 x 25 mL). The combined organic 
fractions were washed with a saturated solution of NaCl, dried over anhydrous Na2SO4 and 
evaporated to dryness. Ester  was obtained as a pale yellow oil 84%. 
1H NMR (CDCl3, 400MHz): δ 3.83 (s, 3H, OCH3),  7.48 (m, 2H, Ar),  7.51 (m, 2H, Ar),  10.46 
(s, 1H, CHO); 13C NMR (CDCl3, 100MHz): δ 52.70 (OCH3), 128.30 (C Ar), 130.33 (C Ar), 
131.92 (C Ar), 132.36 (C Ar), 132.95 (C Ar), 136.97 (C Ar), 166.63 (COOCH3), 192.04 (CHO); 
MS (ESI, m/z): 187 [MNa]+.
O
O
OH
2,6-dimethyl-phenoxyacetic acid 2.44 g (0.02 moli) of 2,6-dimethyl phenol were dissolved in 
10 mL of 50% aqueous  solution of NaOH. After 2h of stirring in the mixture were added 2.03 
g (0.02 mol) of cloroacetic acid and the mixture was heated to 110-120°C, pH was maintained at 
9. After 1h the solution was cooled in the ice bath and acidified with H2SO4 2N until pH was 
slightly acidic. The precipitate was flittered off. Crystallization from toluene with hexane as non-
solvent yielded 2.6 g (73%) of  a white solid.
Mp: 119-120.5 °C; 1H-NMR (CDCl3, 400MHz): δ 2.28 (s, 6H, CH3 x2), 4.33 (s, 2H, CH2O), 
6.8-7.01 (m, 3H, Ar); 13C-NMR (CDCl3, 100MHz): δ 16.2  (CH3), 68.63  (CH2O), 124.78 (C4 Ar), 
129.12-130.68 (Ar), 154.85 (C1 Ar), 173.79 (CO).
N
Cbz
O
Benzyl 2-oxoindoline-1-carboxylate (2)  To a solution of indolinone (250 mg, 1,9 mmol) and 
dibenzyl dicarbonate (591 mg, 2.1 mmol) in THF (50 mL) at room temperature Na2CO3 x 10 
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H2O( 815.5 mg, 1.9 mmol) was added. The reaction mixture was stirred for 10h. Then the solid 
was filtered and washed with THF (30 mL). The filtrates were combined and concentrated 
under reduced pressure. Trituration with diethyl ether furnished 250 mg (49%) of  white solid. 
Mp 109-10° C; 1H NMR (CDCl3, 400Mz): δ 3.66 (s, 2H, CH2CO),  5.45  (s, 2H, CH2O-),  7.12 – 
7.55 (m, 8H, Ar),  7.87 (d, 1H, J= 8.3 Hz, Ar); 13C NMR (CDCl3, 100 MHz): δ 36.42 (CH2CO), 
68.51 (OCH2Ph), 115.22 (C Ar), 123.33 (C Ar), 124.21 (C Ar), 124.53 (C Ar), 128.16 (C Ar), 
128.19 (C Ar), 128.49 (C Ar), 128.67 (C Ar) 135.05 (C Ar), 140.58 (C Ar), 150.77 (CO Cbz), 
172.61 (CON); ; MS (ESI, m/z): 290 [MNa]+.
N
Cbz
OH
Benzyl 2-hydroxyindoline-1-carboxylate (3) To a solution of a Cbz protected lactam 2 (1.30, 
4.86 mmmol) in anhydrous THF, cooled to -78°C under argon atmosphere, a solution of (1.2M, 
6 mL) diisobutyhl-aluminum hydride (DIBALH) in toluene was  slowly added. After 2h the 
reaction was quenched with acetone (2.5 mL) at -78° and saturated aqueous solution of NH4Cl 
(7,5 mL). The system was allowed to reach the room temperature and stirred for additional 40 
minutes  and then filtrated threw  celite pad. The organic phase was then separated and aqueous 
phase was extracted with ethyl acetate. The combined organic fractions were then washed with 
saturated solution of NaCl and dried over anhydrous Na2SO4. The solvent was removed by 
distillation under reduced pressure and the crude product was  purified by column 
chromatography using ethyl acetate/petroleum ether 1/1. The product was isolated as colorless 
oil. (42%)
1H NMR (CDCl3, 400Mz): δ 2.97-3.01 (m, 1H, CH2CHOH), 3.31-3.33  (m, 2H, CH2CHOH), 
3.57 (br, 1H, OH), 5.33 (br, 2H, OCH2Ph), 6.02 (br, 1H, CHOH), 7.17-7.43 (m, 4H, Ar); 13C 
NMR (CDCl3, 100 MHz): 36.52 (CH2CHOH), 67.47-68.65 (CH2Ph), 83.54-83.85 (CHOH), 
123.40-128.33 (C Ar), 136.45-140.67, 150.87 (CO); MS (ESI, m/z): 292 [MNa]+.
6.3.1.1 General procedure for the synthesis of phosphonates 
Butyl lithium solution in hexane (1.6 M, 6eq) was added dropwise to a stirred solution of 
dimethyl methanephosphonate (6eq) in THF (100 mL) under a argon atmosphere at 78 C °. 
The solution was stirred for 10 min at 78 C°. A solution of ester  (1 eq) in THF (80 mL) was 
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added dropwise and stirred for 2 h at 78 C°, whereupon TLC monitoring (AcOEt) showed that 
the reaction had gone to completion. Water  was added to the reaction solution and the aqueous 
layer was  neutralized with HCl 1M. The THF and the water were removed in vacuo and the 
residue was partitioned between AcOEt  and water. The aqueous layer was extracted with 
AcOEt (3 x 30 mL). The combined organic fractions were washed with a saturated solution of 
NaCl (10mL), dried over Na2SO4 and concentrated to dryness. The product was purified by 
crystallization from petroleum ether.
BocHN
O
P
O
OCH3
OCH3
Dimethyl [(3S)-4-phenyl-3-[N-(tert-butyloxycarbonyl)amino]-2-oxobutyl]phosphonate 
(5a) The general procedure yielded 10.5 g (94%) of a white solid starting from methyl ester of 
N-Boc-L-phenylalanine (8.02 g, 0.03 mol), butyl lithium solution in hexane (1.6 M, 67 mL, 0.18 
mol) and dimethyl methanephosphonate (19.23 mL, 0.18 mol).  
Mp 74–76 C°; [α]D = -52 (c=0.4, MeOH); 1H NMR (CDCl3, 400 MHz): δ 1.39 (s, 9H, C(CH3)3); 
[2.93  (dd, 1H,  J1=8.3 Hz, J2=14.2 Hz,) and 3.18 (dd, 1H, J1=6.1  Hz, J2=14.2 Hz), CH2Ph]; [3.10 
(dd, 1H,  J1=14.2 Hz, J2=22.0 Hz) and 3.26 (dd, 1H,  J1=14.2 Hz, J2=22.0 Hz), CH2PO]; 3.75 (d, 
3H, OCH3, JH-P=11.5 Hz); 3.77 (d, 3H, OCH3, JH-P=11.5 Hz); 4.55 (m, 1H, CHNH); 5.43  (d, 1H, 
NH, J=7.8  Hz); 7.24 (m, 5H, CH, Ar). 13C NMR (CDCl3, 100 MHz): δ 28.31 (C(CH3)3); 36.97 
(CH2Ph); 38.31 (d, CH2P, J=130 Hz); 53.15 (CH3O); 61.27 (CHNH); 80.14  (C(CH3)3); 
126.95-129.38 (C Ar); 136.56  (C Ar); 155.34 (CO Boc); 201.03 (d, CO, J=5.5 Hz);  MS (ESI, m/
z): 410 [MK]+, 394 [MNa]+, 372 [MH]+.
CbzHN
O
P
O
OCH3
OCH3
(S)-methyl 2-(benzyloxycarbonylamino)-3-phenylpropanoate (5b) The general procedure 
yielded 4.3 g (84%) of a white solid starting from methyl ester of N-Cbz-L-phenylalanine (4 g, 
12.77 mmol), butyl lithium solution in hexane (1.6 M, 48 mL, 76.62  mmol) and dimethyl 
methanephosphonate (8.3 mL, 76.62 mmol).
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Mp 69-71°C; [α]D =-24 (c 1.80, CHCl3); 1H NMR (CDCl3, 400 MHz): δ [2.85 (dd, 1H,  J1=8.4 
Hz, J2=14.2 Hz,) and 3.08 (dd, 1H, J1=6.2 Hz, J2=14.2 Hz), CH2Ph]; [3.10 (dd, 1H,  J1=14.2 Hz, 
J2=22.0 Hz) and 3.22(dd, 1H,  J1=14.2 Hz, J2=22.0 Hz), CH2PO]; 3.71 (d, 3H, OCH3, JH-P=11.5 
Hz); 3.75 (d, 3H, OCH3, JH-P=11.5 Hz); 4.63 (m, 1H, CHNH); 5.09 (s, 2H, OCH2Ph) 5.43 (d, 
1H, NH, J=7.8 Hz); 7.09-7.38 (m, 10H, CH, Ar); 13C NMR (CDCl3, 100 MHz): δ 37.27 
(CH2Ph); 38.47 (d, CH2P, J=130 Hz); 53.79 (CH3O); 60.77  (CHNH); 67.18 (OCH2Ph) 
127.25-129.49(C Ar); 137.74 (C Ar); 137.77 (C Ar); 157.49 (CO Cbz); 203.32 (d, CO, J= 5.5 Hz); 
MS (ESI, m/z): 444 [MK]+, 428 [MNa]+, 406 [MH]+.
6.3.1.2 General procedure for the synthesis of enones
A) Aldehyde solution (1 eq) was added to a stirred solution of phosphonate (1 eq) in EtOH 
under argon atmosphere at room temperature, K2CO3 was added in small portions over a 
period of 15 min. Reaction mixture was stirred at room temperature for 16h. The reacting 
solution was  filtered and neutralized with glacial acetic acid. The solvent was removed in vacuo. 
The residue was partitioned between AcOEt and saturated solution of Na2S2O5. The aqueous 
phase was repeatedly extracted with AcOEt. The organic layers were combined and washed 
with saturated NaHCO3, brine and dried over anhydrous Na2SO4. Solvent was removed in 
vacuo and product was  purified by column chromatography using EtO2 / petroleum ether  1/ 1 
as eluent.
B) To a suspension of oven dried K2CO3 (3eq) in anhydrous  acetonitrile (120 mL) phosphonate 
(1eq) is  added. The mixture was stirred at room temperature for 15 minutes. Then the solution 
of aldehyde (1eq) in anhydrous acetonitrile was added and the system was gently stirred at room 
temperature and argon atmosphere for 48h. The reaction was quenched with 10% aqueous 
solution of citric acid (w/v) and then extracted with ethyl acetate. The organic phase was 
washed with H2O, saturated solution of NaCl and tried over anhydrous NaSO4. The solvent was 
removed under reduced pressure and the residue purified by flash chromatography on silica gel 
column using a mixture of  ethyl acetate/dichloromethane 4/6 as eluent.
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BocHN
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Cbz
N
(S)-benzyl 2-(3-(tert-butoxycarbonylamino)-2-oxo-4-phenylbutyl)indoline-1-carboxylate 
(7)  The general procedure B yielded 264 mg (19%) of a transparent oil starting form 
phosphonate 5a (1  g, 2.70 mmol) and aldehyde 3 (1.1 g, 4.04 mmol) and K2CO3 (681 mg, 4.94 
mmol).
1H NMR (CDCl3, 400MHz): δ 1.44 (s, 9H, C(CH3)3), 2.74-3.02 (m, 2H, COCH2, 1H, CHNCH2, 
1H, CH2Ph), 3.29  (m, 1H, CH2Ph), 3.39 (m, 1H, CHNCH2), 4.99  (m, 1H, NH), 5.04 (s, 2H, 
OCH2Ph), 5.10 (m, 1H, CHNH), 5.22 (br, 1H, CHNCH2), 6.99-7.46 (m, 14H, CH Ar); 13C NMR 
(CDCl3, 100MHz): δ 28.33 (C(CH3)3), 37.95 (CH2Ph), 38.00 (CHNCH2)42.78  (COCH2), 61.87 
(CHNCH2), 62.01 (CHNH), 67.54  (OCH2Ph), 80.01 (C(CH3)3), 120.72 (C Ar), 126.11-130.56 (C 
Ar), 137.74 (C Ar), 152.76 (CO Cbz), 157.86 (CO Boc), 200.34 (CO); MS (ESI, m/z): 537 
[MNa]+.
BocHN
O COOCH3
(S,E)-methyl 2-(4-(tert-butoxycarbonylamino)-3-oxo-5-phenylpent-1-enyl)benzoate (8a) 
The general procedure A furnished 3.2 g (58%) of a white solid starting from phosphonate 5a 
(5g, 13.5 mmol), methyl 2-formylbenzoate (3.31 g, 20.2 mmol) and K2CO3 (1.87 g, 13.5 mmol).
1H NMR (CDCl3, 400MHz): δ 1.38 (s, 9H, (CH3)3C),  [3.12 (dd, 1H, J1=5.9 Hz, J2=13.7 Hz) and 
3.19 (dd, 1H, J1=6.2 Hz, J2=13.7), CH2Ph],  3.93 (s, 3H, OCH3),  5.0 (m, 1H, CHNH),  5.36 (d, 
1H, CHNH),  6.53 (d, 1H, J= 16.1 Hz, COCH=),  7.19 – 7. 27 (m, 5H, Ar),  7.45 – 7.48 (m, 3H, 
Ar),  7.98 (d, 1H, Ar),  8.41 (d, 1H, J= 16.1 Hz, PhCH=); 13C NMR (CDCl3, 100MHz): δ 28.42 
(C(CH3)3), 38.66, (CH2Ph), 52.55  (CHNH), 58.79 (OCH3), 77.51 (C(CH3)3, 126.90 (Ar), 127.94 
(Ar), 128.51 (COCH=), 129.69 (Ar),  129.89 (Ar), 130.96 (Ar), 132.47 (Ar), 136.36 (Ar), 144.34 
(PhCH=) 155.22 (CO Boc), 167.05 (COOCH3), 197.50 (CO); MS (ESI, m/z): 432.2 [MNa]+.
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CbzHN
O COOCH3
(S,E)-methyl 2-(4-(benzyloxycarbonylamino)-3-oxo-5-phenylpent-1-enyl)benzoate (8b) 
The general procedure A yielded 1.4 g (63%) of a white solid starting form phosphonate 5b (2 
g, 4.94 mmol) and methyl 2-formylbenzoate (1.2 g, 7.41 mmol) and K2CO3 (681 mg, 4.94 
mmol).
1H NMR (CDCl3, 400MHz): δ [3.18 (dd, 1H, J1=5.8 Hz, J2=13.6 Hz) and 3.24 (dd, 1H, J1=6.5 
Hz, J2=13.7 Hz), CH2Ph], 3.97 (s, 3H, OCH3), 5.06 (m, 1H, CHNH), 5.14 (s, 2H, OCH2Ph), 
5.60 (d, 1H, CHNH), 6.53   (d, 1H, J= 16.1 Hz, COCH=), 7.14-7.48  (m, 13H, Ar), 7.99 (d, 1H, 
Ar), 8.47 (d, 1H, J= 16.1 Hz, PhCH=); 13C NMR (CDCl3, 100MHz): δ 38.61 (CH2Ph), 52.58 
(OCH3), 59.14 (CHNH), 66.90 (OCH2Ph), 125.96-135.32 (14C Ar + 1C COCH=), 144.08 
(PhCH=), 155.71 (CO Boc), 167.04 (COOCH3), 196.99 (CO); MS (ESI, m/z): 466 [MNa]+
6.3.1.3 General procedure for the synthesis of enaminones
A) In a closed caped vial TBAF x 3H2O (2 eq) and TMSiN3 (2  eq) were added in THF (3  mL). 
After 5 min, solution of enone in THF was added and reaction mixture was  stirred for 24h at 
50°C. Solvent was removed under reduced pressure and crude product was crystalized from 
MeOH.
B) In a closed caped vial TBAF x 3H2O (2 eq) and TMSiN3 (2 eq) were added in toulene (3 
mL). After 5 min, solution of enone in toulene was added and reaction mixture was stirred for 
24h at 90°C. Solvent was removed under reduced pressure and crude product was crystalized 
from MeOH
BocHN
O HN
O
(S,Z)-tert-butyl 3-oxo-4-(3-oxoisoindolin-1-ylidene)-1-phenylbutan-2-ylcarbamate (9a) 
The general procedure A gave 370 mg (40%) of pale yellow  solid starting from enone 8a  (950 
mg, 2.32 mmol), TBAF x 3H2O (2,1 g, 6.96 mmol) and TMSiN3 (924 μL, 6.96 mmol)
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Mp: 180  -183 °C; [α]D = -1.4 (c=1, CHCl3); 1H-NMR (CDCl3, 500MHz): δ 1.44 (s, 9H, C(CH3)
3),  3.13 (d, 2H, J=4.9 Hz, CH2Ph),  4.74 (m, 1H, CHNH),  5.35 (d, 1H, J=5.9 Hz, CHNH), 6.0 
(s, 1H, CH=),  7.18 – 7.26 (m, 5H, CH Ar),  7.59 (m, 3H, CH Ar),  7.89 (m, 1H, CH Ar),  10.19 
(s, 1H, NHCO); 13C-NMR (CDCl3, 125MHz): δ 28.50 (C(CH3)3), 38.57 (CH2Ph), 60.26 
(CHNH), 79.80 (C(CH3)3), 95.67 (CH=), 121.24-132.24 (C Ar), 136.17 (C Ar) 136.89 
(CH=CN), 148.11 (CO Boc), 168.73 (CONH), 199.10 (CO); MS (ESI, m/z): 415.2 [MNa]+.
CbzHN
O HN
O
(S,Z)-benzyl  3-oxo-4-(3-oxoisoindolin-1-ylidene)-1-phenylbutan-2-ylcarbamate (9b) The 
general procedure A gave 133 mg (39%) of a yellow  solid starting from enone 8b (360 mg, 0.81 
mmol), TBAF x 3H2O (511 mg, 1.62 mmol) and TMSiN3 (321 μL, 2.44 mmol)
1H-NMR (CDCl3, 500MHz): δ 3.15  (d, 2H, J=6.3 Hz, CH2Ph), 4.83 (dd, 1H, J1=13.7 Hz, J2=6.7 
Hz, CHNH), 5.12 (s, 2H, OCH2Ph), 5.70 (d, 1H, J=7.6 Hz, CHNH), 5.99 (s, 1H, CH=), 7.14 (m, 
2H, CH Ar), 7.22-7.34  (m, 8H, CH Ar), 7.56 (m, 1H, CH Ar), 7.64 (m, 2H, CH Ar), 7.87 (m, 1H, 
CH Ar), 10.22  (s, 1H, NHCO); 13C-NMR (CDCl3, 125MHz): δ 38.48 (CH2Ph), 60.82 (CHNH), 
66.92 (OCH2Ph), 95.69 (CH=), 121.31-135.89 (C Ar), 136.68 (CH=CN), 155.57  (CO Cbz), 
169.02 (CONH), 193.04 (CO); MS (ESI, m/z): 449 [MNa]+.
N
ONBoc
O
Ph
tert-butyl 2-benzyl-3,9-dioxo-2,3-dihydropyridazino[6,1-a]isoindole-1(9H)-carboxylate 
The general procedure B gave 145 mg (75%) of pale yellow  solid starting from 8a (200 mg, 0.5 
mmol), TBAF x 3H2O (308  mg, 1.0 mmol) and TMSiN3 (129 μL, 1 mmol)
Mp=191 – 192 °C; 1H-NMR (CDCl3, 400MHz): δ 1.34  (s, 9H, C(CH3)3),  [3.31 (d, 1H, J=12.8 
Hz, CH2Ph) and 3.55 (d, 1H, J=12.8 Hz, CH2Ph)], 5.71 (br, 1H), 5.76  (s, 1H, CH=), 7.03 (m, 5H, 
CH Ar), 7.55 – 7.64 (m, 3H, CH Ar), 7.87 (d, 1H, J=7.5  Hz, CH Ar); 13C-NMR (CDCl3, 
100MHz): δ 28.20 (C(CH3)3), 41.30 (CH2Ph), 74.56 (CHNH), 80.14 (C(CH3)3), 102.43  (CH=), 
124.15-133.21 (C Ar), 153.24 (CO Boc), 163.78 (CONH), 199.91 (CO); MS (ESI, m/z): 413 
[MNa]+.
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6.3.1.4 General procedure for the reduction of enaminones
A) To a solution of enaminone (1eq) in THF(1%H2O), cooled to 0°C, lithium borohydride 
(5eq) was added. When TLC (diethyl ether/petroleum ether 1/1) showed complete 
consumption of the reagent, the reaction was quenched with glacial acetic acid and the solvent 
was removed by distillation under reduced pressure. The crude residue was  partitioned between 
ethyl acetate and saturated solution of NaHCO3, the acqueus phase was extracted with ethyl 
acetate. The combined organic fractions were washed with saturated solution of NaCl and then 
dried over anhydrous Na2SO4. The solvent was removed by distillation under reduced pressure 
and the product was purified by recrystallization from di-iso-propyl ether or by column 
chromatography using dichloromethane/methanol 9/1 as eluent.
B) To a suspension of lithium tri-tert-butoxyaluminiumhydride (3 eq) in absolute ethanol, cooled 
to -78°C under argon atmosphere, was  carefully added the solution  of enaminone (1 eq) in 
absolute ethanol controlling that temperature does not exceed -60°C. After 4h the reaction was 
quenched with aqueous solution of citric acid 10% (w/v) and extracted repeatedly with ethyl 
acetate. The combined organic fractions were washed with brine and dried over anhydrous 
Na2SO4. The solvent was removed by distillation under reduced pressure and the product was 
purified by column chromatography using dichloromethane/methanol 9/1.
C) To a solution of enaminone (1eq) in THF(1%H2O), cooled to 0°C, sodium borohydride 
(5eq) was added. After 30 minutes the reaction was quenched with glacial acetic acid and the 
solvent was removed by distillation under reduced pressure. The crude residue was partitioned 
between ethyl acetate and saturated solution of NaHCO3, the acqueus phase was extracted with 
ethyl acetate. The combined organic fractions were washed with saturated solution of NaCl and 
then dried over anhydrous Na2SO4. The solvent was removed by distillation under reduced 
pressure and the product was purified by recrystallization from di-iso-propyl ether or by column 
chromatography using diethyl ether/petroleum ether 1/1 as eluent.
D) To a solution of enaminone (1 eq) in dry MeOH, cooled to -78°C under argon atmosphere, 
was added L-Selectride 1.0M in THF (3 eq). After 3h the mixture was acidified to pH 5 with 
HCl 1N and the solvent was removed by distillation under reduced pressure. The residue was 
partitioned between ethyl acetate  and saturated solution of NaHCO3, the aqueous phase was 
repeatedly extracted with ethyl acetate. The combined organic fractions were washed with brine 
and dried over anhydrous Na2SO4. The solvent was removed by distillation under reduced 
Experimental Part
107
pressure and the product was purified by column chromatography using dichloromethane/
methanol 9/1.
BocHN
OH HN
O  
tert-butyl (2S,3R,Z)-3-hydroxy-4-(3-oxoisoindolin-1-ylidene)-1-phenylbutan-2-
ylcarbamate  (S,R-10a)  The general procedure B yielded 23 mg (49%) of pale yellow  solid 
starting from enaminone 9a (50 mg, 0.13 mmol) and LTBAH (99.1 mg, 0.39 mmol).
1H-NMR (CDCl3, 500MHz): δ 1.39 (s, 9H, C(CH3)3), 2.93 (d, 2H, J= 5.5 Hz, CH2Ph), 3.96 (m, 
1H, CHNH), 4.19 (br, 1H, OH), 4.81  (br, 1H, CHNH), 4.92  (br, 1H, CHOH), 5.49 (d, 1H, J= 
4.6  Hz, CH=), 7.18-7.22 (m, 3H, CH Ar), 7.25-7.30 (m, 2H, CH Ar), 7.50 (m, 1H, CH Ar), 
7.57-7.63 (m, 2H, CH Ar), 7.84 (d, 1H, J=7.6 Hz, CH Ar), 9.01 (s, 1H, NHCO); 13C-NMR 
(CDCl3, 125MHz): δ 28.23 (C(CH3)3), 30.91  (CH2Ph), 58.07 (CHNH), 64.21 (CHOH), 80.52  (C
(CH3)3), 103.25 (CH=), 119.68-131.87 (C Ar), 157.58 (CO Boc), 170.36 (CONH);  MS (ESI, m/
z): 417 [MNa]+.
BocHN
OH HN
O
tert-butyl (2S,3S,Z)-3-hydroxy-4-(3-oxoisoindolin-1-ylidene)-1-phenylbutan-2-
ylcarbamate  (S,S-10a) The general procedure D  yielded 43 mg (84%) of white solid starting 
from enaminone 9a (50 mg, 0.13 mmol) and L-selectride (73 mg, 0.38 mmol).
1H-NMR (CDCl3, 400MHz): δ 1.24 (s, 9H, C(CH3)3), 2.91-2.97 (m, 2H, CH2Ph), 3.98 (br, 1H, 
CHNH), 4.47  (br, 1H OH), 4.65 (br, 1H CHOH), 5.12 (d, 1H, J=9.4 Hz, CHNH), 5.54  (d, 1H, 
J=4.9 Hz, CH=), 7.16-7.30 (m, 5H, CH Ar), 7.42-7.58 (m, 3H, CH Ar), 7.79 (d, 1H, J=7.6 Hz, 
CH Ar), 9.16 (s, 1H, CONH); 13C-NMR (CDCl3, 100MHz): δ 28.22 (C(CH3)3), 37.58 (CH2Ph), 
56.95 (CHNH), 70.84 (CHOH), 80.46 (C(CH3)3), 106.35 (CH=), 119.98-138.11 (C Ar) 156.34 
(CO Boc), 168.80 (CONH); MS (ESI, m/z): 417 [MNa]+.
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6.3.1.5 General procedure for the synthesis of inhibitors
To the solution of acid (DmPOA or picolinic acid) in anhydrous DMF under Ar atmosphere 
was added NMM (2eq), HOBT (1eq), and deprotected isoster core (1eq). The mixture was 
cooled to 0°C and EDC (1.15eq) was added. The mixture, was stirred for 1h at 0°C and pH was 
maintained at 8-8.5, then was allowed to reach room temperature and stirred for additional 16h. 
The solvent was removed by distillation under reduced pressure and the crude mixture was 
partitioned between ethyl acetate and water, the organic layer was washed with aqueous  solution 
of citric acid 10% (w/v), saturated solution of NaHCO3, saturated solution of NaCl and dried 
over anhydrous NaSO4. The product can be purified by column chromatography using 
dichloromethane/methanol 1/1. 
N
H O HN
O
O
O
Ph
(S,Z)-2-(2,6-dimethylphenoxy)-N-(3-oxo-4-(3-oxoisoindolin-1-ylidene)-1-phenylbutan-2-
yl)acetamide (11) The general procedure afforded 188 mg (81 %) of orange solid starting from 
deprotected enaminone 9a (200mg, 0.51  mmol) and DmPOA (101 mg, 0.56 mmol), NMM (112 
μL,1.02 mmol), HOBT (69 mg, 0.51 mmol) and EDC (91 mg, 0.59 mmol).
1H-NMR (CDCl3, 500MHz): δ 2.20 (s, 6H, CH3 x2), [3.25 (dd, 1H, J1=14.0 Hz, J2=6.7  Hz) and 
3.31 (dd, 1H, J1=14.0 Hz, J2=6.8 Hz), CH2Ph], 4.29 (m, 2H, OCH2CO), 5.19 (dd, 1H, J1=14.1 
Hz, J2=6.5 Hz, CHNH), 6.10 (s, 1H, CH=), 6.94 (m, 3H, CH Ar and 1H NH), 7.21 (m, 4H, CH 
Ar), 7.63 (m, 3H, CH Ar), 7.73 (m, 1H, CH Ar), 7.87 (m, 1H, CH Ar), 10.25 (NHCO); 13C-NMR 
(CDCl3, 125MHz): δ 16.24 (CH3 x2), 38.08  (CH2Ph), 58.66 (CHNH), 70.28 (OCH2CO), 95.78 
(CH=), 121.37-136.65 (C Ar), 148.39 (CH=CN), 154.29 (ArC-O), 168.67 (CONH), 168.95 
(CONH), 197.43 (CO); MS (ESI, m/z): 477 [MNa]+.
N
H O HN
O
O
Ph
N
(S,Z)-N-(3-oxo-4-(3-oxoisoindolin-1-ylidene)-1-phenylbutan-2-yl)picolinamide (12) The 
general procedure afforded 174 mg (86 %) of yellow  solid starting from deprotected enaminone 
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9a (200mg, 0.51 mmol) and picolinic acid (69 mg, 0.56 mmol), NMM (112 μL,1.02 mmol), 
HOBT (69 mg, 0.51 mmol) and EDC (91 mg, 0.59 mmol).
1H-NMR (CDCl3, 500MHz): δ 3.27  (d, 2H, J=6.7 Hz, CH2Ph), 5.21 (dd, 1H, J1=14.6 Hz, J2=6.8 
Hz, CHNH), 6.05 (s, 1H, CH=), 7.20 (m, 4H CH Ar and 1H NH), 7.43 (m, 1H, CH Ar), 7.62 (m, 
3H, CH Ph), 7.86  (m, 2H, CH Ph), 8.17 (d, 1H, J=7.8 Hz, CH Ar), 8.59 (m, 1H, CH Ar), 8.74 (d, 
1H, CH Ar), 10.20 (s, 1H, CONH); 13C-NMR (CDCl3, 125MHz): δ 38.33 (CH2Ph), 59.41 
(CHNH), 96.02 (CH=), 121.36-137.29 (C Ar), 148.41 (CH=CN), 149.37 (ArC-O), 164.02 
(CONH), 168,84 (CONH), 198.80 (CO); MS (ESI, m/z): 420 [MNa]+.
N
H OH HN
O
O
O
Ph
2-(2,6-dimethylphenoxy)-N-((2S,3R,Z)-3-hydroxy-4-(3-oxoisoindolin-1-ylidene)-1-
phenylbutan-2-yl)acetamide (13)  The general procedure afforded 24 mg (40 %) of pale 
yellow  solid starting from deprotected enamino alcohol (S,R)-10a (50 mg, 0.13 mmol) and 
DmPOA (25 mg, 0.14 mmol), NMM (29 μL, 0.26 mmol), HOBT (18 mg, 0.13 mmol) and EDC 
(23 mg, 0.15 mmol).
1H-NMR (CDCl3, 500MHz): δ 2.22 (s, 6H, CH3 x2), [3.02 (dd, 1H, J1=14.3 Hz, J2=6.9  Hz) and 
3.09 (dd, 1H, J1=14.3 Hz, J2=6.8 Hz), CH2Ph)], 3.85 (m, 1H, CHNH), 4.25  (m, 2H, OCH2CO 
and 1H, OH), 4.97 (br, 1H, CHOH), 5.54 (d, 1H, J=4.5  Hz, CH=), 7.12 (m, 3H, CH Ar and 1H, 
NH), 7.29 (m, 1H, CH Ar), 7.54 (m, 4H, CH Ar), 7.69 (m, 1H, CH Ar), 7.78 (m, 1H, CH Ar), 
7.86 (m, 1H, CH Ar), 7.92 (m, 1H, CH Ar), 9.45  (s, 1H, CONH); 13C-NMR (CDCl3, 125MHz): δ 
16.02 (CH3 x2), 31.02 (CH2Ph), 56.30 (CHNH), 69.89 (OCH2CO), 70.02 (CHOH), 105.04 
(CH=), 120.43-135.67 (C Ar), 146.32 (CH=CN), 150.02 (ArC-O), 169.79 (CONH), 170.43 
(CONH); MS (ESI, m/z): 479 [MNa]+.
N
H HN
O
O
Ph
N OH
N-((2S,3R,Z)-3-hydroxy-4-(3-oxoisoindolin-1-ylidene)-1-phenylbutan-2-yl)picolinamide 
(14)  The general procedure afforded 22 mg (43 %) of pale yellow  solid starting from 
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deprotected enamino alcohol (S,R)-10a (50 mg, 0.13 mmol) and picolinic acid (17 mg, 0.14 
mmol), NMM (29 μL, 0.26 mmol), HOBT (18 mg, 0.13 mmol) and EDC (23 mg, 0.15 mmol).
1H-NMR (CDCl3, 500MHz): δ 3.05 (d, 2H, J=6.0 Hz, CH2Ph), 3.81 (m, 1H, CHNH), 4.20 (br, 
1H, OH), 4.89  (br, 1H, CHOH), 5.60 (d, 1H, J=4.5 Hz, CH=), 7.19  (m, 1H, CH Ar), 7.24 (m, 
4H, CH Ar and 1H, NH), 7.39 (m, 1H, CH Ar), 7.48 (m, 1H, CH Ar), 7.56 (m, 1H, CH Ar), 7.62 
(m, 1H, CH Ar), 7.93 (m, 1H, CH Ar), 8.02 (m, 1H, CH Ar), 8.42 (m, 1H, CH Ar), 8.77 (m, 1H, 
CH Ar), 9.22 (s, 1H, CONH); 13C-NMR (CDCl3, 125MHz): δ 32.03 (CH2Ph), 56.87 (CHNH), 
70.54 (CHOH), 104.85 (CH=), 119.98-135.25 (C Ar), 147.03 (CH=CN), 149.32 (ArC-O), 
166.53 (CONH), 171.00 (CONH); MS (ESI, m/z): 422 [MNa]+
N
H HN
O
O
O
Ph
OH
2-(2,6-dimethylphenoxy)-N-((2S,3S,Z)-3-hydroxy-4-(3-oxoisoindolin-1-ylidene)-1-
phenylbutan-2-yl)acetamide (15)  The general procedure afforded 24 mg (46 %) of pale 
yellow  solid starting from deprotected enamino alcohol (S,S)-10a (50  mg, 0.13 mmol) and 
picolinic acid (17 mg, 0.14 mmol), NMM (29 μL, 0.26 mmol), HOBT (18 mg, 0.13 mmol) and 
EDC (23 mg, 0.15 mmol).
1H-NMR (CDCl3, 500MHz): δ 2.16 (s, 6H, CH3 x2), 3.00 (m, 2H, CH2Ph), 3.90 (br, 1H, CHNH), 
4.23 (m, 2H, OCH2CO),  4.50 (br, 1H, OH), 5.27 (br, 1H, CHOH), 5.59 (d, 1H, J=5.0 Hz, 
CH=), 7.19 (m, 3H, CH Ar and 1H, NH), 7.31 (m, 1H, CH Ar), 7.62 (m, 4H, CH Ar), 7.76 (m, 
1H, CH Ar), 7.83 (m, 1H, CH Ar), 7.89 (m, 1H, CH Ar), 7.98 (m, 1H, CH Ar), 9.79 (s, 1H, 
CONH); 13C-NMR (CDCl3, 125MHz): δ 15.98 (CH3 x2), 38.08 (CH2Ph), 55.11 (CHNH), 69.58 
(OCH2CO), 75.82 (CHOH), 108.21  (CH=), 120.13-139.47 (C Ar), 146.87 (CH=CN), 151.22 
(ArC-O), 169.14 (CONH), 171.46 (CONH); MS (ESI, m/z): 479 [MNa]+
N
H HN
O
O
Ph
N OH
N-((2S,3S,Z)-3-hydroxy-4-(3-oxoisoindolin-1-ylidene)-1-phenylbutan-2-yl)picolinamide 
(16)  The general procedure afforded 20 mg (40 %) of pale yellow  solid starting from 
deprotected enamino alcohol (S,S)-10a (50 mg, 0.13 mmol) and picolinic acid (17 mg, 0.14 
mmol), NMM (29 μL, 0.26 mmol), HOBT (18 mg, 0.13 mmol) and EDC (23 mg, 0.15 mmol).
Experimental Part
111
1H-NMR (CDCl3, 500MHz): δ 3.02 (m, 2H, CH2Ph), 3.93 (m, 1H, CHNH), 4.48 (br, 1H, OH), 
5.19 (br, 1H, CHOH), 5.48 (d, 1H, J=4.9 Hz, CH=), 7.21 (m, 1H, CH Ar), 7.29 (m, 4H, CH Ar 
and 1H, NH), 7.38(m, 1H, CH Ar), 7.48 (m, 1H, CH Ar), 7.56 (m, 1H, CH Ar), 7.62 (m, 1H, CH 
Ar), 7.93 (m, 1H, CH Ar), 8.04 (m, 1H, CH Ar), 8.38 (m, 1H, CH Ar), 8.69 (m, 1H, CH Ar), 9.70 
(s, 1H, CONH); 13C-NMR (CDCl3, 125MHz): δ 38.12 (CH2Ph), 56.14 (CHNH), 76.02 
(CHOH), 108.15 (CH=), 120.28-136.24 (C Ar), 147.33 (CH=CN), 149.52 (ArC-O), 166.83 
(CONH), 171.34 (CONH); MS (ESI, m/z): 422 [MNa]+
6.3.2 Chapter 3
CbzHN
O
OCH3
(S)-methyl 2-(benzyloxycarbonylamino)-3-methylbutanoate To a solution of L-valine 
methyl ester (1 g, 7.63 mmol) in DCM (20 mL) a triethylamine (2.1 mL, 15.27 mmol) and benzyl 
N-succinimidyl carbonate (2.1 g, 8.77 mmol) was added. The mixture was stirred for 2h at room 
temperature. The reaction was quenched with 20% (w/v) solution of citric acid (15 mL), the 
orgainic phase was separated while the acqueus phase was extracted with DCM (3x15mL). The 
combined organic fractions were washed with saturated solution of NaHCO3, saturated 
solution of NaCl and then dried over anhydrous NaSO4. The solvent removal yielded 1.8 g 
(89%) of  transparent oil.
1H NMR (CDCl3, 400  MHz): δ 0.87 (d, 3H, J=6.9 Hz, CH(CH3)2 x1), 0.94  (d, 3H, J=6.8 Hz, 
CH(CH3)2 x1), 2.11 (m, 1H, CH(CH3)2), 3.68 (s, 2H, -OCH3), 4.29  (dd, 1H, J1= 9.1 Hz, J2= 4.8 
Hz, CHNH), 5.07 (s, 2H, CH2Ph), 5.26 (d, 1H, J=9.8 Hz, CHNH), 7.32 (m, 5H, Ar).
CbzHN
O
P
O
OCH3
OCH3
(S)-benzyl 1-(dimethoxyphosphoryl)-4-methyl-2-oxopentan-3-ylcarbamate (5c) The 
general procedure from par. 6.3.1.1 yielded 2.6 g (72%) of a white solid starting from methyl 
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ester of N-Cbz-L-valine (3  g, 0.01 mol), butyl lithium solution in hexane (1.6 M, 0.07 mol) and 
dimethyl methanephosphonate (7.58 mL, 0.07 mol).
1H NMR (CDCl3, 400 MHz): δ 0.83 (d, 3H, J=6.8 Hz, CH(CH3)2 x1), 1.02 (d, 3H, J=6.8 Hz, 
CH(CH3)2 x1), 2.30  (m, 1H, CH(CH3)2), [3.06 (dd, 1H,  J1=14.0 Hz, J2=22.2  Hz) and 3.22 (dd, 
1H,  J1=14.0 Hz, J2=22.2 Hz), CH2PO], 3.70 (d, 3H, OCH3, JH-P=11.7  Hz), 3.75  (d, 3H, OCH3, 
JH-P=11.6 Hz), 4.42 (dd, 1H, J1= 9.3 Hz, J2= 4.8 Hz, CHNH), 5.12 (s, 2H, CH2Ph), 5.94 (d, 1H, 
J=9.7 Hz, CHNH), 7.36 (m, 5H, Ar); 13C NMR (CDCl3, 100 MHz): δ 19.04 (CH(CH3)2), 30.20 
(CH(CH3)2), 36.89 (d, CH2P, J=131 Hz), 53.21 (CH3O), 63.59 (CHNH), 67.18 (CH2Ph), 128.23 
(oAr), 128.30 (mAr), 129.12 (pAr), 137.77 (Ar-C-CO), 157.37 (CO Cbz), 199.85 (CO).
BocHN
O
Ph
(4S)-1,5-difenil-4-(tert-butossicarbonilammino)-1-pent-3-one (19) The general procedure A 
described in par. 6.3.1.2 yielded 2.6 g (69%) of  white solid, starting from benzaldehyde (1.09 
mL, 10.7 mmol), phosphonate 5a (4 g, 10.7 mmol) and K2CO3 (1.48 g, 10.7 mmol).
1H NMR (CDCl3, 400 MHz): δ 1.44 (s, 9H, C(CH3)3); 3.11 (m, 2H, CH2Ph); 4.92 (m, 1H, 
CHNH); 5.41 (d, 1H, J=7.3 Hz, NH); 6.69 (d, 1H, J=15.7 Hz, =CH-CO); 7.16-7.45  (m, 10H, Ar 
x2); 7.60 (d, 1H, J=15.7 Hz, CH=CH-CO); 13C NMR (CDCl3, 100 MHz): δ 28.44 (C(CH3)3); 
38.55 (CH2Ph); 59.2  (CHNH); 79.7 (C(CH3)3); 123.14 (Ar); 126.9 (Ar); 128.5 (=CH-CO); 128.6 
(Ar); 129.0 (Ar); 129.6 (Ar); 130.9 (Ar); 134.3 (Ar C1); 136.3 (Ar C1); 144.3 (=CH-CH2); 155.1 
(CONH); 197.3 (CO); MS (ESI, m/z): 390 [MK]+, 374 [MNa]+, 352 [MH]+.
BocHN
O
Ph
(S,E)-tert-butyl  6-methyl-3-oxo-1-phenylhept-4-en-2-ylcarbamate (20) The general 
procedure A described in par. 6.3.1.2  yielded 1.94 g (70%) of white solid, starting from 
isobutyraldehyde (1.05 g, 8.8  mmol), phosphonate 5a  (3.25 g, 8.8 mmol) and K2CO3 (1.21 g, 8.8 
mmol).
1H NMR (CDCl3, 400 MHz): δ 1.00 (dd, 6H, J1=6.7 Hz, J2=2.7 Hz, CH(CH3)2), 1.41 (s, 9H, C
(CH3)3), 2.39 (m, 2H, CH2Ph), 4.80 (m, 1H, CHNH), 5.27 (m, 1H, CHNH), 5.99 (d, 1H, J=15.7 
Hz, =CHCO), 6.83 (dd, 1H, J1=15.8 Hz, J2=6.6 Hz, =CHCH(CH3)2), 7.10 (m, 2H, oAr), 7.23 
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(m, 3H, m+pAr); 13C NMR (CDCl3, 100 MHz): δ 21.17 (CH(CH3)2), 28.41 (C(CH3)3), 31.36 
(CH(CH3)2), 58.36 (CHNH), 79.71 (C(CH3)3), 124.63 (Ar), 126.90 (Ar), 128.47 (Ar), 129.56 (Ar), 
136.31 (Ar), 155.93 (CO Boc), 197.97 (CO); MS (ESI, m/z): 356 [MK]+, 340 [MNa]+, 318[MH]
+.
CbzHN
O
(S,E)-benzyl 2,7-dimethyl-4-oxooct-5-en-3-ylcarbamate (21)  The general procedure A 
described in par. 6.3.1.2 yielded 382 mg (90%) of a transperent oil, starting from 
isobutyraldehyde (127  μL, 1.40 mmol), phosphonate 5c (500 mg, 1.40 mmol) and K2CO3 (193 
mg, 1.40 mmol).
1H-NMR (CDCl3, 500MHz): δ 0.78 (d, 3H, J=6.8 Hz, 1xCH(CH3)2), 1.01 (d, 3H, J=6.8 Hz, 
1xCH(CH3)2), 1.07  (d, 9H, J=6.8 Hz, 2x CH(CH3)2), 2.15 (m, 1H, CH(CH3)2), 2.48 (m, 1H, CH
(CH3)2), 4.59 (dd, 1H, J1=8.6 Hz, J2=3.9 Hz, CHNH), 5.10 (s, 2H, CH2Ph), 5.54 (d, 1H, J=10.4 
Hz, CHNH), 6.12 (d, 1H, J=15.8 Hz, =CHCO), 6.92 (dd, 1H, J1=15.8 Hz, J2=6.8 Hz, =CHCH
(CH3)2), 7.36 (m, 5H, Ar); 13C-NMR (CDCl3, 125.4 MHz): δ 19.76 (1xCH(CH3)2), 20.93 (1xCH
(CH3)2), 31.21 (1xCH(CH3)2),  31.41 (1xCH(CH3)2), 62.57 (CHNH), 66.83 (CH2Ph), 101.33 
(=CHCO), 125.08 (C Ar), 128.11 (C Ar), 128.18 (C Ar), 128.59 (C Ar), 155.84  (CO Boc), 198.96 
(CO Boc); MS (ESI, m/z): 326 [MNa+], 304 [MH]+.
O
(E)-Calchone (22)  A 1.93 g (16 mmol) of acetophenone was put in mortar together with 640 
mg (16  mmol) of NaOH. After 3 minutes of grinding benzaldehyde (1.70 g, 16 mmol) was 
added. The mixture was grinded for additional 10 minutes and to the yellow  slurry water was 
added. The white precipitate was filtered and washed with water. The procedure furnished 2.2 g 
(68%) of  product.
1H-NMR (CDCl3, 400MHz): δ 7.40 (m, 3H, Ar), 7.47-7.56 (m, 3H, Ar and 1H, =CHPh), 7.62 
(m, 2H, Ar), 7.79 (d, 1H, J= 15.7 Hz, =CHCO), 8.01 (m, 2H, Ar).
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O OH
3-hydroxy-1-phenylheptan-1-one To the solution of acetophenone (1.5 g, 12.5 mmol) in dry 
THF under the argon atmosphere at -78° C solution of LDA (1.3 g, 12.5 mmol) in 10 mL of 
THF was added dropwise. After 30  min of stirring at -78°C under argon the solution of 
valeraldehyde (1.07 g, 12.5 mmol) in THF was  added. The solution was stirred for additional 2h 
at -78° and then quenched with 20% (w/v) aqueous solution of citric acid and extracted 
repeatedly with ethyl acetate. The combined organic fractions were washed with saturated 
solution of  NaHCO3 and brine. Solvent removal yielded 2.1 g (80%) of  transparent oil.
1H-NMR (CDCl3, 270MHz): δ 0.92 (m, 3H, -CH3), 1.21-1.52 (m, 6H, -CH2CH2CH2CH3), 3.10 
(m, 2H, COCH2CHOH), 3.65 (br, 1H, OH), 4.20 (m, 1H, CHOH), 7.43-7.56 (m, 3H, p+mAr), 
7.92 (m, 2H, oAr); 13C-NMR (CDCl3, 67.5MHz): δ 16.00 (-CH3), 23.63 (-CH2CH3), 28.93 (-
CH2CH2CH3), 38.01 (-CH2CH2CH2CH3), 48.94 (COCH2CHOH), 68.78 (CHOH), 128.78 
(oAr), 128.88 (mAr), 133.20 (pAr), 137.02 (Ar-C-CO), 199.45 (CO).
O
(E)-1-phenylhept-2-en-1-one (23)  To a solution of 3-hydroxy-1-phenylheptan-1-one (1g, 4.85 
mmol) in toluene tosylic acid (921 mg, 4.85 mmol) was added. After 2h of stirring at r.t, water 
was added. After extraction with ethyl acetate combined  organic fractions were washed with 
saturated solution of NaHCO3 and brine. Solvent removal yielded 838 mg (92%) of transparent 
oil.
1H-NMR (CDCl3, 400MHz): δ 0.90 (m, 3H, -CH3), 1.20-1.48 (m, 4H, -CH2CH2CH3), 2.28 (m, 
2H, =CHCH2-), 6.78 (d, 1H, J= 15.4 Hz, COCH=), 7.03 (m, 1H, CH=CHCH2-), 7.36-7.44 (m, 
3H, p+mAr), 7.91 (m, 2H, oAr); 13C-NMR (CDCl3, 100MHz): δ 14.04 (-CH3), 22.12 (-
CH2CH3), 31.41 (-CH2CH2CH3), 32.15  (-CH2CH2CH2CH3), 126.88 (COCH=), 128.76 (oAr), 
128.80 (mAr), 133.34 (pAr), 137.81 (Ar-C-CO), 149.00 (CH=CHCH2-), 191.85 (CO); MS (ESI, 
m/z): 211 [MNa]+.
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(S,Z)-tert-butyl 5-amino-3-oxo-1,5-diphenylpent-4-en-2-ylcarbamate (24) The general 
procedure A described in par. 6.3.1.3 gave 180 mg (45%) of  pale yellow solid starting from 
enone 19 (350 mg, 1.10 mmol), TBAF x 3H2O (694 mg, 2.2 mmol) and TMSiN3 (434 μL, 3.3 
mmol).
1H NMR (CDCl3, 400 MHz): δ 1.36 (s, 9H, C(CH3)3), 3.05 (m, 2H, CH2Ph), 4.54 (m, 1H, 
CHNH), 5.28 (br, 1H, HNH), 5.29 (s, 1H, CHCNH2), 5.45 (d, 1H, J=7.7 Hz, CHNH), 7.19-7.30 
(m, 5H, Ar), 7.40-7.60 (m, 5H, Ar), 9.81 (br, 1H, HNH); 13C NMR (CDCl3, 100 MHz): δ 28.46 
(C(CH3)3), 40.03 (CH2Ph), 59.36 (CHNH), 79.32 (C(CH3)3), 93.11 (COCHCNH2), 126.35 (Ar), 
126.52 (Ar), 128.31 (Ar), 129.06 (Ar), 129.65 (Ar), 130.95 (Ar), 136.85 (Ar), 155.34 (OCONH), 
162.36 (COCHCNH2), 195.64 (CO); MS (EI, m/z): 366 [M]+.
BocHN
O
Ph
NH2
tert-butyl (S,Z)-5-amino-6-methyl-3-oxo-1-phenylhept-4-en-2-ylcarbamate (25)  The 
general procedure A described in par. 6.3.1.3 gave 194 mg (43%) of pale yellow  solid starting 
from enone 20 (430 mg, 1.36 mmol), TBAF x 3H2O (858 mg, 2.72 mmol) and TMSiN3 (534 μL, 
4.01 mmol).
1H-NMR (CDCl3, 500MHz): δ 1.07 (m, 6H, CH(CH3)2), 1.40 (s, 9H, C(CH3)3), 2.25 (m, 1H, CH
(CH3)2, 2.99 (d, 2H, J=6.6Hz, CH2Ph), 4.43 (m, 1H, CHNH), 4.85 (s, 1H, CHCNH2), 5.10 (br, 
1H, HNH), 5.40 (d, 1H, J=7.5 Hz, NH), 6.97 – 7.42 (m, 5H, Ar), 9.75 (br, 1H, HNH); 13C-
NMR (CDCl3, 125.4 MHz): δ 21.26 (CH(CH3)2), 28.33 (C(CH3)3), 34.54 (CH(CH3)2), 39.92 
(CH2Ph), 61.13 (CHNH), 79.90 (C(CH3)3), 92.27 (COCHCNH2), 127.30 (C Ar), 128.80 (C Ar), 
129.52 (C Ar), 137.74 (C Ar), 157.64 (CO Boc), 165.22 (COCHCNH2), 197.43 (CO); MS (ESI, 
m/z): 355.2 [MNa+].
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O NH2
benzyl (S,Z)-6-amino-2,7-dimethyl-4-oxooct-5-en-3-ylcarbamate (26)  The general 
procedure A described in par. 6.3.1.3 gave 76 mg (37%) of pale yellow  solid starting from enone 
21 (199 mg, 0.65 mmol), TBAF x 3H2O (410 mg, 1.3 mmol) and TMSiN3 (259 μL, 1.96 mmol).
1H-NMR (CDCl3, 500MHz): δ 0.83  (d, 3H, J= 6.8 Hz, 1x CH(CH3)2), 0.96  (d, 3H, J= 6.8 Hz, 
1xCH(CH3)2), 1.14 (d, 6H,  J=  6.9 Hz, 2xCH(CH3)2-Val), 2.30 (m, 1H, CH(CH3)2-Val), 2.33 (m, 
1H, CH(CH3)2), 4.14 (dd, 1H, J1= 8.7 Hz, J2= 4.9  Hz, CHNH), 5.06  (s, 1H, CHCNH2), 5.08 (s, 
2H, CH2Ph), 5.16 (br, 1H, HNH), 5.69 (d, 1H, J= 8.5 Hz, CHNH), 7.30 – 7.36 (m, 5H, Ar), 9.80 
(br, 1H, HNH) ; 13C-NMR (CDCl3, 125.4MHz): δ 17.58 (CH(CH3)2), 19.71 (CH(CH3)2), 21.14 
(CH(CH3)2-Val), 32.33 (CH(CH3)2-Val), 35.01 (CH(CH3)2), 63.30 (CHNH), 66.67 (CH2Ph), 
91.46 (COCHCNH), 127.05 (Ar), 128.03 (Ar), 128.09 (Ar), 128.53 (Ar), 156.67 (OCONH), 172. 
21 (COCHCNH2), 195.68 (CO); MS (ESI, m/z): 341 [MNa+].
O NH2
(Z)-3-amino-1,3-diphenylprop-2-en-1-one (27)  The general procedure A described in par. 
6.3.1.3   gave 76 mg (37%) of pale yellow  solid starting from calchone 22 (100 mg, 0.48 mmol), 
TBAF x 3H2O (302 mg, 0.96 mmol) and TMSiN3 (200 μL, 1.44 mmol).
1H-NMR (CDCl3, 400MHz): δ 5.48 (br, 1H, HNH), 6.14 (s, 1H, =CHCNH2), 7.43-7.50 (m, 6H, 
Ar),  7.62 (dd, 2H, J1=7.6 Hz, J2=1.5  Hz), 7.93 (dd, 2H, J1= 7.7 Hz, J2= 1.4  Hz, Ar), 10.42 (br, 
1H, HNH); 13C-NMR (CDCl3, 67.5 MHz): δ 91.50 (CHCNH2), 126.16 (Ar), 127.02 (Ar), 128.10 
(Ar), 128.85 (Ar), 130.54 (Ar), 130. 86 (Ar), 130.86 (Ar), 137.42 (Ar), 140.16 (Ar), 162.76 
(COCHCNH2), 190.05 (CO); MS (ESI, m/z): 246 [MNa]+, 224 [MH]+.
O NH2
(Z)-3-amino-1-phenylhept-2-en-1-one (28)  The general procedure A described in par. 6.3.1.3 
gave 190 mg (58%) of yellow   oil starting from enone 26 (300 mg, 1.60 mmol), TBAF x 3H2O 
(1.01 g, 3.2 mmol) and TMSiN3 (629 μL, 3.2 mmol).
Experimental Part
117
1H-NMR (CDCl3, 500MHz): δ 0.96 (m, 3H, -CH3), 1.41 (m, 2H, -CH2CH3), 1.63 (m, 2H, -
CH2CH2CH3), 2.26 (m, 2H, -CH2CNH2), 5.22 (br, 1H, HNH), 5.75 (s, 1H, CHCNH2), 7.40 (m, 
3H, m+pAr), 7.87  (m, 2H, oAr), 10.29 (br, 1H, HNH); 13C-NMR (CDCl3, 125.4MHz): δ 13.59 (-
CH3), 22.35 (-CH2CH3), 30.21 (CH2CH2CH3), 36.62 (CNH2CH2-), 91.72 (CHCNH2), 127.14 
(oAr), 128.35 (mAr), 131.04 (pAr), 140.43 (Ar-C-CO), 167.09 (COCHCNH2), 189.79 (CO); MS 
(ESI, m/z): 204 [MH]+, 225 [MNa]+.
BocHN
Ph
O N3
(1S)-acido-(4-azido-1-benzil-5-metil-2-osso-esil)-carbammico tert-butil estere (29) A 
solution of TMSiN3 (2.1 mL, 15.77 mmol) and acetic acid (902 μL, 15.77 mmol), in dry DCM 
was stirred under at room temperature. After 20 min a solution of enone 20  (1 g, 3.15 mmol), 
and brucine (124 mg, 0.32 mmol) in DCM was added. The reaction was followed by TLC. 
When the conversion was complete the crude mixture was eluted with DCM through a short 
silica gel column. The solvent was evaporated under reduced pressure and product was isolated 
by crystallization from hexane (800 mg, 71%).
1H-NMR (CDCl3, 400MHz): δ  0.84, 0.87, 0.91 (3d, 6H, J=7.0 Hz, CH3 two diast), 1.39 (2s, 
9H,C(CH3)3), 1.71 (m, 1H, CH(CH3)2), 2.32 (dd, 0.82H, J1=17.5 Hz, J2=3.0 Hz, CH2CO diast A), 
2.56 (m, 0.18H, CH2CO diast B), 2.58 (dd, 0.82H, J1=18.0 Hz, J2=9.5 Hz, CH2CO diast A), 3.01 
(m, 2H, CH2Ph), 3.67 (m, 0.82H, CHN3 diast A), 2.77 (m, 0.18H, CHN3 diast B), 4.49 (m, 1H, 
NCHCH2), 5.08 (m, 1H, NH), 7.20 (m, 5H, Ar); 13C-NMR (CDCl3, 100MHz): δ 17.79 (-CH3), 
17.84 (-CH3), 19.09 (-CH3), 19.20 (-CH3), 28.2 (CH3)3),  32.50 (CH(CH3)2), [37.34 and 37.72 
(CH2Ph)], [42.68 and 43.11 (CH2CO)], [60.36 and 60.66 (CHN3)], [63.48 and 63.67 (HNCH)], 
[80.11 e 80.21 (C(CH3)3)], 127.15 (Ar), 127.17 (Ar), 128.78 (Ar), 128.84 (Ar), 129.13 (Ar), 129.35 
(Ar), 136.12 (Ar), 136.18 (Ar), [155.29 and 155.31 (CONH)], [206.91  and 207.49 (CO)]; MS 
(ESI, m/z): 383 [MNa]+, 361 [MH]+.
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O2-cyclohexylidene-1-phenylethanone (30)  To a stirred solution of methyl dimethyl 
phosphonate (930 mg, 7.5 mmol) in dry THF (20 mL), is added BuLi (7.5 mmol, 15% in 
hexane) at -78°C under Ar atmosphere. After stirring for 1h at -78°C, benzonitrile (700 mg, 6.8 
mmol) is  added and a mixture is warmed to -5°C for 1h. Ciclohexane was added dropwise and 
the mixture is  warmed to r.t. After 1.5h of stirring at r.t 5M H2SO4 (6 mL) was added and 
stirring was continued for 1h. The product was extracted with ethyl acetate 3x 15 mL and the 
combined organic fractions  were washed with saturated solution of NaHCO3 and brine. Solvent 
removal yielded 639 mg (47%) of  transparent oil.
1H-NMR (CDCl3, 500MHz): δ 1.64-1.73  (m, 6H, -CH2CH2CH2-), 2.32 (m, 2H, =CCH2x1), 2.77 
(m, 2H, =CCH2x1), 6.60 (s, 1H, CH=), 7.44-7.57 (m, 3H, m+pAr), 7.93 (m, 2H, oAr); 13C-NMR 
(CDCl3, 125.4MHz): δ 26.16 (-CH2), 27.18  (-CH2), 28.26 (-CH2), 30.53 (=CH2), 38.30 (=CH2), 
118.79 (COCH=), 128.40 (oAr), 128.47 (mAr), 128.64 (pAr), 139.36 (Ar-C-CO), 162.96 (=C
(CH2)2), 192.86 (CO); MS (ESI, m/z): 201 [MH]+, 223 [MNa]+, 239 [MK]+.
O
3-methyl-1-phenylbut-2-en-1-one (31) To a stirred solution of methyl dimethyl phosphonate 
(1.6 g, 11.7 mmol) in dry THF (40 mL), is  added BuLi (12.9 mmol, 15% in hexane) at -78°C 
under Ar atmosphere. After stirring for 1h at -78°C, benzonitrile (1.2 g, 12.9  mmol) is added 
and a mixture is  warmed to -5°C for 1h. Acetone (2.3 g) was added dropwise and the mixture is 
warmed to r.t. After 1.5h of stirring at r.t 5M H2SO4 (15 mL) was added and stirring was 
continued for 1h. The product was extracted with ethyl acetate 3x 25 mL and the combined 
organic fractions were washed with saturated solution of NaHCO3 and brine. After flash 
chromatography (diethyl ether / petroleum ether 1/1) were isolated 100 mg (5%) of transparent 
oil. 
1H-NMR (CDCl3, 400MHz): δ 1.99 (s, 3H, =C(CH3)2 x1), 2.19 (s, 3H, =C(CH3)2 x1), 6.73  (s, 1H, 
COCH=), 7.42 (m, 3H, m+pAr), 7.90 (m, 2H, oAr); 13C-NMR (CDCl3, 100MHz): δ 21.23 (=C
(CH3)2 x1), 28.03 (=C(CH3)2 x1), 121.23 (CH=), 128.22 (oAr), 128.48 (mAr), 132.32 (pAr), 
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139.31 (Ar-C-CO), 156.72 (=C(CH3)2), 198.12 (CO); MS (ESI, m/z): 161 [MH]+, 183 [MNa]+, 
199[MK]+.
O N3
3-azido-3-methyl-1-phenylbutan-1-one (32)  In a septum sealed glass vessel TBAF x 3H2O 
(297 mg, 0.94 mmol) and TMSiN3 (187 μL, 1.42 mmol) were added in THF. After 5 min, 
solution of enone 30 (76 mg, 0.47 mmol) in THF was added and reaction mixture was inserted 
in microwave reactor at 80° (200W) and stirred for 20 min. Solvent was  removed under reduced 
pressure and crude product was eluted in chromatographic column using DCM: MeOH = 9:1.
1H-NMR (CDCl3, 500MHz): δ 1.47 (s, 6H, N3C(CH3)2), 3.15 (s, 2H, COCH2), 7.44 (m, 3H, m
+pAr), 7.92 (m, 2H, oAr); 13C-NMR (CDCl3, 125.4MHz): δ 26.29 (-CH3 x2), 60.29 (COCH2), 
128.14 (oAr), 128.39 (mAr), 132.22 (pAr), 137.49  (Ar-C-CO), 191.47 (CO); MS (ESI, m/z): 226 
[MNa]+.
O
N3
2-(1-azidocyclohexyl)-1-phenylethanone (33)  In a septum sealed glass vessel TBAF x 3H2O 
(1.1 g, 3.5 mmol) and TMSiN3 (604 mg, 5.25 mmol) were added in THF. After 5 min, solution 
of enone 31 (350 mg, 1.75 mmol) in THF was added and reaction mixture was inserted in 
microwave reactor at 80° (200W) and stirred for 20 min. Solvent was removed under reduced 
pressure and crude product was eluted in chromatographic column using DCM: MeOH = 9:1.
1H-NMR (CDCl3, 500MHz): δ 1.55-1.64 (m, 6H, -CH2CH2CH2-), 1.99  (m, 4H, =C(CH2)2-), 3.16 
(s, 2H, COCH2), 7.43-7.53 (m, 3H, m+pAr), 7.95 (m, 2H, oAr); 13C-NMR (CDCl3, 125.4MHz): 
δ 22.11 (-CH2), 22.15 (-CH2), 25.49 (-CH2), 28.27 (-CH2), 34.94 (-CH2), 47.93 (-CH2), 63.07 
(COCH2), 128.34 (oAr), 128.48  (mAr), 128.58 (pAr), 137.09 (Ar-C-CO), 197.68 (CO); MS (ESI, 
m/z): 266 [MNa]+.
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6.3.3 Chapter 3
BocHN
O
Ph
Ph
tert-butyl (S,E)-3-oxo-1,7-diphenylhept-4-en-2-ylcarbamate (33)  The general procedure A 
described in par. 6.3.1.2  yielded 4.9 g (80%) of white solid, starting from phenyl 
propionaldehyde (2.20 g, 16.3 mmol), phosphonate 5a  (6.0 g, 16.3 mmol)) and K2CO3 (2.25  g, 
10.7 mmol).
1H NMR (CDCl3, 400 MHz): δ 1.44 (s, 9H, C(CH3)3), 2.49 (m, 2H, =CHCH2-), 2.75 (m, 2H, -
CH2CH2Ph), 2.90 (m, 2H, -CH2Ph), 4.75 (m, 1H, CHNH), 5.25 (br, 1H, CHNH), 6.10 (d, 1H, J= 
16.2 Hz, COCH=), 6.92 (m, 1H, =CHCH2), 6.98-7.34 (m, 10H, Ar); 13C NMR (CDCl3, 100 
MHz): δ 28.41 (C(CH3)3), 34.25 (-CH2CH2Ph), 34.34 (-CH2CH2Ph), 38.48 (CH2Ph), 58.40 
(CHNH), 77.45  (C(CH3)3), [126.38, 126.92, 127.82, 128.41, 128.47, 128.63, 129.59, 136.19, 
140.59, 8x C Ar and 1x COCH=], 48.55 (=CHCH2), 155.19 (CO Boc), 197.35 (CO).
BocHN
O
Ph
Ph
N3
tert-butyl (2S,5S)-5-azido-3-oxo-1,7-diphenylheptan-2-ylcarbamate (34a) A solution of 
TMSiN3 (3.3  mL, 33 mmol) and acetic acid (1.9 mL, 33 mmol), in dry DCM (150 mL) was 
stirred under at room temperature. After 20 min a solution of enone 33  (2.5 g, 6.6 mmol), and 
brucine (0.56 g, 1.32 mmol) in DCM (50 mL) was added. The reaction was followed by TLC. 
When the conversion was complete the crude mixture was eluted with DCM through a short 
silica gel column. The solvent was evaporated under reduced pressure and major 
diastereoisomer 34a was isolated by crystallization from hexane (1.3g, 47%) 
1H NMR (CDCl3, 400 MHz): δ 1.40 (s, 9H, C(CH3)3); 1.69 (q, 2H, J= 7.32 Hz, -CH2CH2Ph), 
2.35 (dd, 1H, J1=16.0 Hz, J2=4.1 Hz, NHCHCH2Ph), 2.63 (m, 3H, 1H NHCHCH2Ph and 2H -
CH2CH2Ph), 2.98 (m, 2H, COCH2-), 3.80 (m, 1H, CHN3), 4.48 (m, 1H, CHNH), 5.04 (d, 1H, 
CHNH), 7.13-7.29 (m, 10H, Ar); 13C NMR (CDCl3, 100 MHz): δ 28.36 (C(CH3)3), 32.26 (-
CH2CH2Ph), 36.26 (NHCHCH2Ph), 37.65 (N3CHCH2-), 45.50  (COCH2-), 57.37  (CHNH), 
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60.52 (CHN3), 80.33 (C(CH3)3), [126.27, 127.26, 128.46, 128.64, 128.90, 129.26, 136.03, 140.80, 
8x C Ar), 155. 32 (CO Boc), 207.10 (CO).
BocHN
O
Ph
Ph
N3
tert-butyl (2S,5R)-5-azido-3-oxo-1,7-diphenylheptan-2-ylcarbamate (34b) Minor 
diastereoisomer isolated by evaporation of  the mother solution of  previous reaction.
1H NMR (CDCl3, 400 MHz): δ 1.43 (s, 9H, C(CH3)3), 1.73 (m, 2H, -CH2CH2Ph), 2.42 (dd, 1H, 
J1=16.2 Hz, J2=4.0 Hz, NHCHCH2Ph), 2.67 (m, 3H, 1H NHCHCH2Ph and 2H -CH2CH2Ph), 
3.01 (m, 2H, COCH2-), 3.89 (m, 1H, CHN3), 4.50 (m, 1H, CHNH), 5.06 (d, 1H, CHNH), 
7.19-735 (m, 10H, Ar)
BocHN
OH
Ph
Ph
N3
tert-butyl (2S,3R,5S)-5-azido-3-hydroxy-1,7-diphenylheptan-2-ylcarbamate (35a)  To a 
solution of azido ketone 34a  (1.74 g, 4.12 mmol) in methanol (50 mL) at 0° C NaBH4 (160 mg, 
4.12 mmol) was added portionwise. After completion, reaction mixture was quenched by 
saturated ammonium chloride solution and extracted with ethyl acetate (2  x  75 mL). The 
combined organic layer was  washed with brine and dried over sodium sulphate. The solvent was 
evapoprated under reduced pressure and major distereoisomer 35a was recrystallized from 
petroleum ether (1.1 g, 63 %). 
1H NMR (CDCl3, 400 MHz): δ 1.37 (s, 9H, C(CH3)3); 1.58 (m, 2H, HOCHCH2-); 1.89  (m, 2H, 
N3CHCH2-); 2.71  (m, 3H, 2H -CH2CH2Ph and 1H CH2Ph), 2.86  (dd, 1H, J1= 15.0 Hz, J2= 5.0 
Hz, CH2Ph), 3.36 (br, 1H, CHOH), 3.68 (m, 1H, -CHN3), 3.82 (m, 1H, CHNH), 3.89 (m, 1H, 
CHOH), 4.51 (br, 1H, CHNH), 7.19-7.32 (m, 10H, Ar); 13C NMR (CDCl3, 100  MHz): δ 28.32 
(C(CH3)3), 32.51 (-CH2CH2Ph), 36.33 (NHCHCH2Ph), 37.03 (OHCHCH2-), 37.85 
(N3CHCH2-), 57.11 (CHNH), 59.36 (-CHN3), 71.00 (CHOH), 80.17 (C(CH3)3), [126.52, 127.02, 
128.46, 128.61, 128.71, 129.24, 137.93, 141.17, C Ar], 155.2 (CO Boc); 
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BocHN
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tert-butyl  (2S,3S,5S)-5-azido-3-hydroxy-1,7-diphenylheptan-2-ylcarbamate (35b) The 
remaining residue of above reduction reaction was recrystallized two time with petroleum ether 
to get the minor distereoisomer (0.45 g, 25.8 %)
1H NMR (CDCl3, 400 MHz): δ 1.41 (s, 9H, C(CH3)3); 1.71 (m, 2H, HOCHCH2CHN3); 1.84 (m, 
2H, N3CHCH2-); 2.65 (m, 3H, 2H -CH2CH2Ph and 1H CHOH), 2.89 (m, 2H, NHCHCH2Ph), 
3.49 (br, 1H, CHN3), 3.71 (m, 2H, 1H CHOH and 1H CHNH), 4.87  (m, 1H, CHNH), 7.14-7.31 
(m, 10H, Ar); 13C NMR (CDCl3, 100 MHz): δ 28.30 (C(CH3)3), 31.97 (-CH2CH2Ph), 36.38 (-
CH2CH2Ph), 38.45 (OHCHCH2-), 38.71 (NHCHCH2Ph), 55.83 (CHNH), 60.44 (CHN3), 68.90 
(CHOH), 79.53 (C(CH3)3), [126.15, 126.43, 128.30, 128.44, 128.53, 128.62, 138.19, 140.89 (C 
Ar)], 156.09 (CO Boc).
BocHN
OH
Ph
Ph
N
N
N
O Ph
tert-butyl(2S,3R,5S)-3-hydroxy-5-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)-1,7- 
diphenylheptan-2-ylcarbamate (36) To a solution of azido alcohol 35a (0.32 g, 0.75 mmol) in 
tert- butanol (25 mL) in a sealed tube, CuSO4 (18 mg, 0.075 mmol), Cu-wire turnings and 
phenyl propargyl ether (0.12 mL, 0.9 mmol) were added sequentially. After completion reaction 
mixture was evaporated and crude mass was between ethyl acetate and water. Aqueous phase 
was extracted with ethyl acetate and the combined organic layers were washed with brine and 
dried over sodium sulphate. The solvent was evaporated and residue was purified by flash 
chromatography with ethyl acetate and petroleum ether (4:6) as  eluant giving triazole (0.35 g, 
83%) as a solid 
1H NMR (CDCl3, 400 MHz): δ 1.36 (s, 9H, C(CH3)3), 1.89 (m, 1H, HOCHCH2-), 2.16 [m, 2H, 
(1H HOCHCH2- and 1H -CH2CH2Ph)], 2.45 [m, 3H, (2H -CH2CH2Ph and 1H -CH2CH2Ph)], 
2.70 (m, 2H, CH2Ph), 3.08 (br, 1H, CHOH), 3.70 (br, 1H, CHNH), 3.85  (br, 1H, CHOH), 4.48 
(br, 1H, CHTriazole), 4.77 (br, 1H, CHNH), 5.22 (two d, 2H, J=12.2 Hz each, -CH2OPh), 6.95-7.31 
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(m, 15H, Ar), 7.55 (s, 1H, CHTriazole); 13C NMR (CDCl3, 100 MHz): δ 28.01 (C(CH3)3), 31.98 (-
CH2CH2Ph), 36.27 (NHCHCH2Ph), 37.07 (NCHCH2-), 38.51 (HOCHCH2-), 57.26 (CHNH), 
58.10 (-CHTriazole), 61.98  (-CH2OPh), 69.87  (CHOH), 80.13 (C(CH3)3), 114.86 (CHTriazole), 
[121.23, 123.13, 126.21, 126.29, 127.13,  128.34, 129.52, 131.02, 132.00, 137.38, 138.56, 140.31, 
143.82 (C Ar x12 and CTriazole], 158.23 (CO Boc); MS (ESI, m/z): 579 [MNa]+, 595 [MK]+
BocHN
OH
Ph
Ph
N
N
N
tert-butyl (2S,3R,5S)-3-hydroxy-5-(4-isobutyl-1H-1,2,3-triazol-1-yl)-1,7-diphenylheptan-2- 
ylcarbamate  (37)  Following above described procedure the product was obtained as a white 
solid 0.23 g (66%) starting from 35a (0.30 g, 0.7 mmol), 4-methyl-1-pentyne (0.1 mL, 0.8 mmol) 
and CuSO4 (17 mg, 0.07 mmol) in the presence of  copper wire.
1H NMR (CDCl3, 400 MHz): δ 0.91 (d, 3H, J= 2.2 Hz, -CH(CH3)2 x1), 0.93 (d, 3H, J= 2.2  Hz, -
CH(CH3)2 x1), 1.35 (s, 9H, C(CH3)3), 1.87 (m, 1H, HOCHCH2-), 1.92 (m, 1H, -CH(CH3)2), 1.97 
(m, 2H, 1H  HOCHCH2- and 1H -CH2CH2Ph), 2.14 (m, 3H, 1H -CH2CH2Ph and 2H -
CH2CH2Ph), 2.58 (m, 2H, -CH2CH(CH3)2), 2.72 (m, 2H, NHCHCH2Ph), 3.09 (m, 1H, CHOH), 
3.70 (m, 1H, CHNH), 3.81 (br, 1H, CHOH), 4.50 (br, 1H, CHNH), 4.73 (m, 1H, CHNTriazole), 
7.06-7.29 (m, 11H, 10H Ar and CHTriazole); 13C NMR (CDCl3, 100 MHz): δ 22.40 (1x CH(CH3)2), 
22.41 (1x CH(CH3)2), 28.30 (C(CH3)3), 28.74 (CH(CH3)2), 32.35 (-CH2CH2Ph), 34.86 (-CH2CH
(CH3)2), 35.04 (-CH2CH2Ph), 37.44  (NHCHCH2Ph), 40.13 (HOCHCH2-), 57.11 (CHNH), 
57.93 (CHNTriazole), 80.28 (C(CH3)3), 114.29 (CHTriazole), [126.49, 126.79, 128.64, 128.75, 128.81, 
129.38, 138.00, 140.82, 14.99  (C Ar x8 and CTriazole)], 157.5 (CO Boc); MS (ESI, m/z): 529 
[MNa]+, 545 [MK]+.
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tert-butyl(2S,3S,5S)-3-hydroxy-5-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)-1,7-
diphenylheptan-2-ylcarbamate (38)  Following above described procedure the product was 
obtained as a white solid 0.43 g (79%) starting from 35b (0.41 g, 1.0 mmol), phenyl propargyl 
ether (0.16 mL, 1.2 mmol) and CuSO4 (24 mg, 0.1 mmol) in the presence of  copper wire.
1H NMR (CDCl3, 400 MHz): δ 1.36 (s, 9H, C(CH3)3), 2.03 (m, 1H, HOCHCH2-), 2.07  (m, 3H, 
1H HOCHCH2- and 2H -CH2CH2Ph), 2.38 (m, 2H, -CH2CH2Ph), 2.86 (m, 3H, 2H 
NHCHCH2Ph and 1H CHOH), 3.42 (m, 1H, CHOH), 3.73 (m, 1H, CHNH), 4.60 (m, 1H, 
CHNTriazole), 4.86 (m, 1H, CHNH), 5.14 (two d, 2H, J= 12.5 Hz each, -CH2OPh), 6.96-7.32 (m, 
15H, Ar); 13C NMR (CDCl3, 100 MHz): δ 28.31 (C(CH3)3), 31.91 (-CH2CH2Ph), 37.07 
(NHCHCH2Ph), 38.24 (-CH2CH2Ph), 40.13 (HOCH2-), 55.28 (CHNH), 59.06 (CHTriazole), 62.04 
(-CH2O-), 68.61 (CHOH), 80.39 (C(CH3)3), [114.83, 121.29, 126.20, 126.34, 126.40, 126.46, 
128.12, 128.34, 129.43, 129.51, 129.56, 129.60, 138.05, 140.26 (12x  C Ar, CHTriazole and CTriazole)], 
158.19 (CO Boc); MS (ESI, m/z): 579 [MNa]+, 595 [MK]+.
BocHN
Ph
N
N
N
OH
Ph
tert-butyl (2S,3S,5S)-3-hydroxy-5-(4-isobutyl-1H-1,2,3-triazol-1-yl)-1,7-diphenylheptan-2- 
ylcarbamate  (39) In cap closed vial azido-alcohol 35b  (200 mg, 0.49  mmol), 4-methyl-1-
pentyene (57 μL, 0.49 mmol), CuI (9.5 mg, 0.05 mmol) were dissolved in 5 mL of CH3CN/
H2O 1/1 mixture. The vial was put in microwave reactor setting the temperature on 100°C 
(200W) for 30 min. After 30 min water was added and the product was extracted with ethyl 
acetate. The combined organic layers were washed with saturated solution of NaCl and dried 
over anhydrous sodium sulphate. The solvent removed in  vacuo  and the crude mixture was 
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purified by flash chromatography with ethyl acetate and petroleum ether (4:6) as eluant giving 
triazole (149 mg, 62%) as a solid
1H NMR (CDCl3, 400 MHz): δ 0.87 (m, 6H, CH(CH3)2), 1.40 (s, 9H, C(CH3)3), 1.51 (m, 2H, 1H 
-CH(CH3)2 and 1H HOCHCH2-), 1.92 (m, 3H, 1H HOCHCH2- and 2H -CH2CH2Ph), 2.21 (m, 
2H, -CH2CH2Ph), 2.36 (m, 2H, -CH2CH(CH3)2), 2.77 (m, 3H, 1H NHCHCH2Ph and 1H 
CHOH), 3.45 (br, 1H, CHOH), 3.75 (m, 1H, CHNH), 4.55 (m, 1H, CHNTriazole), 4.88 (m, 1H, 
CHNH), 7.04-7.28 (m, 11H, 10H Ar and 1H CHTriazole); 13C NMR (CDCl3, 100 MHz): δ 20.80 
(CH(CH3)2), 28.23 (C(CH3)3), 28.71 (CH(CH3)2), 31.91 (-CH2CH2Ph), 34.73 (-CH2CH(CH3)2), 
37.25 (-CH2CH2Ph), 38.30 (NHCHCH2Ph), 40.23 (HOCHCH2-), 55.37 (CHNH), 58.71 
(CHNTriazole), 68.75 (CHOH), 79.64 (C(CH3)3), 120.68 (CHTriazole), [126.15, 126.18, 128.28, 
128.35, 128.50, 129.11, 138.14, 140.46, 146.86 (C Ar x8 and CTriazole)], 156.32.
6.3.3.1 General procedure for the synthesis of inhibitors
Triazolyl alcohol (1 eq) was stirred with 40% TFA in dichloromethane for 1 hour. After 
complete deprotection of Boc, solvent was evaporated under reduced pressure to get the free 
amine which was used for further reaction without purification. To a solution of acid (1.05 eq) 
in dichloromethane , HOBt (1 eq) was added followed by N-methyl morpholine (2 eq) at 0 °C 
and stirred for some while. Amine was added dropwise to the reaction mixture followed by 
EDC (1.1 eq) and stirred for 6-8 hrs in room temperature. After completion 5% citric acid 
solution was added to the reaction until pH 6 and separated. Organic layer was  washed with 
NaHCO3 solution followed by brine and dried over sodium sulphate. Solvent was evaporated 
and purified by flash chromatography with ethyl acetate and petroleum ether (1:1) as eluant.
N
O
N
H
Ph
OH N
N
N
O Ph
Ph
N-((2S ,3R,5S)-3-hydroxy-5-(4-(phenoxymethyl)-1H-1,2,3-tr iazol-1-yl)-1 ,7-
diphenylheptan-2- yl)picolinamide (40) The general procedure furnished 90 mg (91%) of 
inhibitor 40 starting from deprotected triazoyl alcohol 36  (80 mg, 0.17 mmol), picolinic acid (24 
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mg, 0.19 mmol), HOBt (23 mg, 0.17 mmol), NMM (0.04 mL, 0.34  mmol), EDC (32 mg, 0.2 
mmol).
1H NMR (CDCl3, 400 MHz): δ 1.67 (m, 1H, HOCHCH2-), 1.92  (m, 1H, HOCHCH2-), 2.16 (m, 
1H, -CH2CH2Ph), 2.41 (m, 3H, 1H -CH2CH2Ph and 2H -CH2CH2Ph), 2.84 (m, 2H, 
HNCHCH2Ph), 3.21  (m, 1H, CHOH), 4.18 (m, 1H, CHNH), 4.46 (m, 1H, CHOH), 4.76 (m, 1H, 
CHTriazole), 5.22 ( two  d, 2H, J=12.2 Hz each, -CH2OPh), 6.94-7.29 (m, 15H, Ar), 7.42  (m, 1H, 
Ar), 7.56 (s, 1H, CHTriazole), 7.82 (m, 1H, Ar), 8.09 (m, 1H, Ar), 8.16 (d, 1H, J= 6.8 Hz, CONH), 
8.50 (m, 1H, Ar); 13C NMR (CDCl3, 100 MHz): δ 32.22 (-CH2CH2Ph), 36.71 (HNCHCH2Ph), 
37.25 (-CH2CH2Ph), 38.53 (HOCHCH2-), 57.80 (CHNH), 58.37 (CHNTriazole), 62.25 (-CH2O-), 
70.13 (CHOH), 115.12 (CHTriazole), [121.46, 122.51, 123.76, 126.40, 126.77, 126.94, 128.58, 
128.73, 128.90, 129.25, 129.75, 129.82, 137.45, 137.71, 140. 58, 143.91, 148.49, 149.18, 158.52 
(C Ar x17 and CTriazole), 166.11 (CONH); MS (ESI, m/z): 584 [MNa]+, 600  [MK]+.
O
N
H
Ph
OH N
N
N
O Ph
PhO
2-(2,6-dimethylphenoxy)-N-((2S,3R,5S)-3-hydroxy-5-(4-(phenoxymethyl)-1H-1,2,3-
triazol-1- yl)-1,7-diphenylheptan-2-yl)acetamide (41)  The general procedure furnished 70 
mg (70%) of inhibitor 41 starting from deprotected triazoyl alcohol 36 (78 mg, 0.17 mmol), 2,6-
dimethylphnoxyacetic acid (34 mg, 0.19 mmol), HOBt (23 mg, 0.17 mmol), NMM (0.04  mL, 
0.34 mmol), EDC (32 mg, 0.2 mmol). 
1H NMR (CDCl3, 400 MHz): δ 1.95 (m, 1H, OHCHCH2-), 2.07 (s, 6H, CH3 x2), 2.20 (m, 2H, 
1H OHCHCH2- and 1H -CH2CH2Ph), 2.47  (m, 3H, 1H -CH2CH2Ph and 2H -CH2CH2Ph), 2.77 
(dd, 1H,  J1= 14.2 Hz, J2= 10.6 Hz, HNCHCH2Ph), 2.86 (dd, 1H, J1=14.2  Hz, J2=5.2 Hz, 
HNCHCH2Ph), 3.24 (m, 1H, CHOH), 4.06 (br, 1H, CHNH), 4.07 (d, 1H, J=14.6  Hz, -
OCH2N-), 4.20 (d, 1H, J=15.1 Hz, -OCH2N-), 4.36 (br, 1H, CHOH), 4.77  (m, 1H, CHTriazole), 
5.23 (two d, 2H, J2=12.3 Hz each, -CH2O-), 6.91-7.29 (m, 19H, 18H Ar and 1H CONH), 7.60 (s, 
1H, CHTriazole); 13C NMR (CDCl3, 100 MHz): δ 16.06 (2x CH3), 32.20 (-CH2CH2Ph), 35.87 
(HNCHCH2Ph), 37.28 (-CH2CH2Ph), 38.77  (HOCHCH2-), 57.34  (CHNH), 58.21 (CHNTriazole), 
62.14 (-CH2O-), 68.83 (CHOH), 70.19 [-CH2 (DmPOA)], 114.90 (CHTriazole), [121.27, 123.38, 
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124.88, 126.26, 126.89, 128.36, 128.57, 128.79, 128.95, 129.11, 129.53, 130.31, 137.03, 140.24, 
143.81, 153.82, 158.20, (C Ar x16 and CTriazole)], 170.36 (CONH); MS (ESI, m/z): 641 [MNa]+, 
657 [MK]+.
O
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2-(o-tolyloxy)-N-((2S,3R,5S)-3-hydroxy-5-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)-1,7- 
diphenylheptan-2-yl)acetamide (42)  The general procedure furnished 78 mg (80%) of 
inhibitor 42  starting from deprotected triazoyl alcohol 36 (74 mg, 0.16  mmol), 2-
methylphenoxyacetic acid (32 mg, 0.19 mmol), HOBt (22 mg, 0.16 mmol), NMM (0.04 mL, 
0.32 mmol), EDC (37 mg, 0.19 mmol).
1H NMR (CDCl3, 400 MHz): δ 1.87 (m, 1H, OHCHCH2-), 2.12 (s, 3H, CH3), 2.17 (m, 2H, 1H 
OHCHCH2- and 1H -CH2CH2Ph), 2.43 (m, 3H, 1H -CH2CH2Ph and 2H -CH2CH2Ph), 2.68 
(dd, 1H, J1=14.1 Hz, J2=6.5 Hz, HNCHCH2Ph), 2.79 (dd, 1H, J1=14.1 Hz, J2=5.0 Hz, 
HNCHCH2Ph), 3.13 (m, 1H, CHOH), 4.06 (m, 1H, CHNH), 4.27 (d, 1H, J=7.8 Hz, CHOH), 
4.33 (d, 1H, J=15.1 Hz, -OCH2N-), 4.34 (d, 1H, J=15.1 Hz, OCH2N-), 4.76 (m, 1H, CHTriazole), 
5.17 (m, 2H, -CH2O-), 6.58 (dd, 2H, J1= 19.1 Hz, J2=8.1 Hz, Ar), 7.03-7.32 (m, 18H 17H Ar and 
CONH), 7.55 (s, 1H, CHTriazole); 13C NMR (CDCl3, 100 MHz): δ 16.00 (CH3), 31.90 (-
CH2CH2Ph), 35.88 (HNCHCH2Ph), 36.94 (-CH2CH2Ph), 38.32  (HOCHCH2-), 56.68 (CHNH), 
57.98 (CHNTriazole), 61.92 (-CH2O-), 67.07 (CHOH), 69.57 [-CH2 (DmPOA)], 111.30  (C sp2), 
114.82 (CHTriazole), [121.22, 123.15, 126.21, 126.86, 128.30, 128.81, 128.97, 129.11, 129.49, 
129.57, 130.34, 136.65, 137.05, 140.16, 143.83, 155.09, 158.21, 158.20 (C sp2 x18)], 170.09 
(CONH);  MS (ESI, m/z): 627 [MNa]+, 643 [MK]+.
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N-((2S,3R,5S)-3-hydroxy-5-(4-isobutyl-1H-1,2,3-triazol-1-yl)-1,7-diphenylheptan-2- yl)
picolinamide (43)  The general procedure furnished 85 mg (85%) of inhibitor 43  starting from 
deprotected triazoyl alcohol 37 (80 mg, 0.19 mmol), picolinic acid (29 mg, 0.21 mmol), HOBt 
(25 mg, 0.25 mmol), NMM (0.04 mL, 0.38 mmol), EDC (43 mg, 0.23 mmol).
1H NMR (CDCl3, 400  MHz): δ 0.90 (d, 3H, J=2.2 Hz, 1x CH(CH3)2), 0.92 (d, 3H, J=2.2 Hz, 1x 
CH(CH3)2), 1.92 (m, 2H, 1H OHCHCH2- and 1H CH(CH3)2), 2.10 (m, 1H, -CH2CH2Ph), 2.25 
(m, 1H, OHCHCH2-), 2.43 (m, 3H, 1H -CH2CH2Ph and 2H -CH2CH2Ph), 2.57 (m, 2H, -
CH2CH(CH3)2), 2.83 (m, 2H, HNCHCH2Ph), 3.23 (m, 1H, CHOH), 4.23 (m, 1H, CHNH), 4.67 
(m, 1H, CHOH), 4.73 (m, 1H, CHNTriazole), 7.05-7.26 (m, 10H, Ar), 7.43 (m, 1H, Ar), 7.82 (m, 
1H, Ar), 8.10 (m, 1H, Ar), 8.16 (d, 1H, J=7.0 Hz, CONH), 8.55 (m, 1H, Ar); 13C NMR (CDCl3, 
100 MHz): δ 22.35 (CH(CH3)2), 28.66 (CH(CH3)2), 32.24 (-CH2CH2Ph), 34.76 (-CH2CH(CH3)
2), 36.64 (HNCHCH2Ph), 37.34 (-CH2CH2Ph), 38.77 (OHCHCH2-), 57.21 (CHNH), 57.86 
(CHNTriazole), 69.94 (CHOH), [121.74, 121.82, 122.24, 126.12, 126.42, 126.56, 128.33, 128.46, 
128.55, 129.07, 137.38, 140.56, 146.53, 148.15, 149.02 (15 C sp2), 165.44 (CONH); MS (ESI, m/
z): 534 [MNa]+, 550 [MK]+.
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2-(2,6-dimethylphenoxy)-N-((2S,3R,5S)-3-hydroxy-5-(4-isobutyl-1H-1,2,3-triazol-1-
yl)-1,7- diphenylheptan-2-yl)acetamide (44)   The general procedure furnished 86 mg (73%) 
of inhibitor 44 starting from deprotected triazoyl alcohol 37 (85 mg, 0.20 mmol), 2,6-
dimethylphenoxy acetic acid (41 mg, 0.22 mmol), HOBt (27 mg, 0.20 mmol), NMM (0.05 mL, 
0.40 mmol), EDC (46 mg, 0.24 mmol).
1H NMR (CDCl3, 500 MHz): δ 0.92 (d, 6H, J=6.0 Hz, CH(CH3)2), 1.96 (m, 2H, 1H 
OHCHCH2- and 1H CH(CH3)2), 2.07  [s, 6H, 2x -CH3 (DmPOA)], 2.18 (m, 2H, 1H 
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OHCHCH2- and 1H -CH2CH2Ph), 2.43 (m, 3H, 1H -CH2CH2Ph and 2H -CH2CH2Ph), 2.59 (m, 
2H, -CH2CH(CH3)2), 2.79 (dd, 1H, J1= 14.2  Hz, J2=10.0 Hz, HNCHCH2Ph), 2.85 (dd, 1H, J1= 
14.2 Hz, J2=5.1  Hz, HNCHCH2Ph), 3.27 (m, 1H, CHOH), 4.05 [d, 1H, J=15.1 Hz, -CH2 
(DmPOA)], 4.19 (m, 1H, CHNH), 4.21 [d, 1H, J=15.1 Hz, -CH2 (DmPOA)], 4.69 (br, 1H, 
CHOH), 4.74 (m, 1H, CHNTriazole), 6.92 (m, 4H, Ar), 7.10 (m, 4H, Ar), 7.18-7.27 (m, 5H, Ar), 
7.30 (s, 1H, CHTriazole); 13C NMR (CDCl3, 125 MHz): δ 16.04 [2x CH3 (DmPOA)], 22.33 (CH
(CH3)2), 28.64 (CH(CH3)2), 29.70 (-CH2CH2Ph), 32.28 (-CH2CH(CH3)2), 34.75 (HNCHCH2Ph), 
35.81 (-CH2CH2Ph), 37.45 (OHCHCH2-), 56.57 (CHNH), 56.62 (CHNTriazole), 62.14 (-OCH2-), 
69.85 (CHOH), [121.53, 121.64, 124.81, 126.23, 126.72, 128.35, 128.46, 128.54, 129.05,  130.32, 
137.34, 140.49, 146.69, 153.89 (14x  C sp2), 169.86 (CONH); MS (ESI, m/z): 591 [MNa]+, 607 
[MK]+.
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N-((2S ,3S ,5S)-3-hydroxy-5-(4-(phenoxymethyl)-1H-1,2,3-tr iazol-1-yl)-1 ,7-
diphenylheptan-2- yl)picolinamide (45) The general procedure furnished 90 mg (90%) of 
inhibitor 45 starting from deprotected triazoyl alcohol 38  (80 mg, 0.17 mmol), picolinic acid (24 
mg, 0.19 mmol), HOBt (23  mg, 0.17 mmol), NMM (0.04 mL, 0.34 mmol), EDC (40 mg, 0.20 
mmol).
1H NMR (CDCl3, 500 MHz): δ 1.77 (m, 1H, OHCHCH2-), 2.04  (m, 1H, OHCHCH2-), 2.14 (m, 
2H, 1H -CH2CH2Ph and 1H -CH2CH2Ph), 2.21 (m, 2H, 1H -CH2CH2Ph and 1H -CH2CH2Ph), 
2.98 (m, 2H, HNCHCH2Ph), 3.12 (br, 1H, CHOH), 3.62 (m, 1H, CHOH), 4.20 (m, 1H, CHNH), 
4.68 (m, 1H, CHNTriazole), 5.14 (two d, 2H, J=12.4 Hz each, -OCH2-), 6.98 (m, 5H, Ar), 7.15-7.29 
(m, 11H, Ar), 7.39  (s, 1H, CHTriazole), 7.79 (m, 1H, Ar), 8.13 (d, 1H, J=7.8 Hz, Ar), 8.37 (d, 1H, 
J=8.9 Hz, CONH), 8.53 (m, 1H, Ar); 13C NMR (CDCl3, 125 MHz): δ 31.84 (-CH2CH2Ph), 
36.76 (HNCHCH2Ph), 37.97 (-CH2CH2Ph), 40.31 (OHCHCH2-), 55.08 (CHNH), 59.06 
(CHNTriazole), 62.07 (-CH2O-), 68.70 (CHOH), 114.83 (CHNTriazole), [121.26, 122.29, 126.15, 
126.36, 126.56, 128.28, 128.33, 128.47, 128.60, 129.19, 129.54, 137.37, 137.91, 140.26, 143.91, 
148.22, 149.34, 158.21 (18 C sp2), 164.82 (CO); MS (ESI, m/z): 584 [MNa]+, 600 [MK]+.
Chapter 6
130
ON
H
Ph
OH N
N
N
O Ph
PhO
2-(2,6-dimethylphenoxy)-N-((2S,3S,5S)-3-hydroxy-5-(4-(phenoxymethyl)-1H-1,2,3-
triazol-1- yl)-1,7-diphenylheptan-2-yl)acetamide (46) The general procedure furnished 86 
mg (75%) of  inhibitor 46 starting from deprotected triazoyl alcohol 38 (85 mg, 0.18 mmol), 2,6-
dimethylphenoxy acetic acid (37 mg, 0.2 mmol), HOBt (25 mg, 0.18 mmol), NMM (0.04 mL, 
0.36 mmol), EDC (42 mg, 0.22 mmol).
1H NMR (CDCl3, 500 MHz): δ 2.09 (m, 1H, OHCHCH2-), 2.16 [s, 6H, CH3 (DmPOA)], 2.19 
(m, 2H, 1H OHCHCH2- and 1H -CH2CH2Ph), 2.39 (m, 3H, 1H -CH2CH2Ph and 2H 
CH2CH2Ph), 2.94 (m, 3H, 2H  HNCHCH2Ph and 1H CHOH), 3.61 (m, 1H, CHOH), 4.21 (m, 
3H, 2H -OCH2- and 1H CHNH), 4.66 (m, 1H, CHNTriazole), 5.13 [s, 2H, -OCH2- (DmPOA)], 
6.93-7.03 (m, 9H, 8H Ar and 1H CONH), 7.17-7.31 (m, 10H, Ar), 7.43 (s, 1H, CHTriazole); 13C 
NMR (CDCl3, 125 MHz): δ 16.22 [2x CH3 (DmPOA)], 31.74 (-CH2CH2Ph), 36.92 
(HNCHCH2Ph), 37.90 (-CH2CH2Ph), 40.38  (OHCHCH2-), 54.34  (CHNH), 59.08 (CHNTriazole), 
59.08 (-OCH2-), 68.83 (CHOH) 70.19 [-CH2 (DmPOA)], 114.80 (CHTriazole), [121.31, 122.10, 
124.77, 126.25, 126.73, 128.25, 128.29, 128.54, 128.68, 129.12, 129.56, 129.58, 130.34, 137.16, 
140.16, 154.15, 158.18 (17 C sp2)], 169.37 (CONH);  MS (ESI, m/z): 641 [MNa]+, 657 [MK]+.
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2-(o-tolyloxy)-N-((2S,3S,5S)-3-hydroxy-5-(4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl)-1,7- 
diphenylheptan-2-yl)acetamide (47)  The general procedure furnished 69 mg (79%) of 
inhibitor 47 starting from deprotected triazoyl alcohol 38 (75 mg, 0.16  mmol), 2-methylphenoxy 
acetic acid (30 mg, 0.18  mmol), HOBt (22 mg, 0.16 mmol), NMM (0.04 mL, 0.32 mmol), EDC 
(37 mg, 0.19 mmol).
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1H NMR (CDCl3, 500 MHz): δ 1.92 (m, 1H, OHCHCH2-), 2.12  (m, 2H, 1H OHCHCH2- and 
1H -CH2CH2Ph), 2.21 [s, 3H, CH3 (oMePOA)], 2.36 (m, 3H, 1H -CH2CH2Ph and 2H 
CH2CH2Ph), 2.84 (m, 3H, 2H  HNCHCH2Ph and 1H CHOH), 3.55 (m, 1H, CHOH), 4.13 (m, 
1H, CHNH), 4.43 (two d, 2H, J=14.9 Hz each, -OCH2-), 4.55 (m, 1H, CHNTriazole), 5.16  (s, 2H, 
oMePOA), 6.71 (d, 1H, J= 8.1 Hz, Ar), 6.90-7.04 (m, 6H, Ar), 7.11-7.33 (m, 14H, 12H Ar, 1H 
CHNH and 1H CHTriazole); 13C NMR (CDCl3, 125 MHz): δ 16.27 [-CH3 (oMePOA)], 31.82 (-
CH2CH2Ph), 36.90 (HNCHCH2Ph), 38.07 (-CH2CH2Ph), 40.23  (OHCHCH2-), 54.08 (CHNH), 
59.05 (CHNTriazole), 62.03 (-OCH2-), 67.34 (CHOH), 68.48 [OCH2 (oMePOA)], 111.39 (C sp2), 
114.81 (CHTriazole), [121.31, 121.91, 126.25, 126.65, 126.73, 126.91, 127.13, 128.28, 128.54, 
128.70, 129.12, 129.26, 129.56, 131.15, 137.46, 140.07, 155.26, 158.08 (18x  C sp2)], 168.89 
(CONH); MS (ESI, m/z): 627 [MNa]+, 643 [MK]+. 
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2-(2,6-dimethylphenoxy)-N-((2S,3S,5S)-3-hydroxy-5-(4-isobutyl-1H-1,2,3-triazol-1-yl)-1,7- 
diphenylheptan-2-yl)acetamide (48) The general procedure furnished 65 mg (57%) of 
inhibitor 48 starting from deprotected triazoyl alcohol 39 (85 mg, 0.20 mmol), 2,6-
dimethylphenoxy acetic acid (41 mg, 0.22 mmol), HOBt (27 mg, 0.20 mmol), NMM (0.05 mL, 
0.40 mmol), EDC (46 mg, 0.24 mmol).
1H NMR (CDCl3, 500 MHz): δ 0.92 (d, 6H, J=6.6 Hz, CH(CH3)2), 1.95  (m, 1H, CH(CH3)2), 2.05 
(m, 1H, OHCHCH2-), 2.17  [s, 6H, 2x CH3 (DmPOA)], 2.19-2.29 (m, 3H, 1H OHCHCH2- and 
2H -CH2CH2Ph), 2.41 (m, 2H, -CH2CH2Ph), 2.57 (dd, 2H, J1=7.4 Hz, J2=4.5 Hz, -CH2CH(CH3)
2), 2.93 (br, 1H, CHOH), 2.95 (m, 2H, HNCHCH2Ph), 3.61 (m, 1H, CHOH), 4.20 (m, 1H, 
CHNH), 4.22 [two d, 2H, -CH2 (DmPOA)], 4.61 (m, 1H, CHNTriazole), 6.93-7.28 (m, 15H, 13H 
Ar, 1H CHTriazole and 1H CONH).
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N-((2S,3S,5S)-3-hydroxy-5-(4-isobutyl-1H-1,2,3-triazol-1-yl)-1,7-diphenylheptan-2-yl)
picolinamide (49)  General procedure furnished 72  mg (74%) of inhibitor 49 starting from 
deprotected triazoyl alcohol 39 (80 mg, 0.19 mmol), picolinic acid (29 mg, 0.21 mmol), HOBt 
(25 mg, 0.25 mmol), NMM (0.04 mL, 0.38 mmol), EDC (43 mg, 0.23 mmol).
1H NMR (CDCl3, 500 MHz): δ 0.92 (d, 6H, J=6.5 Hz, CH(CH3)2), 1.95 (m, 1H, CH(CH3)2), 
2.02-2.24 (m, 3H, 1H OHCHCH2- and 2H -CH2CH2Ph), 2.33 (m, 2H, -CH2CH2Ph), 2.54 (m, 
2H, -CH2CH(CH3)2), 2.96  (br, 1H, CHOH), 2.98 (m, 2H, HNCHCH2Ph), 3.62 3.61  (m, 1H, 
CHOH), 4.23 (m, 1H, CHNH), 4.63 (m, 1H, CHNTriazole), 7.02-7.26 (m, 12H, 11H Ar and 1H 
CHTriazole), 7.43  (m, 1H, Ar), 7.85 (m, 1H, Ar), 7.14 (d, 1H, J=4.7 Hz Hz, Ar), 8.36 (d, 1H, J=9.1 
Hz, CONH), 8.54 (d, 1H, J=7.8 Hz, Ar); 13C NMR (CDCl3, 125 MHz): δ 22.31 (CH(CH3)2), 
28.64 (CH(CH3)2), 31.88 (-CH2CH2Ph), 34.75  (-CH2CH(CH3)2), 37.01  (HNCHCH2Ph), 38.04  (-
CH2CH2Ph), 40.39 (OHCHCH2-), 55.14 (CHNH), 58.71  (CHNTriazole), 68.94 (CHOH), [120.62, 
122.26, 126.14, 126.33, 126.53, 128.28, 128.47, 128.56, 129.19, 137.35, 137.92, 140.42, 144.60, 
146.97, 149.39 (sp2 x 15)], 156.15 (CONH).
6.3.4 Chapter 5
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(S)-tert-butyl 1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-ylcarbamate (51)  To a 
solution of Boc-L-phenylalanine (5g, 18.8 mmol) in DCM (40 mL) cooled to -15°C was added 
4.13 mL (37.6 mmol) of N-methyl-morpholine (NMM) and 2.44  mL (18.8 mmol) of 
isobutylchloroformiate. After 2h of stirring at -15°C, 1.96 g (20.05 mmol) of N,O-
dimethylhydroxyamine was added. The mixture was stirred for 1h at -15°C and for additional 3h 
at r.t. The reaction was quenched with 50 mL of water, the organic layer was separated and 
washed with 10% (w/v) solution of citric acid, water, saturated solution of NaCl and dried over 
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anhydrous Na2SO4. After column chromatography DCM/MeOH 1/1 product was isolated as 
transparent oil (4.97g, 86%)
1H-NMR (CDCl3, 270MHz): δ 1.42 (s, 9H, C(CH3)3), 2.88 (m, 1H, -CH2Ph), 3.04 (m, 1H, -
CH2Ph), 3.16 (s, 3H, -NCH3), 3.65 (s, 3H, -OCH3), 4.96 (m, 1H, CHNH), 5.16 (br, 1H, CHNH), 
7.16-7.29 (m, 5H, Ar); 13C-NMR (CDCl3, 67.5MHz): δ 28.07 (C(CH3)3), 38.80 (CH2Ph), 51.48 
(CHNH), 61.47 (-NCH3), 76.52 (-OCH3), 79.50 (C(CH3)3), [126.70, 128.28, 129.25, 136.54 (Ar)], 
155.09 (CO Boc), 172.22 (CO).
BocHN
Ph
O
(S)-tert-butyl 1-oxo-3-phenylpropan-2-ylcarbamate (52) To solution of Weinrebb amide 51
(2.4g, 7.78 mmol) in dry diethyl ether (21 mL), lithium aluminium hydride (LAH) (385 mg, 10.11 
mmol) was added in small portions at 0°C. After 1h of stirring at r.t, the product was extracted 
with three portions of ethyl acetate. The combined  organic layers were washed with brine and 
dried over anhydrous Na2SO4. After the solvent removal we have obtained 1.84 g (95%) of 
white solid which was used without purification in further reactions.
1H-NMR (CDCl3, 270MHz): δ 1.44 (s, 9H, C(CH3)3), 3.11 (m, 2H, -CH2Ph), 4.42 (m, 1H, 
CHNH), 5.05 (br, 1H, CHNH), 7.19 (m, 5H, Ar), 9.64 (s, 1H, CHO).
BocHN
Ph
(S)-tert-butyl 1-phenylbut-3-en-2-ylcarbamate (53) To a stirred suspension of the 
methyltriphenilphosphonium bromide (Ph3P+CH3Br-) (4.00g, 11.2 mmol) in dry toluene a 0.5M 
solution of potassium bis(trimethylsilyl)amide (KHMDS) (22.4 mL) was added dropwise at 0°C 
under argon atmosphere. The yellow  mixture was stirred for 1h and then cooled to -78°C. A 
solution of dry aldehyde in toluene was then added in one portion. The resulting yellow  mixture 
was then stirred at r.t. and after 20 min reaction was quenched with saturated solution of NH4Cl 
and extracted with diethyl ether. The combined organic layers were washed with brine and dried 
over anhydrous NaSO4. After column chromatography petroleum using ether/ethyl acetate 1/1 
as eluant 1.4g (58%) of  white solid were obtained.
[α]D =16.9 (c 10, CHCl3); 1H-NMR (CDCl3, 400MHz): δ 1.40 (s, 9H, C(CH3)3), 2.82 (m, 2H, -
CH2Ph), 4.42 (m, 2H, 1H CHNH and CHNH), 5.06 (m, 2H, =CH2), 5.78 (m, 1H, CH=), 7.16 
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(m, 5H, Ar); 13C-NMR (CDCl3, 100MHz): δ 28.43 (C(CH3)3), 41.54 (CH2Ph), 53.53 (CHNH), 
79.50 (C(CH3)3), 114.81 (=CH2), [126.55, 128.40, 129.64, 137.47, 138.12 (4H Ar and 1H CH=), 
155.27 (CO Boc); MS (ESI, m/z): 270 [MNa]+.
N
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(S)-tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (54) To a 0°C solution of Boc-L-
proline (1g, 4.64  mmol) in 6 mL of dry THF is slowly added under argon atmosphere the 2M 
solution of BH3.DMS (4.64 mL) in toluene. The solution is stirred at 0°C under argon during 
3h and then at r.t. during 22h more. The solution is  then cooled to 0°C and 40 mL of water is 
slowly added. The product is extracted with ethyl acetate (3x20 mL), the combined organic 
fractions were washed with brine and dried over anhydrous NaSO4. The solvent removal yielded 
700 mg (75%) of  transparent oil.
1H-NMR (CDCl3, 400MHz): δ 1.47  (m, 9H, C(CH3)3), 1.79-2.18 (m, 4H, -CH2CH2-), 3.33-3.61 
(m, 4H, 2H CH2OH and 2H NCH2-), 3.96 (br, 1H, CHOH), 4.81 (br, 1H CHN)
N
Boc
O
(S)-tert-butyl 2-formylpyrrolidine-1-carboxylate (55)  To a solution of Boc-L-prolinol 54 
(700 mg, 3.48 mmol) in 15  mL of DCM was added pyridinium chlorocromate (PCC) (1.05g, 
4.89 mmol), acetic acid (325 μL, 5.68 mmol) and molecular sieves. After 2h the dark brown 
precipitate was filtered off on pad of celite and the organic solution was washed with saturated 
solution on NaHCO3 and brine. The  solvent removal yielded 480 mg (70%) of a pale yellow  oil 
which was used without purification in further reactions.
1H-NMR (CDCl3, 400MHz): δ 1.45 (m, 9H, C(CH3)3), 1.83-1.89 (m, 4H, -CH2CH2-), 3.45  (m, 
2H, NCH2-), 4.05 (m, 1H, CHN), 9.45 (m, 1H, CHO)
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(S)-tert-butyl 2-vinylpyrrolidine-1-carboxylate (56) To a stirred suspension of the 
methyltriphenilphosphonium bromide (Ph3P+CH3Br-) (728 mg, 2.04 mmol) in dry toluene a 
0.5M solution of potassium bis(trimethylsilyl)amide (KHMDS) (4.08  mL) was added dropwise 
at 0°C under argon atmosphere. The yellow  mixture was stirred for 1h and then cooled to 
-78°C. A solution of dry aldehyde (340 mg, 1.70 mmol) in toluene was  then added in one 
portion. The resulting yellow  mixture was then stirred at r.t. and after 20 min reaction was 
quenched with saturated solution of NH4Cl and extracted with diethyl ether. The combined 
organic layers were washed with brine and dried over anhydrous NaSO4. After column 
chromatography petroleum using ether/ethyl acetate 1/1  as eluant 55 mg (16%) of white solid 
were obtained.
[α]D =-13.4 (c 2.1, CHCl3); 1H-NMR (CDCl3, 400MHz): δ 1.43 (m, 9H, C(CH3)3), 1.65-1.81 (m, 
4H, -CH2CH2-), 3.40 (m, 2H, NCH2-), 4.25 (m, 1H, CHN), 5.05 (m, 2H, =CH2), 5.73 (m, 1H, 
CH=); MS (ESI, m/z): 220 [MNa]+.
HO O
HN
O
3-(hydroxymethyl)benzyl  allylcarbamate (m-57)  To a solution of 1,3 -benzedimethanol (200 
mg, 1.45 mmol) at 0°C in dry CH3CN (10 mL) and under argon atmosphere was added 300 μL 
of dry pyridine and  of N,N’-disuccimydil dicarbonate (370 mg, 1.45 mmol) in small portions. 
After 30 min allylamine (99 mg, 1.74 mmol) was added.  After 16h the solvent was  removed by 
distillation under reduced pressure  and the crude product was purified by column 
chromatography using DCM/MeOH 9/1 as eluent. The procedure yielded 213 mg (67%) of 
transperant oil.
1H-NMR (CDCl3, 500MHz): δ 2.20 (br, 1H, CH2OH), 3.80 (m, 2H, CH2NH), 4.68 (s, 2H, 
CH2OH), 4.90 (br, 1H, CH2NH), 5.09 (m, 4H, 2H CH2O- and 2H =CH2), 5.82 (m, 1H, CH=), 
7.30 (m, 4H, Ar);  13C-NMR (CDCl3, 100MHz): δ 43.57 (CH2NH), 65.10 (CH2OH), 66.72 
(CH2O-), 116.21 (=CH2), [124.00, 126.66, 126.79, 127.35, 128.84, 129.90 (Ar)], 134.47 (CH=), 
156.32 (CO); MS (ESI, m/z): 244 [MNa]+, 260 [MK]+.
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[3-({[(prop-2-en-1-yl)carbamoyl]oxy}methyl)phenyl]methyl N-[(2S)-1-phenylbut-3-en-2-
yl]carbamate (m-58)  To a suspension of N,N’-disuccimydil dicarbonate (190 mg, 0.73 mmol) 
in dry CH3CN under argon atmosphere was added 200 μL of dry pyridine and m-57 (135 mg, 
0.61 mmol). After 30 min 107 mg of deprotected 53 (0.61 mmol) was added. After 16h solvent 
was removed by distillation under reduced pressure and to the crude mixture water 5 mL was 
added. The white precipitate was filtered and the filtrate was washed with water. The procedure 
yielded 260 mg (93%) of  a white solid.
1H-NMR (CDCl3, 500MHz): δ 2.81-2.88 (m, 2H, CH2Ph), 3.82 (m, 2H, -NCH2-) 4.50 [br, 1H, 
CHNH(Phe)], 4.77 [br, 1H, CHNH(Phe)], 4.85 (br, 1H, CH2NH), 5.01-5.11 (m, 8H, 4H CH2O- 
and 4H =CH2), 5.75 (m, 2H, CH=), 7.14-7.37 (m, 9H, Ar); 13C-NMR (CDCl3, 125MHz): δ 41.46 
(CH2Ph), 43.50 (CH2NH), 53.35 (CHNH), [66.48, 66.50  (CH2O-)], 114.93 (=CH2), 116.12 
(=CH2), [123.86, 126.61, 127.76, 129.45, 129.49, 134.38, 136.36, 136.85, 137.02, 137.23, 138.60, 
138.69 (12 x C sp2)], 156.14 (CO), 156.89 (CO); MS (ESI, m/z): 417 [MNa]+, 433 [MK]+.
O
NH
O O
HN
O
Ph
[2-({[(prop-2-en-1-yl)carbamoyl]oxy}methyl)phenyl]methyl N-[(2S)-1-phenylbut-3-en-2-
yl]carbamate(o-58) To a suspension of N,N’-disuccimydil dicarbonate (257 mg, 1.00 mmol) in 
dry CH3CN under argon atmosphere was  added 100 μL of dry pyridine and o-57  (135  mg, 0.61 
mmol). After 30 min 107 mg of deprotected 53 (0.61 mmol) was added. After 16h solvent was 
removed by distillation under reduced pressure and to the crude mixture water 5 mL was added. 
The white precipitate was filtered and the filtrate was washed with water. The procedure yielded 
343 mg (87%) of  a white solid.
1H-NMR (CDCl3, 500MHz): δ 2.85 (m, 2H, CH2Ph), 3.78 (m, 2H, -NCH2-) 4.47 [br, 1H, CHNH
(Phe)], 4.77 [br, 1H, CHNH(Phe)], 4.84 (br, 1H, CH2NH), 5.07-5.17 (m, 8H, 4H CH2O- and 4H 
=CH2), 5.79 (m, 2H, CH=), 7.16-7.32 (m, 9H, Ar); 13C-NMR (CDCl3, 125MHz): δ 41.23 
(CH2Ph), 43.46 (CH2NH), 54.02 (CHNH), [64.30, 64.33  (CH2O-)], 115.12 (=CH2), 116.12 
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(=CH2), [129.47, 129.55, 131.81, 131.91, 135.41, 136.99, 137.60, 137.82, 138.40 (9 x  C sp2)], 
156.00 (CO), 156.62 (CO); MS (ESI, m/z): 417 [MNa]+, 433 [MK]+.
O
NH
O OH
Ph
(S)-2-(hydroxymethyl)benzyl 1-phenylbut-3-en-2-ylcarbamate (o-57) To a solution of 1,3 -
benzedimethanol (300 mg, 2.17 mmol) at 0°C in dry CH3CN  and under argon atmosphere was 
added 300 μL of dry pyridine and N,N’-disuccimydil dicarbonate (500 mg, 1.95 mmol) in small 
portions. After 30 min deprotected 53  (279 mg, 1.95 mmol) was added.  After 16h the solvent 
was removed by distillation under reduced pressure  and the crude product was purified by 
column chromatography using petroleum ether/ethyl acetate 1/1 as eluent. The procedure 
yielded 424 mg (70%) of  transperant oil.
1H-NMR (CDCl3, 500MHz): δ 2.42 (br, 1H, CH2OH), 2.84 (m, 2H, CH2Ph), 4.47 (br, 1H, 
CHNH), 4.70 (m, 3H, 1H CHNH and 2H CH2OH), 5.08-5.11 (m, 4H, 2H CH2O- and 2H 
=CH2), 5.77 (m, 1H, CH=), 7.14-7.30 (m, 9H, Ar); 13C-NMR (CDCl3, 125MHz): δ 41.21 
(CH2Ph), 53.72 (CHNH), 62.84  (CH2OH), 64.26 (CH2O-), 115.18  (=CH2), [126.63, 128.33, 
128.40, 128.43, 128.52, 128.92, 129.00, 134.28, 136.93, 137.51, 139.18 (10 Ar and CH=)], 155.60 
(CO).
O
NH
O O
HN
O
Ph Ph
2-((tert-butoxycarbonyl((S)-1-phenylbut-3-en-2-yl)carbamoyloxy)methyl)benzyl tert-
butyl (S)-1-phenylbut-3-en-2-yliminodicarbonate (60)  To a suspension of N,N’-disuccimydil 
dicarbonate (742 mg, 2.90 mmol) at in dry CH3CN (10 mL) and under argon atmosphere was 
added 300 μL of dry pyridine and 1,2  -benzedimethanol (200 mg, 1.45 mmol). After 30 min 
deprotected 53 (2.90 mmol) was added.  After 16h solvent was removed by distillation under 
reduced pressure and to the crude mixture water 5 mL was added. The white precipitate was 
filtered and the filtrate was washed with water. The procedure yielded 589 mg (84%) of a white 
solid.
Chapter 6
138
1H-NMR (CDCl3, 500MHz): δ 2.84 (m, 4H, -CH2Ph), 4.47 (br, 2H, CHNH), 4.73 (br, 2H, 
CHNH), 5.10 (m, 8H, 4H -CH2O- and 4H =CH2), 5.76 (m, 2H, CH=), 7.19,-7.31 (m, 14H, Ar); 
13C-NMR (CDCl3, 100MHz): δ 41.27 (CH2Ph), 54.04 (CHNH), 64.17 (CH2O-), 115.15 (=CH2), 
[126.61, 128.39, 128.46, 129.37, 129.49, 134.85, 137.03, 137.61 (Ar) and (CH=)], 155.41 (CO)
O
HN
O O
NH
O
pentane-1,5-diyl  bis(allylcarbamate) (61) To a suspension of N,N’-disuccimydil dicarbonate 
(2.56 mg, 10.56 mmol) at in dry CH3CN (10  mL) and under argon atmosphere was  added 500 
μL of dry pyridine and 503 μL of 1,5-pentadiol (4.80 mmol). After 30  min 790 μL allylamine 
(10.56 mmol) was added. After 16h solvent was removed by distillation under reduced pressure 
and to the crude mixture water 5 mL was added. The white precipitate was filtered and the 
filtrate was washed with water. The procedure yielded 1.18 g(91%) of  a white solid.
1H-NMR (CDCl3, 270MHz): δ 1.39 (m, 2H, -OCH2CH2CH2CH2CH2O-), 1.59 (m, 4H, -
OCH2CH2CH2CH2CH2O-), 3.77 (m, 4H, -CH2N-), 4.04 (m, 4H, -OCH2-), 4.77  (br, 2H, 
CH2NH), 5.11 (m, 4H, =CH2), 5.83 (m, 2H, CH=); 13C-NMR (CDCl3, 67.5MHz): δ 22.34 (-
OCH2CH2CH2CH2CH2O-), 28.60 (-OCH2CH2CH2CH2CH2O-), 42.90 (CH2NH), 64.77 
(CH2O-), 115.92 (=CH2), 131.78 (CH=), 156.56 (CO).
O
HN
O O
NH
O
1,2-phenylenebis(methylene)  bis(allylcarbamate)  (o-62)  Following the above described 
procedure we have obtained 593 mg (90%) starting from N,N’-disuccimydil dicarbonate (1.22 g, 
4.78 mmol), 1,2-benzedimethanol (300 mg, 2.17 mmol) and 357 μL allylamine (272 mg, 4.78 
mmol).
1H-NMR (CDCl3, 270MHz): δ 3.72 (m, 4H, CH2NH), 4.82 (br, 2H, CH2NH), 5.07 (m, 8H, 4H 
CH2O- and 4H =CH2), 5.70 (m, 2H, CH=), 7.19 (m, 4H, Ar); 13C-NMR (CDCl3, 67.5MHz): δ 
43.49 (CH2NH), 64.36 (CH2O-), 116.15 (=CH2), [128.55, 129.55, 134.34 (Ar)], 134.88 (CH=), 
156.06 (CO).
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1,4-phenylenebis(methylene)  bis(allylcarbamate)  (p-62) Following the above described 
procedure we have obtained 593 mg (90%) starting from N,N’-disuccimydil dicarbonate (815 
mg, 3.18 mmol), 1,2-benzedimethanol (200 mg, 1.45 mmol) and 357 μL allylamine (272  mg, 
4.78 mmol).
1H-NMR (CDCl3, 500MHz): δ 3.75 (m, 4H, CH2NH), 4.74 (br, 2H, CH2NH), 5.04 (m, 8H, 4H 
CH2O- and 4H =CH2), 5.76 (m, 2H, CH=), 7.28 (s, 4H, Ar); 13C-NMR (CDCl3, 125MHz): δ 
43.49 (CH2NH), 66.39 (CH2O-), 116.13 (=CH2), [128.26, 124.15 (Ar)], 134.36 (CH=), 154.98 
(CO).
O
NH
O O
HN
O
1,3-phenylenebis(methylene)  bis(allylcarbamate) (m-62) Following the above described 
procedure we have obtained 1.23 g (80%) starting from N,N’-disuccimydil dicarbonate (2.85  g, 
11.13 mmol), 1,2-benzedimethanol (700 mg, 5.06 mmol) and 832 μL allylamine (635 mg, 11.13 
mmol).
1H-NMR (CDCl3, 400MHz): δ 3.82 (m, 4H, CH2NH), 4.86 (br, 2H, CH2NH), 5.19 (m, 8H, 4H 
CH2O- and 4H =CH2), 5.82 (m, 2H, CH=), 7.33 (m, 4H, Ar); 13C-NMR (CDCl3, 125MHz): δ 
43.53 (CH2NH), 64.46 (CH2O-), 116.14 (=CH2), [128.55, 129.01, 129.55, 134.34 (Ar)], 134.76 
(CH=), 156.00 (CO).
O
BocN
O O
NBoc
O
tert-butyl pentane-1,5-diyl bis(allyliminodicarbonate)  (61a) To a solution of diene 61 (400 
mg, 1.48  mmol) in dry THF under argon atmosphere at -78°C lithium disopropylamide (LDA) 
(363 mg, 3.4 mmol) in dry THF (4 mL) was added dropwise. After 30 min di-tert-butyl 
dicarbonate (806 mg, 3.7  mmol) was added. After 1h of stirring at -78°C the reaction was 
quenched with saturated solution of NH4Cl and product was extracted with ethyl acetate (3x 15 
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mL). The combined organic layers were washed with brine and dried over anhydrous NaSO4. 
After solvent removal 654 mg (94%) of  pale yellow oil were obtained.
1H-NMR (CDCl3, 400MHz): δ 1.42 (m, 20H, 2H -OCH2CH2CH2CH2CH2O- and 18H C(CH3)3), 
1.73(m, 4H, -OCH2CH2CH2CH2CH2O-), 4.16 (m, 8H, 4H -CH2N- and 4H -OCH2-),  5.16 (m, 
4H, =CH2), 5.80 (m , 2H, CH=); 13C-NMR (CDCl3, 100MHz): δ 22.36 (-
OCH2CH2CH2CH2CH2O-), 28.05 (C(CH3)3), 28.29 (-OCH2CH2CH2CH2CH2O-), 48.57 
(CH2NH), 66.57 (CH2O-), 82.84 (C(CH3)3), 116.56 (=CH2), 133.46 (CH=), 151.83(CO) 153.87 
(CO Boc).
O
BocN
O O
NBoc
O
1,2-phenylenebis(methylene)  tert-butyl bis(allyliminodicarbonate)  (o-62a)  Following the 
above described procedure we have obtained 434 mg (94%) starting from diene o-62 (280 mg, 
0.92 mmol), LDA (226 mg, 2.2 mmol) in 2 mL of  THF and Boc2O (501 mg, 2.3 mmol).
1H-NMR (CDCl3, 500MHz): δ 1.39 (s, 18H, C(CH3)3), 4.22 (m, 4H, CH2NH), 5.09  (m, 8H, 4H 
CH2O-), 5.32 (s, 4H, =CH2), 5.77 (m, 2H, CH=), 7.32 (m, 2H, Ar), 7.43 (m, 2H, Ar) ; 13C-NMR 
(CDCl3, 125MHz): δ 28.18 (C(CH3)3), 48.90 (CH2NH), 68.56 (CH2O-), 80.92 (C(CH3)3), 116.65 
(=CH2), [128.55, 128.92, 129.55, 134.34 (Ar)], 134.88 (CH=), 152.06 (CO), 153.97 (CO Boc).
O
NBoc
O O
BocN
O
1,3-phenylenebis(methylene)  tert-butyl  bis(allyliminodicarbonate)  (m-62a)  Following the 
above described procedure we have obtained 1.42g (89%) starting from diene m-62 (1 g, 3.28 
mmol), LDA (806 mg, 7.54 mmol) in 7 mL of  THF and Boc2O (1.64 g, 7.54 mmol).
1H-NMR (CDCl3, 400MHz): δ 1.45 (s, 18H, C(CH3)3), 4.22 (m, 4H, CH2NH), 5.08 (m, 4H, 
=CH2), 5.20 (s,  4H, CH2O-), 5.82 (m, 2H, CH=), 7.33 (m, 4H, Ar); 13C-NMR (CDCl3, 
100MHz): δ 28.01  (C(CH3)3), 48.67 (CH2NH), 68.09 (CH2O-), 80.71 (C(CH3)3), 116.74 
(=CH2), [127.83, 128.11, 128.86, 133.34 (Ar)], 135.98 (CH=), 151.75 (CO), 153.67 (CO Boc).
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O
1,4-phenylenebis(methylene)  tert-butyl bis(allyliminodicarbonate)  (p-62a)  Following the 
above described procedure we have obtained 450 mg (90%) starting from diene p-62 (300 mg, 
0.99 mmol), LDA (214 mg, 2.00 mmol) in 3 mL of  THF and Boc2O (545 mg, 2.5 mmol).
1H-NMR (CDCl3, 500MHz): δ 1.42 (s, 18H, C(CH3)3), 4.22 (m, 4H, CH2NH), 5.08-5.26 (m, 8H, 
4H CH2O- and 4H =CH2), 5.79 (m, 2H, CH=), 7.32  (s, 4H, Ar); 13C-NMR (CDCl3, 125MHz): δ 
28.11 (C(CH3)3), 48.79 (CH2NH), 68.59 (CH2O-), 82.01 (C(CH3)3), 116.24 (=CH2), [128.76, 
135.15 (Ar)], 135.53 (CH=), 152.16 (CO), 153.46 (CO Boc).
O
NBoc
O O
BocN
O
Ph Ph
2-((tert-butoxycarbonyl((R)-1-phenylbut-3-en-2-yl)carbamoyloxy)methyl)benzyl tert-
butyl (S)-1-phenylbut-3-en-2-yliminodicarbonate (60a)  To a a solution of diene 60 (100 mg, 
0.15 mmol) in CH3CN (5 mL) were added DMAP (6 mg, 0.05 mmol) and Boc2O (82 mg, 0.38 
mmol). After 16h water was added, and the product was extracted with ethyl acetate (3x  10 mL). 
The combined organic layers were washed with 10% (w/v) citric acid, water, brine and dried 
over anhydrous NaSO4. The crude product was  purified by column chromatography using 
petroleum ether/ethyl acetate 1/1 as eluent. The procedure yielded 97 mg (73%) of transparent 
oil.
1H-NMR (CDCl3, 500MHz): δ 1.33 (s, 18H, C(CH3)3), 3.02  (m, 2H, CH2Ph), 5.02 (m, 2H, 
CHNH), 5.16  (m, 8H, 4H -CH2O- and 4H =CH2), 6.04 (m, 2H, CH=), 7.12-7.32 (m, 14H, Ar); 
13C-NMR (CDCl3, 100MHz): δ 28.43 (C(CH3)3), 41.27 (CH2Ph), 54.04 (CHNH), 64.17 
(CH2O-), 83.89 (C(CH3)3), 115.15 (=CH2), [126.61, 128.39, 129.49, 134.85, 137.03, 137.61 (Ar)], 
155.41 (CO).
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1,3-phenylenebis(methylene)  bis(allyl(methyl)carbamate)  (m-62b) To a solution of diene 
m-62  (500mg, 1.64 mmol) in dry THF at 0°C was added 131 mg NaH (60% dispertion in 
mineral oil). After 30 min of stirring at 0°C 200 μL CH3I was added.  After 16h water was 
added, and the product was extracted with ethyl acetate (3x  10 mL). The combined organic 
layers were washed with 10% (w/v) citric acid, water, brine and dried over anhydrous NaSO4. 
The crude product was purified by column chromatography using petroleum ether/ethyl acetate 
1/1 as eluent. The procedure yielded 381 mg (70%) of  transparent oil.
1H-NMR (CDCl3, 500MHz): δ 2.88 (br, 6H, -NCH3), 3.87 (m, 4H, NCH2-), 5.13 (m, 8H, 4H -
CH2O- and 4H =CH2), 5.77 (m, 2H, =CH), 7.31 (m, 4H, Ar).
O
N
O O
N
O
pentane-1,5-diyl  bis(allyl(methyl)carbamate) (61b) Following the above described procedure 
we have obtained 450 mg (90%) starting from diene 61 (400 mg, 1.48 mmol), 118 mg NaH 
(60% dispersed in mineral oil) and 183 μL of  CH3I (2.96 mmol).
1H-NMR (CDCl3, 500MHz): δ 1.25 (br, 2H, -OCH2CH2CH2CH2CH2O-), 1.66 (m, 4H, -
OCH2CH2CH2CH2CH2O-), 2.84 (m, 6H, NCH3), 3.83  (m, 4H -CH2N-), 4.08 (m, 4H,  -OCH2-), 
5.14 (m, 4H, =CH2), 5.75 (br, 2H, CH=).
6.3.5.1 General procedure for macrocycle closure
A 0.02M solution of Boc-protected diene in DCM was degassed by bubbling argon. Grubbs 
catalyst (7%) was added at r.t. The reaction mixture was heated to reflux for 24h, at which point 
the TLC analysis indicated that reaction was complete. The reaction was  cooled to r.t. ad air was 
bubbled for 3h. The reaction mixture was filtrated on silica pad using DCM/MeOH 9/1 as 
eluent. The mixture was concentrated to give the crude product.
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5,10-di-tert-butyl 4,11-dioxo-3,12-dioxa-5,10-diazabicyclo[12.3.1]octadeca-1(18),7,14,16-
teraene-5,10-dicarboxylate (63) General procedure after recrystallization from isopropanol 
yielded 240 mg (84%) of white solid starting from 300 mg (0.6 mmol) of Boc-protected diene 
m-62a and 36 mg (7%) of  1st generation Grubbs catalyst.
1H-NMR (CDCl3, 500MHz): δ 1.47 (s, 18H, C(CH3)3 isomer A), 1.52 (s, 18H, C(CH3)3 isomer 
B), 4.30 (m, 4H, CH2N isomer A), 4.43 (m, 4H, CH2N isomer B), 5.24  (s, 4H, CH2O- isomer B), 
5.29 (s, 4H, CH2O- isomer A), 5.51 (m, 2H, CH=CH isomer B), 7.13 (m, 4H, Ar isomer A), 7.30 
(m, 4H, Ar isomer B); 13C-NMR (CDCl3, 125MHz): δ 28.00 (C(CH3)3 isomer A), 28.02 (C(CH3)3 
isomer B), 44.31 (CH2N isomer A), 47.12  (CH2N isomer B), 66.94 (CH2O- isomer A), 67.24 
(CH2O- isomer B), 83.19 (C(CH3)3 isomer A), 83.58  (C(CH3)3 isomer B), [123.50, 124.14, 
125.12, 126.18, 127.86, 128.26, 128.33, 128.72, 136.09, 136.84 (10 C sp2 both isomers)], [151.99, 
152.15, 152.53, 152.63 (4x CO both isomers)]; MS (ESI, m/z): 499 [MNa]+, 515 [MK]+.
N
N
O
O
O
O
Boc
Boc
( Z ) - d i - t e r t - b u t y l 3 , 1 0 - d i o x o - 5 , 8 , 1 0 , 1 2 - t e t r a h y d r o b e n z o [ l ] [ 1 , 1 0 , 3 , 8 ]
dioxadiazacyclotetradecine-4,9(1H,3H)-dicarboxylate (64)  General procedure after 
recrystallization from diethyl ether yielded 268 mg (94%) of white solid starting from 300 mg 
(0.6 mmol) of  Boc-protected diene o-62a and 36 mg (7%) of  1st generation Grubbs catalyst.
1H-NMR (CDCl3, 500MHz): δ 1.53 (s, 18H, C(CH3)3), 4.12 (m, 4H, CH2N), 5.12 (s, 4H, CH2O-), 
5.41 (m, 2H, CH=CH), 7.42 (m, 2H, Ar), 7.46 (m, 2H, Ar); 13C-NMR (CDCl3, 125MHz): δ 28.00 
(C(CH3)3), 46.16 (CH2N), 65.83 (CH2O-), 83.26 (C(CH3), [127.42, 129.57, 132.58, 134.20  (3x C 
Ar and CH=), [152.33, 152.52 (2x CO)]; MS (ESI, m/z): 499 [MNa]+, 515 [MK]+.
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di-tert-butyl  2,9-dioxo-1,10-dioxa-3,8-diazacyclopentadec-5-ene-3,8-dicarboxylate (65) 
General procedure yielded 192  mg (82%) of transparent solid starting from 250 mg (0.53 
mmol) of  Boc-protected diene 61a and 32 mg (7%) of  1st generation Grubbs catalyst.
1H-NMR (CDCl3, 500MHz): δ 1.48 (m, 20H, 18H C(CH3)3 and 2H -OCH2CH2CH2CH2CH2O-), 
1.54 (m, 4H, -OCH2CH2CH2CH2CH2O-), 4.18 (m, 8H, 4H CH2O- and 4H CH2N), 5.59 (m, 2H, 
CH=CH); 13C-NMR (CDCl3, 125MHz): δ 27.39 (-OCH2CH2CH2CH2CH2O-), 27.74 (-
OCH2CH2CH2CH2CH2O-), 27.99 (C(CH3), 46.65 (CH2N), 65.35 (CH2O-), 82.96 (C(CH3), 
127.40 (CH=), [152.17, 152.70 (2x CO)]; MS (ESI, m/z): 465 [MNa]+.
N
N
O
O
O
O
3,8-dimethyl-1,10-dioxa-3,8-diazacyclopentadec-5-ene-2,9-dione (66)  General procedure 
yielded 77 mg (44%) of transparent solid starting from 190 mg (0.53  mmol) of Boc-protected 
diene 61b and 39 mg (7%) of  1st generation Grubbs catalyst.
1H-NMR (CDCl3, 400MHz): δ 1.43 (m, 2H -OCH2CH2CH2CH2CH2O-), 1.64 (m, 4H, -
OCH2CH2CH2CH2CH2O-), 2.81 (m, 6H, -NCH3), 3.80  (m, 4H, CH2N), 4.08 (m, 4H, CH2O-), 
5.50 (m, 2H, CH=CH); MS (ESI, m/z): 293 [MNa]+.
N
N
O
O
O
O
5,10-dimethyl-2,12-dioxa-5,10-diazabicyclo[12.3.1]octadeca-1(18),7,14,16-teraene-4,11-
dione (67)  General procedure yielded 61 mg (67%) of transparent solid starting from 100 mg 
(0.30 mmol) of  Boc-protected diene m-62b and 17 mg (7%) of  1st generation Grubbs catalyst.
1H-NMR (CDCl3, 400MHz): δ 1H-NMR (CDCl3, 500MHz): δ 2.99 (m, 6H, NCH3), 4.10 (m, 4H, 
CH2N), 5.21 (br, 4H, CH2O-), 5.57 (br, 2H, CH=CH), 7.09-7.38 (m, 2H, Ar); MS (ESI, m/z): 
327 [MNa]+.
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(5S,8S,Z)-di-tert-butyl 5,8-dibenzyl-3,10-dioxo-5,8,10,12-tetrahydrobenzo[l][1,10,3,8]
dioxadiazacyclotetradecine-4,9(1H,3H)-dicarboxylate (68) General procedure yielded 77 
mg (44%) of transparent solid starting from 100 mg (0.15 mmol) of Boc-protected diene 60a 
and 8 mg (7%) of  2nd generation Grubbs catalyst.
1H-NMR (CDCl3, 400MHz): δ 1.26 (s, 18H, C(CH3)3), 2.88  (m, 2H, CH2Ph), 2.97 (m, 2H, 
CH2Ph), 5.07 (m, 2H, CHN), 5.24 (s, 4H, CH2O), 5.55 (m, 2H, CH=CH), 7.09-7.22 (m, 14H, 
Ar); 13C-NMR (CDCl3, 100MHz): δ 28.90 (C(CH3)3), 39.90 (CH2Ph), 56.54 (CHNH), 65.82
(CH2O-), 83.94 (C(CH3)3), [125.61, 128.02, 129.00, 130.05, 129.89 132.10, 134.83, 138.11 (8C 
sp2)], 152.21 (CO MS (ESI, m/z): 679 [MNa]+, 695 [MK]+.
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Evaluation of biological activity
The assessment of biological activity, and therefore the actual ability to inhibit HIV protease, 
is essential not only to test the synthesized inhibitors but also to have a reference for the 
design of  more effective compounds.[1]
The assay is based on the use of fluorogenic substrates  widely used in biochemistry due to 
their high sensibility. The technique, called “ Intramolecular Fluorescence Resonance Energy 
Transfer “ (FRET)[2] introduces, in a suitable substrate that is recognized by the enzyme, a 
fluorescent group  (fluorescent donor) and a quenching group (quenching acceptor) which is 
actually a chromophore able to absorb  the same wavelengths  which are emitted by 
fluorescence donor group. The substrate used in this  particular biological assay is an 
hexapeptide Abz-Thr-Ile-Nle-Phe(p-NO2)-Gln-Arg-NH2, where p-NO2- phenylalanine acts as 
fluorescence donor while 2-amminobenzoic acid (Abz) acts as quenching acceptor. In this 
biological assay recombinant, commercially available, HIV-1 protease was  used. The 
fluorescence of emission Phe(p-NO2) is at 420 nm (excitation at 325 nm) and is drastically 
reduced by the presence of 2-amminobenzoic acid which provides a quenching effect. The 
effect becomes insignificant at distance superior to 100 Å,  and when the protease hydrolyzes 
the substrate, emission of  fluorescence takes place (Scheme A1)
In this way, the hydrolytic activity of HIV-1 protease can be continuously followed at pH 5.5, 
which is the optimum pH for the hydrolytic activity of the enzyme,[3] simply measuring the 
increase of fluorescence intensity against time. If to a substrate-protease solution is  added a 
compound which acts as an inhibitor of an enzyme, fluorescence increase at a reduced rate and 
the difference in velocityis, proportional to the inhibiting ability.
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Scheme A1
The degree of inhibition is assessed by comparing the initial velocity of the catalyzed reaction 
and the reaction velocity in presence of different amounts of inhibitor, in turn obtained from 
the linear portion of the corresponding curves of fluorescence intensity variation in time 
(Figure A1).
The IC50 value is  obtained by plotting the slopes as a function of different concentrations 
(expressed in logarithmic terms) at which the inhibition is observed and the interpolating value 
corresponding to 50% inhibition.
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Figure A1 Fluorescence curves at different inhibitor concentrations (left); trend of  residual enzyme 
activity against the logarithm of  the inhibitor concentration (right)
Prelimination screenings  of inhibitors  were done at inhibitor concentration of 1 μM and 
residual activity of  HIV-Pr was recored.
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